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Total joint replacement (TJR) is an effective surgical intervention for end-stage joint diseases 
as osteoarthritis and rheumatoid arthritis. Annually approximately 28.000 total hip (THA) 
and 24.000 total knee arthroplasties (TKA) are being performed in The Netherlands.[1] These 
numbers increased in the last 5 years and is expected to increase even more due to the 
rising incidence of obesity and a more active lifestyle of the elderly.[1, 2] The survival-rates of 
THA and TKA show consistent results with failure of only 5 -10% after 10 years and up to 20% 
of revisions at 20 years follow-up.[3-6] Particularly in younger, more active patients the long-
term survival of TJRs is reduced compared to the elderly population (older than 65 years).
[3-8] Revision surgery consists of removal of the loosened components and peri-prosthetic 
interface soft tissue, sometimes augmenting cortical and spongious bone loss with allograft 
bone, and subsequent insertion of new components. Large bone defects, caused by both 
osteolytic lesions as well as stress shielding create not only a technical surgical challenge 
to fixate new implant components, but may also cause intraoperative fractures during 
removal of the implant. Consequently, these revision THA and TKA surgeries are often 
highly demanding for the patient and can be associated with complications, hence creating 
new morbidity, particularly in elderly patients with a poor general health condition.[9-11] 
Additionally, the clinical and functional results of extensive revision arthroplasty surgery are 
less favourable compared to primary arthroplasty surgery.[12-14] Therefore, therapies less 
demanding than this extensive revision surgery or even prevention of extensive bone loss 
during the loosening process would improve quality of patient care. 
 
Aseptic loosening
Aseptic loosening is reported as a major factor limiting the long-term survival of TJRs, 
accounting for about 50% of THA revisions and 30% of TKA revisions.[1, 15, 16] Aseptic 
loosening refers to a process during which stable and osseointegrated implants become 
loose as the bone surrounding the implant is resorbed. This process is regulated by 
a complex interaction between both biomechanical factors (i.e. stress shielding) and 
biological factors (i.e. response to wear debris particles through bone signalling at cellar 
levels).[17, 18] Particulate wear debris, continuously generated by articulating motion at 
the bearing surfaces, has been implicated as one of the primary causes initiating peri-
prosthetic bone loss and implant loosening.[17, 19, 20] Wear debris can be phagocytized by 
various cell types, triggering a continuous localized peri-prosthetic inflammatory response 
through the production of inflammatory mediators. These inflammatory mediators create 
a microenvironment that favours osteoclast formation and subsequently peri-prosthetic 
bone resorption. The rate of peri-prosthetic bone loss may vary between patients due to 
differences in the properties and amount of particulate wear debris, different patterns of 
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biomechanical failure of artificial implants and differences in the individual host immune 
response which can be related to an individual genotype.[21-27] Therefore, evaluation of 
individual biological responses is possibly essential to intervene with the process of aseptic 
loosening.    
Peri-prosthetic interface tissue
During the process of aseptic loosening a loose connective fibrous-like tissue develops at 
the interface between an implant and the bone bed. This so-called peri-prosthetic interface 
tissue exhibits a heterogeneous cellular composition that generally includes monocyte/
macrophage lineage cells (macrophages, foreign body giant cells, and osteoclasts), 
fibroblasts, endothelial cells, osteoblasts and lymphocytes.[28, 29] Most of these cell types 
are able to phagocytize wear debris particles and secrete a number of proteolytic enzymes 
as well as pro-inflammatory and osteoclastogenic cytokines. Proteolytic enzymes, such as 
matrix metalloproteinases (MMP’s), can directly degrade demineralized collagen matrix.
[30] The pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and 
interleukin 1 and 6 (IL-1, IL-6), provoke cellular proliferation, stimulate osteoclast activity and/
or decrease osteoblast function and thereby disrupt the homeostasis of bone metabolism.
[17, 20, 31] Bone metabolism is governed by a delicate balance between bone formation 
by osteoblasts and bone resorption by osteoclasts. This process is tightly regulated by local 
and endocrine factors. In normal bone metabolism there is a balance between levels of 
osteolytic and osteogenic cytokines. In aseptic loosening, this balance is disrupted resulting 
in a net bone loss around the implant.[32] 
 Most studies on peri-prosthetic interface tissue focus on the relation between the local 
production of cytokines and enzymes and their effect on the peri-prosthetic osteolytic 
process. Histological examination reveals a high inter- and intra-sample variation in both 
cellular and cytokine profiles within the peri-prosthetic interface tissue, which may represent 
different stages of loosening in different topological areas.[33-36] This heterogeneity is 
probably due to the variable biological, mechanical, and material microenvironments 
along the bone-implant interface.[33, 36-38] Histological evidence also indicates that peri-
prosthetic interface tissue is not a tissue with solely bone “destructive” properties. Bone 
remodelling around the implant has been shown by the presence of intramembranous 
formation of osteoid, and the production of immature bone with poor quality.[39, 40] 
Furthermore, several cell types within the peri-prosthetic interface tissue have been shown 
to produce osteoblast specific proteins [41] as well as to exhibit an increased expression of 
several bone morphogenetic proteins (BMPs)[42], which are regulators and potent inducers 
of osteoblast differentiation.[43] The local increase of osteogenic proteins, BMPs and bone 
remodelling around the implant may indicate that osteogenesis also takes place in peri-




Targets for treatment  
Through the years, many efforts have been made at improving the quality of primary joint 
replacements and thereby reducing the prevalence of aseptic loosening and the potential 
need for revision surgery. For example, alternative bearing surfaces have been developed 
which significant reduced the amount of wear.[44-47] However, regardless of these efforts, 
aseptic loosening still persists. Therefore continued research into new therapies to treat 
aseptic loosening is necessary to prolong the lifetime of prostheses. So far, studies aiming at 
identifying targets for treatment of aseptic loosening have primarily focused on interfering 
with the osteolytic process. However, only partial inhibition of bone resorption could be 
achieved in studies using non-steroidal anti-inflammatory drugs (NSAIDs) and/or antibodies 
to specific osteolytic mediators.[48-50] The results of the clinical use of bisphosphonates 
to treat bone resorption in aseptic loosening were inconsistent.[51, 52] Alternatively, 
therapeutic agents targeted at improving bone formation in the peri-prosthetic osteolytic 
areas are also likely to countermeasure the osteolytic process. However, hardly any studies 
exist on this topic. In fact, the role of peri-prosthetic interface tissue cells in bone formation 
is yet even unclear. 
Outline of this thesis
The objective of the research described in this thesis is to increase the knowledge on the 
biology behind the process of aseptic loosening. For this purpose, we aim to study the 
loosening process from three different biological perspectives, according to the following 
research questions:
1. Does the cellular content of peri-prosthetic interface tissue shed new light on the 
mechanism of implant loosening?
2. Do peri-prosthetic interface tissue cells possess osteogenic potential, which can 
ultimately be used to prevent or slow loosening?
3. Does the individual host immune response relate to prosthesis migration, which can 
ultimately predict loosening?
The first research question is addressed in Chapters 2 and 3. In Chapter 2, an overview 
of currently known cellular mechanisms involved in aseptic loosening, based on in vitro 
findings, is given. The cellular mechanisms are further explored in Chapter 3, where the 
cellular characteristics of peri-prosthetic interface tissue samples are studied by determining 
cell-specific gene expression patterns and using immunohistochemistry. In Chapters 4 and 
5, the second research question is addressed. In Chapter 4, the possibility to enhance bone 
regeneration, by intervening with signalling pathways which are important for osteogenic 
differentiation, is studied in human and murine cell lines. Results from this study are used in 
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Chapter 5, where we investigate whether cells derived from peri-prosthetic interface tissue 
are capable of differentiation into the osteoblastic lineage. The third research question is 
addressed in Chapter 6, where we investigate the relation between non-specific cytokine 
(innate immune) responses and the early migration of prostheses. Finally, Chapter 7 
concludes this thesis with a summary and general discussion including future directives on 
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Aseptic loosening is the most common long-term cause of implant failure, but its underlying 
biological mechanism is complex and still not elucidated completely. Therefore, this review 
aims to clarify the characteristics of peri-prosthetic tissue based on in vitro findings in order 
to provide an overview of the currently proposed cellular mechanisms involved in implant 
loosening.
Methods 
A systematic search in various databases revealed 51 eligible studies describing in vitro 
findings on peri-prosthetic fibrous tissue obtained from aseptic loosened implants. Besides 
general study characteristics, the following outcome measures were extracted: production 
of biochemical factors, response to particles, osteoclastogenic capacity, and osteogenic 
capacity.
Results  
Both macrophages and fibroblasts seem to be actively involved in osteoclastogenesis and 
pathologic bone resorption through production of inflammatory cytokines, chemokines, 
matrix degrading enzymes, osteoclastogenic factors and angiogenic factors. Particles, 
particularly titanium particles, interfered with all these factors. No papers reported on the 
osteogenic capacity of peri-prosthetic tissue. However, the tissue was shown to produce 
factors that suppress osteoblast function, indicating that (effects on) osteoblasts do play a 
role in the process of loosening.
Conclusion  
This literature study shows that the role of fibroblasts and osteoblasts in aseptic loosening 
is underestimated and that these cells could be potential targets for treatment. However, 
high variability in all reported outcome measures frequently hampered interpretation of 
the results, which underlines the need for a more uniform and in-depth description of 
patient-, prosthesis-, and tissue-related characteristics in future studies in order to address 
the mechanism of aseptic loosening and its potential therapeutic targets more effectively. 
Keywords:  Peri-prosthetic osteolysis; Total joint replacement; Interface tissue; Cell culture
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Introduction
Aseptic loosening is the most common long-term cause of failure in total hip and knee 
arthroplasties, accounting for approximately 70% of revision surgeries after hip replacement.
[1] Peri-prosthetic loosening is a process in which the once firm bond between prosthesis and 
bone or cement is lost.[1] A fibrous loosening membrane with poor mechanical properties is 
formed, triggering bone resorption and prosthesis migration. A complex interplay between 
mechanical and biological factors is known to elicit the loosening process.[2] Particulate 
wear debris has been implicated as one of the primary causes initiating peri-prosthetic 
bone loss and implant loosening. Wear can be phagocytized by various cell types of which 
the most important cellular target is believed to be the macrophage.[3] Phagocytosis of 
wear triggers the immune system causing production of inflammatory mediators that are 
implicated in osteoclast formation and activation. As such, the final cellular consequence 
in the action of wear is an excess of osteoclast activity, which results in disturbed bone 
remodelling and ultimately osteolysis.
Although many reports have been published on the pathogenesis of loosening, the 
precise biological mechanisms underlying this process have still not yet been elucidated 
completely. In a recent review on histological and immunological aspects of aseptic 
loosening, it was concluded that further investigation of peri-prosthetic tissues in terms of 
target cells, pathways and proteins is required.[4] In that review, however, studies based on 
other techniques than histology were excluded and thus potentially important cellular and 
molecular mechanisms may have been missed.
Therefore, this review aims to clarify the characteristics of peri-prosthetic tissue based 
on in vitro findings in order to provide an overview of the currently proposed cellular 
mechanisms involved in implant loosening. Specifically, we aimed to assess the (1) 
production of biochemical factors, (2) response to particles, (3) osteoclastogenic capacity, 
and (4) osteogenic capacity of peri-prosthetic tissue in vitro.
Search criteria and strategy 
Search strategy
A thorough search strategy (see Supplementary data S-1) was composed in collaboration 
with an experienced information specialist (JWS). The following databases were searched 
up to April 2014: PubMed, Medline, Embase, Web of Science, Cochrane Library, CENTRAL, 
CINAHL, Academic Search Premier, and ScienceDirect. The search strategy consisted of 
the following components, each defined by a combination of controlled vocabulary and 
free text terms: 1)  Interface / peri-prosthetic / granulation (synovial) tissue OR interface / 
peri-prosthetic / granulation (pseudo) membrane;  2)  Cell culture / organ culture / tissue 
culture / in vitro / in situ hybridization / polymerase chain reaction / western blotting;  and 
20
Chapter 2
3)  Arthroplasty / (aseptic) loosening / osteolysis / hip OR knee prosthesis / hip OR knee 
replacement. The addition of the specific search terms ‘in situ hybridization, polymerase 
chain reaction and western blotting’ was necessary as known potentially relevant papers 
turned out to be missing in the search in case only direct cell culture related terms were 
used. Additionally, three trial register sites were searched: the WHO International Clinical 
Trials Registry Platform, ClinicalTrials.gov and the ISRCTN registry. There were no initial 
restrictions on language and date.
 
Records excluded  (n = 985)  
- infection (n = 343) 
- not loosening (n = 125) 
- not interface tissue studied (n = 411) 
- not a cell culture study (n = 103) 
- conference abstract = scientific article  (n = 3) 
Records identified through  
database searching 























Additional articles  identified  
through check references  (n = 5) 
Duplicates removed  (n = 69) 
Unique records included 
(n = 1064) 
Full-text articles screened 
(n = 79) 
Full-text articles excluded   (n = 33) 
- no full-text available (n = 1) 
- not interface tissue studied (n = 10) 
- not a cell culture study (n = 8) 
- review article (n = 8) 
- language (Chinese/Japanese; n = 6) 
Eligible articles  included 
(n = 46) 
Total number of articles  included  
 (n = 51) 
Figure 1: PRISMA flow diagram of screening and selection process.
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Screening and inclusion 
A flow diagram of the screening and inclusion process is shown in Figure 1. Eleven hundred 
thirty-three records identified through the electronic searches were collected in an 
electronic reference database. After removal of duplicates, 1064 unique records remained. 
Based on title and abstract, two reviewers (AEO, MAES) independently screened scientific 
articles, conference abstracts and reports from trial registers using the following inclusion 
criteria: 1) the study had to deal with aseptic loosening; 2) the studied material had to be 
peri-prosthetic fibrous tissue; and 3) the outcome measurement(s) had to include particular 
culture of peri-prosthetic tissue or analysis of material obtained during culturing the tissue 
(e.g. RNA or conditioned culture medium). A record was considered eligible when it met 
all three inclusion criteria. In case the title and/or abstract were inconclusive, the record 
remained eligible. Findings of both reviewers were compared and any disagreements 
were resolved by consensus, resulting in the exclusion of 985 records. The full-text of the 
remaining 79 eligible records were evaluated by AEO and included when the above-
mentioned inclusion criteria were met. In case of any doubt regarding the eligibility of a 
paper, the paper was evaluated by MAES as well and agreement on eligibility was achieved 
by consensus. Another 33 records were excluded. References of the 46 included articles 
were checked for potentially eligible studies that were not identified with the original 
search strategy in order to minimize the risk of missing relevant studies, which resulted in 
the additional inclusion of 5 papers. Finally, 51 papers were included for data extraction. 
Data extraction 
From the included papers, data were extracted systematically and collected in a pre-
defined electronic document, the so-called data-extraction form. Recorded article 
information included year of publication, authors (first, last), study group, and running 
title. With respect to the patient characteristics, the number of subjects in the study, 
sociodemographic data of the subjects (gender, age), type of surgery (THA, TKA, other), 
indication for surgery (OA, RA, other), time to revision, and presence of a control group (yes/
no; if yes, number, gender, age) were extracted. Regarding the study characteristics, the 
study aim (primary, secondary), inclusion and exclusion criteria, type of prosthesis fixation 
(cemented, cementless), prosthesis material, source of study material (human, animal), type 
of study material (tissue, conditioned medium, other), tissue/cell culture-related parameters 
(studied cell type(s), passage number used for culture experiment(s), experimental culture 
conditions), and type of methods used besides cell culture (immunohistochemistry, PCR, 
FACS, ELISA, other) were recorded. With respect to the study outcomes, the following data 
were extracted: production of biochemical factors, response to particles, osteoclastogenic 
capacity, and osteogenic capacity.
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The search included 7 papers on animal studies (sheep [5], dog [6, 7], rabbit [8-10] and 
rat [11]), in which animals underwent either spinal, hip or knee surgery. Since findings were 
similar to those found in the human studies, these papers will not be discussed in this 
review. Categorizing the 44 human studies in the predefined study outcomes of interest 
revealed 30 papers describing the production of biochemical factors by cells from the 
peri-prosthetic fibrous tissue and 7 papers in which response to particles was determined. 
The osteoclastogenic capacity of cells from the fibrous tissue was explored in 18 papers, 
whereas no papers on the osteogenic capacity of fibrous tissue cells were found. Two papers 
[12, 13] presented data on in vitro fibrous tissue characteristics other than our predefined 
study outcomes of interest and as such are not further discussed. Data were synthesized in 
descriptive and tabular format because of the heterogeneity of the study outcomes and are 
presented for each study outcome category separately.
Results
Production of biochemical factors
Table 1 summarizes the findings of the 29 papers focusing on the production of biochemical 
factors by cells from the peri-prosthetic fibrous tissue (one paper reported on production of 
biochemical factors in response to particles solely and is therefore mentioned in the section 
‘Response to particles’). Biochemical factors were generally determined in conditioned 
medium from tissue cultures, with 2 papers showing that macrophages were the main cell 
responsible for the measured factors.[14, 15] In 7 papers fibrous tissue fibroblasts were used 
specifically [16-22] and in 1 paper lymphocytes isolated from the fibrous tissue were used.[23] 
Inflammatory mediator production was measured in 19 papers [14-19, 21, 23-34], production 
of matrix molecules/enzymes in 3 papers [20, 22, 35], and 7 papers reported on both.[36-42] 
PGE
2
, IL-1, IL-6 and TNFα were the most common inflammatory mediators measured. 
The extent of osteolysis was reported to correlate with levels of these mediators.[39] 
Findings on comparisons made between cemented and cementless samples varied, 
however, tissues from cementless prostheses more often tended to produce the highest 
mediator levels.[28, 37, 39] One study compared mediator production between hip and 
knee samples and showed tissue from failed hip prostheses to be more active than tissue 
from failed knee prostheses.[39] Another study compared mediator production between 
samples from linear and erosive bone loss and found higher levels in the case of linear bone 
loss.[30] A study in which production of PGE
2
 was compared between deep, intermediate 
and superficial layers of capsule tissue, showed the deeper layer to produce the highest 
PGE
2
 levels.[27] Four papers [15-17, 32] described the production of RANK/RANKL and/or 
m-CSF and observed endogenous production of these mediators. The production seemed 
unaffected by inflammatory cytokines, but could be enhanced by particles.
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CELLULAR MECHANISMS IN ASEPTIC PROSTHESIS LOOSENING
Collagenase and gelatinase were the most common matrix molecules/enzymes 
measured. An imbalance between matrix metalloproteinases (MMPs) and its tissue 
inhibitors (TIMPs) was reported to correlate with clinical severity of loosening.[35] In one 
study, matrix enzyme production was compared between hip and knee samples and tissue 
from failed knee prostheses was shown to produce higher enzyme levels than tissue from 
failed hip prostheses.[39] In addition, comparison of samples from cementless prostheses 
with samples of cemented ones revealed tissues from cementless knee prostheses to 
have the highest biochemical activity. However, in another study in which only tissues 
from hip prostheses were included, the cemented samples were observed to produce the 
highest enzyme levels.[35] The same study also reported on a tendency towards a higher 
gelatinolytic activity in tissue from the proximal region of the stem when compared to 
tissue from the distal part of the stem. 
Response to particles
Response to wear particles has been addressed in numerous studies in literature, however, 
most of them use cell lines instead of primary cells. Consequently, our search strategy 
identified only 7 papers which reported on the response to particles using the target cells 
themselves (see Table 2). Fibrous tissue fibroblasts were used in 5 papers [17, 20, 21, 32, 
43] and fibrous tissue macrophages were used in 2 papers.[23, 44] Response to particles, 
mostly Ti-particles, was studied by measuring the production of inflammatory mediators 
in 4 papers [21, 23, 32, 44], the production of matrix molecules in 1 paper [20], and the 
production of osteoclastogenic factors in 4 papers.[17, 21, 32, 43] Similar to macrophages, 
fibroblasts were shown to be able to respond to particles directly, possibly via phagocytosis.
[32] Responsiveness was higher in fibrous tissue fibroblasts (and rheumatoid arthritis 
synovial fibroblasts) than in normal synovial fibroblasts.[21] Activation of fibroblasts was 
more extensive in cultures where conditioned medium from fibrous tissue membranes was 
added than in cultures where particles were added.[21] Since conditioned medium strongly 
enhanced the fibroblast response to particles [21, 32], inflammatory mediators in addition 













































































































































































































































+ + + -
Ti







































































































































































































































































































































































































































































































































































































































































































































+ + - -
Ti






















































































+ - - -
Ti
































                                
                                
                                

























































































































































































































































































































Table 3 summarizes the findings of the 18 papers focusing on the osteoclastogenic capacity 
of cells from the peri-prosthetic fibrous tissue. Osteoclastogenic capacity was measured 
indirectly in 6 papers [25, 27, 29, 45-47] and directly in 12 papers.[15, 32, 35, 43, 48-55] 
Indirect investigation of the osteoclastogenic capacity was performed by studying the 
effect of conditioned medium on the release of radioactive calcium from bone specimens 
(45Ca release). Conditioned medium obtained from capsular tissue cultures was shown 
to produce higher amounts of factors stimulating 45Ca release than that obtained from 
membrane cultures.[47] In addition, conditioned medium from deeper layers of the capsule 
increased 45Ca release more than that from superficial layers of the capsule.[27] Generally, 
only a few samples of conditioned media obtained from membranes affected 45Ca release, 
which was observed not to differ between samples from failed hip and knee prostheses.[29]
Direct investigation of the osteoclastogenic capacity was performed by studying the 
effect of cells from the fibrous tissue on 45Ca release in 2 papers [35, 52] and by studying 
their capability to induce resorption pits in 9 papers.[15, 43, 48-51, 53-55] Data regarding 
the effect of cells from fibrous membranes on 45Ca release were conflicting, with one study 
showing an induction [52] and another showing no effect.[35] No papers reported on 45Ca 
release by capsule cells. Induction of the formation of resorption pits was reported for both 
capsule cells [43, 48, 49, 51] and membrane cells.[15, 49, 50, 54, 55] 
In one study only the formation of TRAP+ multinucleated cells (osteoclasts) was 
determined and no functional tests were performed.[32] In this paper, as well as in most of 
the other papers mentioned above, cells from the fibrous tissue were reported to become 
osteoclasts after stimulation only. Formation of osteoclasts from fibrous tissue macrophages 
was reported to be RANKL dependent when cultured in the absence of mCSF [15, 49, 50] 
and TNFα dependent when cultured in the presence of mCSF.[54] Fibrous tissue fibroblasts 
were shown to support osteoclast formation of precursor cells rather than to be able to 
become osteoclasts themselves.[43, 51, 55] Generally this supporting activity was reported 
to be dependent upon cell-cell contact, however, one study showed osteoclast formation to 
occur without direct cell-cell contact.[43] Only one study showed fibrous tissue fibroblasts 
themselves to be capable to actively resorb bone.[53]
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Our search strategy revealed no papers in which the osteogenic capacity of peri-prosthetic 
fibrous tissue cells was explored in vitro. Of the included full-text papers, only one paper 
did present some data on the osteogenic potential of the cells. Al-Saffar et al. showed 
by histological assessment that the fibrous tissue of some patients exhibits osteogenic 
characteristics as shown by the presence of intramembranous formation of osteoid.[44] Cells 
present at these sites within the membranes were found to be fibroblasts and macrophages. 
Two papers presented findings on the effect of conditioned medium obtained from 
peri-prosthetic tissue on osteoblasts. Yao et al. observed conditioned medium from Ti 
particle-stimulated peri-prosthetic fibroblast cultures to suppress the gene expression of 
procollagens by MG-63 osteosarcoma cells [20]. Ito et al. showed conditioned medium 
from a peri-prosthetic tissue culture to have no effect on collagen I gene expression, but to 
increase IL-6 gene expression in normal human osteoblasts.[31] Although these findings do 
not shed any light on the osteogenic potential of peri-prosthetic tissue cells, it does imply 
that (effects on) osteoblasts play a role in the process of aseptic loosening.
Discussion
This systematic review provides an overview of the characteristics of peri-prosthetic fibrous 
tissue based on in vitro findings. Fifty-one papers were thoroughly studied in order to extract 
data regarding the production of biochemical factors, response to particles, osteoclastogenic 
capacity, and osteogenic capacity of the tissue. Macrophages and fibroblasts were shown 
to act in concert in aseptic loosening: both cell types seem to be actively involved in 
osteoclastogenesis and pathologic bone resorption through production of inflammatory 
cytokines, chemokines, matrix degrading enzymes, osteoclastogenic factors and angiogenic 
factors. Some studies showed direct correlations of these parameters with the radiographic 
appearance or severity of loosening.[30, 35, 39, 40] Wear particles, in particular Ti-particles, 
interfered with all these parameters. However, the effect of particles on responses of the 
tissue was most powerful in the presence of inflammatory mediators.[21, 32]
An important limitation of the literature, but inextricably linked to research on peri-
prosthetic tissue, is the large heterogeneity with respect to the reported findings. Part of 
the variability is most likely dependent on the type of prosthesis (hip versus knee) and 
type of fixation (cemented versus cementless). However, we found inconsistent findings 
with respect to these variables, with both differences between groups [28, 35, 37, 39] and 
comparable findings between groups [28, 29, 35, 38, 39, 41] reported. Part of the variability 
might also be explained by the cellular composition of peri-prosthetic fibrous tissue. 
However, this literature study showed that macrophages and fibroblasts, the main cell 
types of the tissue, both produce inflammatory mediators and matrix degrading molecules 
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known to be important in the loosening process.[14-22] In addition, both cell types were 
shown to have the potential to induce osteoclastogenesis and bone resorption, either direct 
or indirect.[15, 32, 43, 49-55] Therefore, other patient- and tissue-related characteristics, 
generally not specified in papers such as type of bone loss (linear versus erosive [30]) and in 
situ location and orientation of the tissue (proximal versus distal [35], and superficial versus 
deep tissue layers [27]), may have contributed to the observed variation as well. 
Another limitation of the literature is the large variation in measured study outcomes 
between different studies. Since ‘in vitro findings’ is a broad term, some variation was already 
expected before performing the literature search. Therefore, a priori the study outcomes 
were divided into four categories: production of biochemical factors, response to particles, 
osteoclastogenic capacity, and osteogenic capacity. However, after data extraction, even 
within these categories a high diversity in measured variables was observed which caused 
difficulties in making comparisons between studies. Therefore, studies with a sufficient 
sample size and more detailed and comparable description of study characteristics should 
be conducted in order to greatly improve interpretation of results.
A limitation of the current study is the difficulty to develop a comprehensive search 
strategy. The denomination of peri-prosthetic fibrous tissue is far from uniform and the 
same holds true for the term ‘in vitro studies’. Therefore, potentially eligible studies may have 
been missed. 
Nonetheless, fitting the pieces together leaves us with the reconstruction of a quite 
complex cellular mechanism involved in aseptic loosening (see Figure 2). From this 
proposed mechanism it becomes clear that only limited attention has been paid to the 
involvement of osteoblasts. Most research has focused on studying the interaction between 
particles and in vitro cell line models, which is beyond the scope of this review as we were 
interested in responses of primary peri-prosthetic tissue cells. The few papers studying 
cells obtained from peri-prosthetic fibrous tissue, showed these cells to produce factors 
that suppress osteoblast function and to induce production of inflammatory cytokines.
[20, 31] In addition, peri-prosthetic tissue cells were shown to possibly exhibit osteogenic 
characteristics themselves.[44] These results triggered us to perform an additional PubMed 
search specifically on osteogenesis in aseptic loosening to be sure we did not miss any 
relevant literature on this topic. The search revealed another three relevant papers. The first 
[56] was an extension of previous findings already mentioned in the Results section.[44] 
In the second paper, molecular profiles of cells residing in the peri-prosthetic tissues were 
determined, which showed foamy macrophages to produce amongst others osteopontin, 
osteocalcin, osteonectin, alkaline phosphatase and type I collagen.[57] In contrast, spindle-
shaped mesenchymal cells, possibly fibroblasts, failed to express these genes. These 
findings suggest an overlap in functions between peri-prosthetic tissue macrophages and 
osteoblasts or indicate an ability of these macrophages to transdifferentiate. 
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 Figure 2: Complex cellular mechanisms involved in aseptic loosening. Fibroblasts and macrophages 
are the main cells involved in the process of aseptic loosening. Both cell types act in concert in 
inducing osteoclastogenesis and bone resorption through production of inflammatory cytokines, 
chemokines, matrix degrading enzymes, osteoclastogenic factors and angiogenic factors. In addition, 
fibroblasts seem to stimulate osteoblast function and bone formation through direct and indirect 
actions. Wear particles, in particular Ti-particles, interfere with many of these processes. The proposed 
mechanism depicted here, is solely based on the in this review included papers on in vitro findings 
using peri-prosthetic tissue cells. Additional (cellular) interactions and influences of wear have been 
described in the literature and might play a role in the process of osteolysis as well. However, those 
findings are either based on in vitro experiments using cell line models or are obtained by using other 
techniques than cell culture, and are as such beyond the scope of this review. An arrow indicates 
stimulation and a bar-headed line indicates inhibition. Green-colored particles indicate a stimulation 
of the respective process, whereas red-colored particles indicate an inhibition. The lightning sign 
depicts matrix degradation. The question mark represents findings reported by only one study.
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Lastly, the third paper showed by expression analysis that two key regulators of osteogenesis, 
BMP-4 and FGF-18, were present at lower levels in peri-prosthetic fibrous tissue than in 
synovial tissue.[58] These findings suggest a disturbed osteogenic signalling in patients 
with osteolysis. Taken together, these data show that more research should be conducted 
to delineate the potentially critical role of osteoblasts in peri-prosthetic osteolysis.  
Targets for treatment
Studies aiming at identifying targets for treatment of aseptic loosening have focused on 
blocking bone resorption, either directly or indirectly by inhibition of inflammation. The 
ability of blocking agents to inhibit bone resorption was observed to differ between 
studies and seemed to be dependent on the origin of cells (capsule vs. membrane), cell 
type (fibroblast vs. macrophage), and timing of addition of the blocking agent (early in 
differentiation vs. later on). Non-steroidal anti-inflammatory drugs (NSAIDs) such as tenidap 
and indomethacin were reported to inhibit IL-6, TNFα and PGE
2
 production as well as to 
tend to inhibit MMP synthesis and stimulate TIMP production.[24, 42, 45, 47, 52] Although 
the effect of NSAIDs on all these mediators is favourable to reduce the resorptive process, 
bone resorption in aseptic loosening is too complex to be resolved by NSAIDs alone.
[42, 47] Addition of antibodies to specific inflammatory mediators, such as TNFα and IL-6 
antagonists, also resulted at the most in partial inhibition of bone resorption.[15, 43, 54, 55] 
Despite an important role for the RANK/RANKL signalling in aseptic loosening has been 
widely accepted, OPG, a decoy receptor for RANKL, alone was shown not to be able to fully 
block bone resorption.[50] One paper reported RANK:Fc, a RANKL antagonist, alone to be 
sufficient to block bone resorption completely [43], whereas others showed a combination 
of RANK:Fc and a TNFα antagonist is required to completely abolish bone resorption.[54, 55] 
Taken together, combination therapy seems inevitable to treat bone resorption in aseptic 
loosening.
Peri-prosthetic tissue fibroblasts were reported to play an important role in the process 
of aseptic loosening. These cells were shown to produce a wide range of inflammatory 
mediators, as well as OPG and RANKL, whereby supporting osteoclast formation and 
differentiation.[16-19, 21] In addition, peri-prosthetic tissue fibroblasts were observed to 
release MMPs and acidic components, as such contributing to the degradation of bone 
matrix.[20, 22, 35, 53] Therefore, fibroblasts should be considered a potential target for 
prevention of bone resorption in prosthesis loosening.  
An animal model showed disturbances in biosynthetic processes to be at least as 
important in implant loosening as biodegradative processes.[9] Despite too little attention 
is being paid to the role of osteoblasts and bone formation in aseptic loosening, as shown 
in this review, the few studies that did address this topic showed a potentially critical role 
for this cell. A recent review on the role of osteoblasts in peri-prosthetic osteolysis, reported 
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wear debris to significantly affect both (pre)osteoblast proliferation and function.[59] 
Moreover, particles are known to induce osteoblasts to secrete a variety of inflammatory 
mediators which contribute to the inflammatory cascade that drives osteolysis. Therefore, 
osteoblasts seem a potential therapeutic target in treating aseptic loosening as well. 
Concluding remarks
The cellular mechanism of aseptic loosening is complex and involves the cross-talk 
between a variety of cells and the subsequent production of a wide-range of inflammatory 
mediators and matrix degrading factors. Besides the well-known role of macrophages and 
osteoclasts in the loosening process, the role of fibroblasts and osteoblasts should not be 
underestimated. High variability in all reported outcome measures was generally observed, 
which frequently hampered interpretation of the results. Therefore, future studies should 
aim to provide a more uniform and in-depth description of prosthesis-, patient-, and tissue-
related characteristics in order to address the mechanism of aseptic loosening and its 
potential therapeutic targets more effectively.
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Supplementary data S-1 – Search strategy (April 7th, 2014)
PubMed
(“periprosthetic”[tw] OR periprosth*[tw] OR “peri-prosthetic”[tw] OR peri-prosthet*[tw] OR “interface tissue”[tw] 
OR “interface tissues”[tw] OR “granulation tissue”[tw] OR “granulation tissues”[tw] OR “interface membrane”[tw] 
OR “interface membranes”[tw] OR “granulation membrane”[tw] OR “granulation membranes”[tw] OR “interface 
pseudomembrane”[tw] OR “interface pseudomembranes”[tw] OR “granulation pseudomembrane”[tw] OR 
“granulation pseudomembranes”[tw] OR “interface pseudo-membrane”[tw] OR “interface pseudo-membranes”[tw] 
OR “granulation pseudo-membrane”[tw] OR “granulation pseudo-membranes”[tw] OR “periprosthetic pseudo 
synovial tissue”[tw] OR “interface pseudo synovial tissue”[tw] OR “granulation pseudo synovial tissue”[tw] OR 
“periprosthetic pseudo synovial tissues”[tw] OR “interface pseudo synovial tissues”[tw] OR “granulation pseudo 
synovial tissues”[tw] OR “interface”[ti] OR “granulation”[ti] OR “periprosthetic”[ti] OR “aseptic loosening”[tw] 
OR (aseptic*[tw] AND loosen*[tw]) OR ((granulation[tw] AND membrane[tw]) OR (granulation[tw] AND 
membranes[tw]) OR (interface[tw] AND pseudomembrane[tw]) OR (interface[tw] AND pseudomembranes[tw]) 
OR (granulation AND pseudomembrane[tw]) OR (granulation[tw] AND pseudomembranes[tw]) AND 
(interface[tw] AND pseudo-membrane[tw]) OR (interface[tw] AND pseudo-membranes[tw]) OR (granulation[tw] 
AND pseudo-membrane[tw]) OR (granulation[tw] AND pseudo-membranes[tw]) OR (periprosthetic[tw] AND 
pseudo[tw] AND synovial[tw] AND tissue[tw]) OR (interface[tw] AND pseudo[tw] AND synovial[tw] AND tissue[tw]) 
OR (granulation[tw] AND pseudo[tw] AND synovial[tw] AND tissue[tw]) OR (periprosthetic[tw] AND pseudo[tw] 
AND synovial[tw] AND tissues[tw]) OR (interface[tw] AND pseudo[tw] AND synovial[tw] AND tissues[tw]) OR 
(granulation[tw] AND pseudo[tw] AND synovial[tw] AND tissues[tw])) OR osteolysis[tw] OR “osteolysis”[mesh]) AND 
(“Culture Techniques”[mesh:noexp] OR “Cell Culture Techniques”[mesh] OR “Organ Culture Techniques”[mesh] OR 
“Tissue Culture Techniques”[mesh] OR “Cell Culture”[tw] OR “Organ Culture”[tw] OR “Tissue Culture”[tw] OR “Cells, 
Cultured”[Mesh:NoExp] OR “culture”[tw] OR “cultured”[tw] OR “cultures”[tw] OR Cocultur*[tw] OR “in vitro”[tw] 
OR “In Vitro”[Publication Type] OR “in situ hybridization”[majr] OR “in situ hybridization”[tw] OR “polymerase 
chain reaction”[majr] OR “polymerase chain reaction”[tw] OR “blotting, western”[majr] OR “western blotting”[tw] 
OR “western blot”[tw]) AND (“hip”[mesh] OR “Hip Joint”[Mesh] OR “hip”[tw] OR “hips”[tw] OR tha[tw] OR thr[tw] 
OR “knee”[mesh] OR “knee”[tw] OR “knee joint”[mesh] OR “knees”[tw] OR tka[tw] OR tkr[tw] OR “Arthroplasty, 
Replacement, Hip”[mesh] OR “Arthroplasty, Replacement, Knee”[mesh] OR “Hip Prosthesis”[mesh] OR “Knee 
Prosthesis”[mesh])
Medline
(“periprosthetic”.mp OR periprosth*.mp OR “peri-prosthetic”.mp OR peri-prosthet*.mp OR “interface tissue”.mp 
OR “interface tissues”.mp OR “granulation tissue”.mp OR “granulation tissues”.mp OR “interface membrane”.mp 
OR “interface membranes”.mp OR “granulation membrane”.mp OR “granulation membranes”.mp OR “interface 
pseudomembrane”.mp OR “interface pseudomembranes”.mp OR “granulation pseudomembrane”.mp OR 
“granulation pseudomembranes”.mp OR “interface pseudo-membrane”.mp OR “interface pseudo-membranes”.
mp OR “granulation pseudo-membrane”.mp OR “granulation pseudo-membranes”.mp OR “periprosthetic pseudo 
synovial tissue”.mp OR “interface pseudo synovial tissue”.mp OR “granulation pseudo synovial tissue”.mp OR 
“periprosthetic pseudo synovial tissues”.mp OR “interface pseudo synovial tissues”.mp OR “granulation pseudo 
synovial tissues”.mp OR “interface”.ti OR “granulation”.ti OR “periprosthetic”.ti OR “aseptic loosening”.mp OR (aseptic*.
mp AND loosen*.mp) OR ((granulation.mp AND  membrane.mp) OR (granulation.mp AND membranes.mp) OR 
(interface.mp AND pseudomembrane.mp) OR (interface.mp AND pseudomembranes.mp) OR (granulation.mp 
AND pseudomembrane.mp) OR (granulation.mp AND pseudomembranes.mp) AND (interface.mp AND pseudo-
membrane.mp) OR (interface.mp AND pseudo-membranes.mp) OR (granulation.mp AND pseudo-membrane.mp) 
OR (granulation.mp AND pseudo-membranes.mp) OR (periprosthetic.mp AND pseudo.mp AND synovial.mp AND 
tissue.mp) OR (interface.mp AND pseudo.mp AND synovial.mp AND tissue.mp) OR (granulation.mp AND pseudo.
mp AND synovial.mp AND tissue.mp) OR (periprosthetic.mp AND pseudo.mp AND synovial.mp AND tissues.mp) 
OR (interface.mp AND pseudo.mp AND synovial.mp AND tissues.mp) OR (granulation.mp AND pseudo.mp AND 
synovial.mp AND tissues.mp)) OR osteolysis.mp OR exp osteolysis/) AND (Culture Techniques/ OR exp Cell Culture 
Techniques/ OR exp Organ Culture Techniques/ OR exp Tissue Culture Techniques/ OR “Cell Culture”.mp OR “Organ 
Culture”.mp OR “Tissue Culture”.mp OR “Cells, Cultured”/ OR “culture”.mp OR “cultured”.mp OR “cultures”.mp OR 
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Cocultur*.mp OR “in vitro”.mp OR “In Vitro”.pt OR exp *”in situ hybridization”/ OR “in situ hybridization”.mp OR exp 
*polymerase chain reaction/ OR “polymerase chain reaction”.mp OR exp *”blotting, western”/ OR “western blotting”.
mp OR “western blot”.mp) AND (exp hip/ OR exp Hip Joint/ OR “hip”.mp OR “hips”.mp OR tha.mp OR thr.mp OR exp 
knee/ OR “knee”.mp OR exp knee joint/ OR “knees”.mp OR tka.mp OR tkr.mp OR “Arthroplasty, Replacement, Hip”/ 
OR “Arthroplasty, Replacement, Knee”/ OR exp “Hip Prosthesis”/ OR exp “Knee Prosthesis”/)
(“periprosthetic”.af OR periprosth*.af OR “peri-prosthetic”.af OR peri-prosthet*.af OR “interface tissue”.af OR 
“interface tissues”.af OR “granulation tissue”.af OR “granulation tissues”.af OR “interface membrane”.af OR “interface 
membranes”.af OR “granulation membrane”.af OR “granulation membranes”.af OR “interface pseudomembrane”.af 
OR “interface pseudomembranes”.af OR “granulation pseudomembrane”.af OR “granulation pseudomembranes”.
af OR “interface pseudo-membrane”.af OR “interface pseudo-membranes”.af OR “granulation pseudo-membrane”.
af OR “granulation pseudo-membranes”.af OR “periprosthetic pseudo synovial tissue”.af OR “interface pseudo 
synovial tissue”.af OR “granulation pseudo synovial tissue”.af OR “periprosthetic pseudo synovial tissues”.af OR 
“interface pseudo synovial tissues”.af OR “granulation pseudo synovial tissues”.af OR “interface”.ti OR “granulation”.
ti OR “periprosthetic”.ti) AND (“Culture Techniques”/ OR exp “Cell Culture Techniques”/ OR exp “Organ Culture 
Techniques”/ OR exp “Tissue Culture Techniques”/ OR “Cell Culture”.af OR “Organ Culture”.af OR “Tissue Culture”.af OR 
“Cells, Cultured”/ OR “culture”.af OR “cultured”.af OR “cultures”.af OR Cocultur*.af ) AND (exp “hip”/ OR exp “Hip Joint”/ 
OR “hip”.af OR “hips”.af OR tha.af OR thr.af OR exp “knee”/ OR “knee”.af OR exp “knee joint”/ OR “knees”.af OR tka.af OR 
tkr.af OR exp “Arthroplasty, Replacement, Hip”/ OR exp “Arthroplasty, Replacement, Knee”/ OR exp “Hip Prosthesis”/ 
OR exp “Knee Prosthesis”/)
Embase
(“periprosthetic”.ti,ab OR periprosth*.ti,ab OR “peri-prosthetic”.ti,ab OR peri-prosthet*.ti,ab OR periprosthetic joint 
infection/ OR periprosthetic fracture/ OR “interface tissue”.ti,ab OR “interface tissues”.ti,ab OR granulation tissue/ 
OR “granulation tissue”.ti,ab OR “granulation tissues”.ti,ab OR “interface membrane”.ti,ab OR “interface membranes”.
ti,ab OR “granulation membrane”.ti,ab OR “granulation membranes”.ti,ab OR “interface pseudomembrane”.ti,ab OR 
“interface pseudomembranes”.ti,ab OR “granulation pseudomembrane”.ti,ab OR “granulation pseudomembranes”.
ti,ab OR “interface pseudo-membrane”.ti,ab OR “interface pseudo-membranes”.ti,ab OR “granulation pseudo-
membrane”.ti,ab OR “granulation pseudo-membranes”.ti,ab OR “periprosthetic pseudo synovial tissue”.ti,ab OR 
“interface pseudo synovial tissue”.ti,ab OR “granulation pseudo synovial tissue”.ti,ab OR “periprosthetic pseudo 
synovial tissues”.ti,ab OR “interface pseudo synovial tissues”.ti,ab OR “granulation pseudo synovial tissues”.ti,ab 
OR “interface”.ti OR “granulation”.ti OR “periprosthetic”.ti OR “aseptic loosening”.ti,ab OR (aseptic*.ti AND loosen*.
ti) OR ((granulation.ti,ab ADJ4  membrane.ti,ab) OR (granulation.ti,ab ADJ4 membranes.ti,ab) OR (interface.
ti,ab ADJ4 pseudomembrane.ti,ab) OR (interface.ti,ab ADJ4 pseudomembranes.ti,ab) OR (granulation.ti,ab 
ADJ4 pseudomembrane.ti,ab) OR (granulation.ti,ab ADJ4 pseudomembranes.ti,ab) ADJ4 (interface.ti,ab ADJ4 
pseudo-membrane.ti,ab) OR (interface.ti,ab ADJ4 pseudo-membranes.ti,ab) OR (granulation.ti,ab ADJ4 pseudo-
membrane.ti,ab) OR (granulation.ti,ab ADJ4 pseudo-membranes.ti,ab) OR (periprosthetic.ti,ab ADJ4 pseudo.ti,ab 
ADJ4 synovial.ti,ab ADJ4 tissue.ti,ab) OR (interface.ti,ab ADJ4 pseudo.ti,ab ADJ4 synovial.ti,ab ADJ4 tissue.ti,ab) OR 
(granulation.ti,ab ADJ4 pseudo.ti,ab ADJ4 synovial.ti,ab ADJ4 tissue.ti,ab) OR (periprosthetic.ti,ab ADJ4 pseudo.ti,ab 
ADJ4 synovial.ti,ab ADJ4 tissues.ti,ab) OR (interface.ti,ab ADJ4 pseudo.ti,ab ADJ4 synovial.ti,ab ADJ4 tissues.ti,ab) 
OR (granulation.ti,ab ADJ4 pseudo.ti,ab ADJ4 synovial.ti,ab ADJ4 tissues.ti,ab)) OR osteolysis.ti OR exp *osteolysis/) 
AND (exp *”cell, tissue or organ culture”/ OR “Cell Culture”.ti,ab OR “Organ Culture”.ti,ab OR “Tissue Culture”.ti,ab OR 
“culture”.ti,ab OR “cultured”.ti,ab OR “cultures”.ti,ab OR Cocultur*.ti,ab OR “in vitro”.ti,ab OR exp *”in vitro study”/ OR 
exp*”in situ hybridization”/ OR “in situ hybridization”.ti OR exp *polymerase chain reaction/ OR “polymerase chain 
reaction”.ti OR exp *”western blotting”/ OR “western blotting”.ti OR “western blot”.ti) AND (exp *”hip”/ OR “hip”.ti,ab 
OR “hips”.ti,ab OR tha.ti,ab OR thr.ti,ab OR exp *”knee”/ OR “knee”.ti,ab OR “knees”.ti,ab OR tka.ti,ab OR tkr.ti,ab OR exp 
*Knee Arthroplasty/ OR exp *Hip Arthroplasty/ OR exp *”Hip Prosthesis”/ OR exp *”Knee Prosthesis”/)
(“periprosthetic”.af OR periprosth*.af OR “peri-prosthetic”.af OR peri-prosthet*.af OR periprosthetic joint 
infection/ OR periprosthetic fracture/ OR “interface tissue”.af OR “interface tissues”.af OR granulation tissue/ OR 
“granulation tissue”.af OR “granulation tissues”.af OR “interface membrane”.af OR “interface membranes”.af OR 
“granulation membrane”.af OR “granulation membranes”.af OR “interface pseudomembrane”.af OR “interface 
pseudomembranes”.af OR “granulation pseudomembrane”.af OR “granulation pseudomembranes”.af OR “interface 
pseudo-membrane”.af OR “interface pseudo-membranes”.af OR “granulation pseudo-membrane”.af OR “granulation 
pseudo-membranes”.af OR “periprosthetic pseudo synovial tissue”.af OR “interface pseudo synovial tissue”.af OR 
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“granulation pseudo synovial tissue”.af OR “periprosthetic pseudo synovial tissues”.af OR “interface pseudo synovial 
tissues”.af OR “granulation pseudo synovial tissues”.af OR “interface”.ti OR “granulation”.ti OR “periprosthetic”.ti) AND 
(exp “cell, tissue or organ culture”/ OR “Cell Culture”.af OR “Organ Culture”.af OR “Tissue Culture”.af OR “culture”.af 
OR “cultured”.af OR “cultures”.af OR Cocultur*.af ) AND (exp “hip”/ OR “hip”.af OR “hips”.af OR tha.af OR thr.af OR exp 
“knee”/ OR “knee”.af OR “knees”.af OR tka.af OR tkr.af OR exp Knee Arthroplasty/ OR exp Hip Arthroplasty/ OR exp 
“Hip Prosthesis”/ OR exp “Knee Prosthesis”/)
Web of Science
(TS=(“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR “interface tissue” OR “interface tissues” 
OR “granulation tissue” OR “granulation tissues” OR “interface membrane” OR “interface membranes” OR “granulation 
membrane” OR “granulation membranes” OR “interface pseudomembrane” OR “interface pseudomembranes” 
OR “granulation pseudomembrane” OR “granulation pseudomembranes” OR “interface pseudo-membrane” OR 
“interface pseudo-membranes” OR “granulation pseudo-membrane” OR “granulation pseudo-membranes” OR 
“periprosthetic pseudo synovial tissue” OR “interface pseudo synovial tissue” OR “granulation pseudo synovial tissue” 
OR “periprosthetic pseudo synovial tissues” OR “interface pseudo synovial tissues” OR “granulation pseudo synovial 
tissues”) OR TI=(“interface” OR “granulation” OR “periprosthetic” OR “aseptic loosening” OR (aseptic* AND loosen*) 
OR “osteolysis”)) AND (TS=(“Culture Techniques” OR “Cell Culture Techniques” OR “Organ Culture Techniques” OR 
“Tissue Culture Techniques” OR “Cell Culture” OR “Organ Culture” OR “Tissue Culture” OR “Cells, Cultured” OR “culture” 
OR “cultured” OR “cultures” OR Cocultur*) OR TI=(“in situ hybridization” OR “in situ hybridisation” OR “polymerase 
chain reaction” OR “pcr” OR “western blotting” OR “western blot” OR “in vitro” OR “InVitro”)) AND (TS=(“hip” OR “Hip 
Joint” OR “hip” OR “hips” OR “tha” OR “thr” OR “knee” OR “knee” OR “knee joint” OR “knees” OR “tka” OR “tkr” OR “ Hip 
Arthroplasty” OR “Hip Replacement “ OR “Knee Arthroplasty” OR “Knee Replacement” OR “Hip Prosthesis” OR “Knee 
Prosthesis” OR “joint” OR “joints”)) OR (TI=((“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR 
“interface tissue” OR “interface tissues” OR “granulation tissue” OR “granulation tissues” OR “interface membrane” OR 
“interface membranes” OR “granulation membrane” OR “granulation membranes” OR “interface pseudomembrane” 
OR “interface pseudomembranes” OR “granulation pseudomembrane” OR “granulation pseudomembranes” 
OR “interface pseudo-membrane” OR “interface pseudo-membranes” OR “granulation pseudo-membrane” OR 
“granulation pseudo-membranes” OR “periprosthetic pseudo synovial tissue” OR “interface pseudo synovial tissue” 
OR “granulation pseudo synovial tissue” OR “periprosthetic pseudo synovial tissues” OR “interface pseudo synovial 
tissues” OR “granulation pseudo synovial tissues” OR “interface” OR “granulation” OR “periprosthetic”) AND (“hip” OR 
“Hip Joint” OR “hip” OR “hips” OR “tha” OR “thr” OR “knee” OR “knee” OR “knee joint” OR “knees” OR “tka” OR “tkr” OR “ 
Hip Arthroplasty” OR “Hip Replacement “ OR “Knee Arthroplasty” OR “Knee Replacement” OR “Hip Prosthesis” OR 
“Knee Prosthesis” OR “joint” OR “joints”) AND (loose* OR osteoblast* OR osteoclast* OR fibroblast* OR macrophag* 
OR “synovial fluid”)))
Cochrane
(“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR “interface tissue” OR “interface tissues” 
OR “granulation tissue” OR “granulation tissues” OR “interface membrane” OR “interface membranes” OR “granulation 
membrane” OR “granulation membranes” OR “interface pseudomembrane” OR “interface pseudomembranes” 
OR “granulation pseudomembrane” OR “granulation pseudomembranes” OR “interface pseudo-membrane” OR 
“interface pseudo-membranes” OR “granulation pseudo-membrane” OR “granulation pseudo-membranes” OR 
“periprosthetic pseudo synovial tissue” OR “interface pseudo synovial tissue” OR “granulation pseudo synovial tissue” 
OR “periprosthetic pseudo synovial tissues” OR “interface pseudo synovial tissues” OR “granulation pseudo synovial 
tissues”) AND (“Culture Techniques” OR “Cell Culture Techniques” OR “Organ Culture Techniques” OR “Tissue Culture 
Techniques” OR “Cell Culture” OR “Organ Culture” OR “Tissue Culture” OR “Cells, Cultured” OR “culture” OR “cultured” 
OR “cultures” OR Cocultur*) AND (“hip” OR “Hip Joint” OR “hip” OR “hips” OR “tha” OR “thr” OR “knee” OR “knee” OR “knee 
joint” OR “knees” OR “tka” OR “tkr” OR “ Hip Arthroplasty” OR “Hip Replacement “ OR “Knee Arthroplasty” OR “Knee 
Replacement” OR “Hip Prosthesis” OR “Knee Prosthesis”)
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CENTRAL
(“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR “interface tissue” OR “interface tissues” 
OR “granulation tissue” OR “granulation tissues” OR “interface membrane” OR “interface membranes” OR “granulation 
membrane” OR “granulation membranes” OR “interface pseudomembrane” OR “interface pseudomembranes” 
OR “granulation pseudomembrane” OR “granulation pseudomembranes” OR “interface pseudo-membrane” OR 
“interface pseudo-membranes” OR “granulation pseudo-membrane” OR “granulation pseudo-membranes” OR 
“periprosthetic pseudo synovial tissue” OR “interface pseudo synovial tissue” OR “granulation pseudo synovial tissue” 
OR “periprosthetic pseudo synovial tissues” OR “interface pseudo synovial tissues” OR “granulation pseudo synovial 
tissues”) AND (“Culture Techniques” OR “Cell Culture Techniques” OR “Organ Culture Techniques” OR “Tissue Culture 
Techniques” OR “Cell Culture” OR “Organ Culture” OR “Tissue Culture” OR “Cells, Cultured” OR “culture” OR “cultured” 
OR “cultures” OR Cocultur*) AND (“hip” OR “Hip Joint” OR “hip” OR “hips” OR “tha” OR “thr” OR “knee” OR “knee” OR “knee 
joint” OR “knees” OR “tka” OR “tkr” OR “ Hip Arthroplasty” OR “Hip Replacement “ OR “Knee Arthroplasty” OR “Knee 
Replacement” OR “Hip Prosthesis” OR “Knee Prosthesis”)
CINAHL
(“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR “interface tissue” OR “interface tissues” 
OR “granulation tissue” OR “granulation tissues” OR “interface membrane” OR “interface membranes” OR “granulation 
membrane” OR “granulation membranes” OR “interface pseudomembrane” OR “interface pseudomembranes” 
OR “granulation pseudomembrane” OR “granulation pseudomembranes” OR “interface pseudo-membrane” OR 
“interface pseudo-membranes” OR “granulation pseudo-membrane” OR “granulation pseudo-membranes” OR 
“periprosthetic pseudo synovial tissue” OR “interface pseudo synovial tissue” OR “granulation pseudo synovial tissue” 
OR “periprosthetic pseudo synovial tissues” OR “interface pseudo synovial tissues” OR “granulation pseudo synovial 
tissues”) AND (“Culture Techniques” OR “Cell Culture Techniques” OR “Organ Culture Techniques” OR “Tissue Culture 
Techniques” OR “Cell Culture” OR “Organ Culture” OR “Tissue Culture” OR “Cells, Cultured” OR “culture” OR “cultured” 
OR “cultures” OR Cocultur*) AND (“hip” OR “Hip Joint” OR “hip” OR “hips” OR “tha” OR “thr” OR “knee” OR “knee” OR “knee 
joint” OR “knees” OR “tka” OR “tkr” OR “ Hip Arthroplasty” OR “Hip Replacement “ OR “Knee Arthroplasty” OR “Knee 
Replacement” OR “Hip Prosthesis” OR “Knee Prosthesis”)
Academic Search Premier
(“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR “interface tissue” OR “interface tissues” 
OR “granulation tissue” OR “granulation tissues” OR “interface membrane” OR “interface membranes” OR “granulation 
membrane” OR “granulation membranes” OR “interface pseudomembrane” OR “interface pseudomembranes” 
OR “granulation pseudomembrane” OR “granulation pseudomembranes” OR “interface pseudo-membrane” OR 
“interface pseudo-membranes” OR “granulation pseudo-membrane” OR “granulation pseudo-membranes” OR 
“periprosthetic pseudo synovial tissue” OR “interface pseudo synovial tissue” OR “granulation pseudo synovial tissue” 
OR “periprosthetic pseudo synovial tissues” OR “interface pseudo synovial tissues” OR “granulation pseudo synovial 
tissues”) AND (“Culture Techniques” OR “Cell Culture Techniques” OR “Organ Culture Techniques” OR “Tissue Culture 
Techniques” OR “Cell Culture” OR “Organ Culture” OR “Tissue Culture” OR “Cells, Cultured” OR “culture” OR “cultured” 
OR “cultures” OR Cocultur*) AND (“hip” OR “Hip Joint” OR “hip” OR “hips” OR “tha” OR “thr” OR “knee” OR “knee” OR “knee 
joint” OR “knees” OR “tka” OR “tkr” OR “ Hip Arthroplasty” OR “Hip Replacement “ OR “Knee Arthroplasty” OR “Knee 
Replacement” OR “Hip Prosthesis” OR “Knee Prosthesis”)
ScienceDirect
TITLE-ABSTR-KEY(“periprosthetic” OR periprosth* OR “peri-prosthetic” OR peri-prosthet* OR “interface “ OR “interface 
“ OR “granulation “ OR “granulation “ OR “interface membrane” OR “interface membranes” OR “granulation membrane” 
OR “granulation membranes” OR “interface pseudomembrane” OR “interface pseudomembranes” OR “granulation 
pseudomembrane” OR “granulation pseudomembranes” OR “interface pseudo-membrane” OR “interface pseudo-
membranes” OR “granulation pseudo-membrane” OR “granulation pseudo-membranes” OR “periprosthetic pseudo 
synovial “ OR “interface pseudo synovial “ OR “granulation pseudo synovial “ OR “periprosthetic pseudo synovial “ 
OR “interface pseudo synovial “ OR “granulation pseudo synovial “) AND TITLE-ABSTR-KEY(“Culture” OR “cultured” OR 
“cultures” OR “cocultur*”) AND TITLE(“hip” OR “knee” OR TKR OR THR OR THA OR TKA)
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Numerous studies have investigated the cellular content and/or inflammatory mediators 
within peri-prosthetic tissue to explore the biological mechanisms underlying the aseptic 
loosening process. However, these studies generally have a small sample size and/or 
focus on specific cells or cell products within the tissue. Therefore, in this study, 47 peri-
prosthetic tissue samples were analysed using RT-PCR as well as (immuno)histochemistry 
with a broad panel of cell specific genes and antibodies. Principal component analysis (PCA) 
was applied to the gene expression data to reduce the correlated data of individual genes 
and identified 2 components clustering fibroblast and osteoblast related genes in another 
component than macrophage and endothelial cell related genes. Overall, a high inter-
tissue sample variability in factor loading scores of the components was observed, which 
could not be explained by patient- or prosthesis characteristics. (Immuno)histochemical 
staining of the tissue samples showed the predominant presence of both fibroblasts and 
macrophages with high inter- and intra-tissue sample variation in stained area and staining 
location. No significant associations were found between the stained area and patient- or 
prosthesis characteristics or  gene expression data. Besides macrophages in general, the 
presence of macrophage-subtypes were also studied. In one-third of the samples M1 and 
M2 macrophages were present in comparable amounts, whereas almost two-third showed 
the predominance of M2 macrophages. In conclusion, fibroblasts and osteoblasts seems 
to be at least as important as macrophages in the aseptic loosening process. In addition, in 
particular M2 macrophages seemed to be present in the peri-prosthetic tissue.
Keywords:  peri-prosthetic tissue, RT-PCR, (immuno)histochemisty, macrophage-subtypes, fibroblasts.
51
CHARACTERIZATION OF PERI-PROSTHETIC TISSUE
3
Introduction
Aseptic loosening is the main long-term adverse event associated with total joint 
arthroplasties.[1] Although several theories on the process of loosening have been 
proposed, the contribution of wear-debris particles has been implicated to be the most 
important factor.[2] Particulate wear debris can be phagocytized by several cell types, 
including macrophages, fibroblasts, lymphocytes and osteoclasts, triggering a continuous 
inflammatory-like response with the production of pro-inflammatory and osteoclastogenic 
cytokines.[3] These mediators create a microenvironment that favours osteoclastogenesis 
and subsequently bone resorption, which can ultimately lead to prosthesis loosening. 
Often during the loosening process a fibrous-like peri-prosthetic tissue layer with poor 
mechanical properties is formed. Although many reports have provided information about 
the cellular content and/or inflammatory mediators within this tissue [4-6], the precise 
biological mechanisms underlying the loosening process have still not been elucidated 
completely. Thorough analysis of the peri-prosthetic tissue is therefore still warranted to 
better understand the biological responses around aseptic loosened prostheses. 
 Analysis of peri-prosthetic tissue has predominantly been performed using (immuno)
histochemistry. Based on tissue appearance and cellular content, Morawietz et al. even 
proposed a standardized histopathological classification system for evaluation of peri-
prosthetic tissue, which discriminates four different tissue subtypes.[7] The classification 
system is particularly useful to discriminate between septic and aseptic loosening. 
Discrimination between septic and aseptic loosening has also been studied using gene 
expression analysis, where several differentially expressed genes were found.[8] Gene 
expression analysis has also proven useful in studying the pathogenesis of aseptic loosening 
specifically. Only a few of these studies addressed the cell content of the tissue by gene 
expression analysis. However, these studies generally focused either on the expression 
patterns of inflammatory and osteoclastogenic molecules (e.g. chemokine ligand 18 (CCL18), 
tumor necrosis factor alpha (TNFα), matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinase (TIMPs)) or on the expression of regulators of bone homeostasis 
(e.g. receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG), 
bone morphogenetic protein 4 (BMP4) and fibroblast growth factor 18 (FGF18)).[9-13] In 
addition, these studies generally have a small sample size and/or focus on specific cells or 
cell products within the tissue (e.g. macrophages, giant cells and fibroblast-like cells). 
 To obtain new or additional insights in the pathogenesis of aseptic loosening, we 
explored the cellular content of peri-prosthetic tissue in a relatively large sample size. We 
used qRT-PCR to identify cell-specific gene expression patterns in peri-prosthetic tissues 
next to the more commonly used technique of (immuno)histochemistry using a broad 





Peri-prosthetic tissue samples harvested from aseptically loosened femoral stems or 
acetabular components of 47 patients were obtained during revision surgery of total hip 
replacements. The peri-prosthetic tissue was collected as “waste” material and as such 
should not be traceable to specific patients. Therefore, due to Dutch Medical Ethics laws and 
legislation, only limited donor characteristics are available (see Table 1). Collected samples 
were kept in sterile NaCl 0.9% at 4°C, for a maximum of 24 hours, until they were processed 
in two ways. One portion was immediately submerged in RNAlater® (RNA stabilization 
Reagent; Qiagen Inc., Valencia, CA) to maintain RNA integrity and stored at -20°C. A second 
portion was fixed in 3.7% buffered formaldehyde and embedded in paraffin. Previous 
studies have noted morphological variability in cellularity and composition of samples 
taken from peri-prosthetic tissue.[5, 7] To account for this variability, both tissue portions 
consisted of material from several regions within each harvested sample. The study was 
approved by the Medical Ethics Committee of Leiden University Medical Center (C12-107). 
Quantitative RT-PCR
Tissue samples (~0.2-0.4 gr) were snap frozen in liquid nitrogen and homogenized on ice 
using a pounder. Total RNA was isolated from cells using RNA-Bee (Tel-Test Inc., Friendswood, 
TX, USA). cDNA was synthesized using M-MLV reverse transcriptase (Promega, Fitchburg, 
WI, USA) according to the manufacturer’s instructions. Quantitative RT-PCR was performed 
using the Quantitect SYBRgreen PCR kit (Qiagen, Venlo, The Netherlands) with an iQ5 PCR 
cycler (BioRad, Hercules, CA, USA). Cell specific primer sets, all spanning at least one intron, 
were developed for osteoblasts, fibroblasts, endothelial cells and macrophages (see Table 
2). Data were normalized relative to GAPDH expression. Levels of gene expression were 
expressed as fold-change relative to expression in cell type specific positive controls (e.g. 
SaOS-2 cells, HDFA cells, human endothelial cells and human monocytes respectively) using 
the 2-ΔΔCq method. RNA samples of 15 out of 47 donors were not suitable for analysis as result 
of low RNA quality or quantity or absence of  GAPDH expression (needed for normalization). 
Of the missing donors, RNA isolated from explant cultures (passage 0) was used. Again, not 
all samples had sufficient RNA quality or quantity or lacked GAPDH expression. In total, 
samples of 41 donors could be used in gene expression analyses. 
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Table 1: Demographic data from included peri-prosthetic tissue samples. 
Donor Sex Age Bearing Fixation Years in situ Cup/Stem
1 F 81 Metal-PE Cemented >5 Cup
2 M 74 Metal-PE Cementless >5 Cup
3 F 85 Metal-PE Cemented >5 Cup
4 M 74 CE-CE Cementless >5 Stem
5 M 74 CE-PE Cementless >5 Cup
6 F 80 Metal-PE Cemented >5 Stem
7 M 81 N/A Cemented >5 Stem
8* F 58 Metal-PE Cementless 2-5 Cup
9 F 82 Metal-PE Cemented >5 Cup
10 F 82 Metal-Metal Cemented >5 Cup
11 M 55 N/A N/A N/A N/A
12* M 75 Metal-PE Cementless >5 Stem
13 F 75 Metal-PE Cementless >5 Cup
14 F 80 Metal-PE Cementless >5 Cup
15* M 66 CE-PE Cementless >5 N/A
16* M 84 Metal-PE Cemented >5 Cup
17 M 59 Metal-PE Cemented >5 Stem
18 M 81 Metal-PE Cemented >5 Cup
19* M 81 Metal-PE Cemented >5 Stem
20* F 92 Metal-PE Cemented >5 Stem
21 F 79 Metal-PE Cemented >5 Stem
22 M 55 Metal-Metal Cementless >5 Cup
23* F 73 Metal-PE Cemented >5 Cup
24 F 80 Metal-PE Cemented >5 Cup
25 F 73 N/A Cementless >5 Stem
26* F 75 CE-PE Cementless >5 Cup
27* F 82 Metal-PE Cemented >5 Cup
28 M 79 Metal-PE Cemented >5 Stem+Cup
29 F 80 Metal-PE Cementless >5 Cup
30* F 86 CE-PE Cemented >5 Cup
31 M 32 Metal-PE Cemented 2-5 Cup
32 F 76 CE-PE Cementless >5 Cup
33* F 74 Metal-PE Cemented >5 Stem+Cup
34 M 69 Metal-PE Cemented >5 N/A
35 M 84 Metal-PE Cemented >5 Stem
36 F 71 Metal-PE Cementless >5 N/A
37 M 66 Metal-PE Cemented >5 Cup
38 F 80 Metal-PE Cemented 2-5 Stem
39 F 81 Metal-PE Cemented >5 Stem
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Table 1: Demographic data from included peri-prosthetic tissue samples. (Continued)
Donor Sex Age Bearing Fixation Years in situ Cup/Stem
40 F 95 Metal-PE Cemented >5 Cup
41* M 71 CE-PE Cementless >5 N/A
42* F 81 CE-PE Cemented >5 Cup
43* M 64 CE-PE Cementless >5 Stem+Cup
44* F 76 Metal-PE Cementless >5 Cup
45* F 63 Metal-PE Cementless >5 Cup
46 F 48 Metal-PE Cemented >5 Cup
F = Female, M = Male, PE = Polyethylene, CE = Ceramics, N/A = not available, *Could not be used in PCA analysis





Alkaline Phosphatase (ALP) 5’-TAAAGCAGGTCTTGGGGTGC-‘3 5’-GGGTCTTTCTCTTTCTCTGGCA-‘3
Osteocalcin (OCN) 5’-CCCAGCGGTGCAGAGTC-‘3 5’-TCAGCCAACTCGTCACAGTC-‘3
S100 calcium-binding protein A4 
(S100A4)
5’-TTGGTTTGGTGCTTCTGAGATGT-‘3 5’- TCACCCTCTTTGCCCGAGTA-‘3
Vimentin (VIM) 5’- CCAAACTTTTCCTCCCTGAACC-‘3 5’- CGTGATGCTGAGAAGTTTCGTTGA-‘3
Endoglin (ENG = CD105) 5’- TCACCACAGCGGAAAAAGGT-‘3 5’- CAGGAACTCGGAGACGGATG-‘3
Platelet endothelial cell adhesion 
molecule (PECAM-1 = CD31)
5’- AGACGTGCAGTACACGGAAG-‘3 5’- CTTTCCACGGCATCAGGGA-‘3
Cluster of Differentiation 68 
(CD68)
5’- AGGCTGGCTGTGCTTTTCTC-‘3 5’- TCTCTGTAACCGTGGGTGTC-‘3
Histology and (immuno)histochemistry
Serial tissue sections of 6 µm thickness were cut using a microtome (RM2235, Leica, 
Germany). Composition and cellularity were assessed using a haematoxylin and eosin (HE) 
stain. To determine the presence of a variety of different cell types, immunohistochemical 
staining was carried out using antibodies directed against CD68 (prediluted; Abcam, 
Cambridge, United Kingdom), a pan macrophage marker; CD86 (1:200; GeneTex, Irvine, 
CA, USA), a marker for M1 macrophages[14]; CD206 (1:500; Abcam), a marker for M2 
macrophages[15]; CD31 (1:500; Dako, Hamburg, Germany), a marker for endothelial 
cells; vimentin (1:200; Dako), a marker for fibroblasts and SATB2 (1:300; Atlas Antibodies, 
Stockholm, Sweden), a marker for osteoblasts.[16] Furthermore, Alizarin Red S (20mg/mL; 
Sigma-Aldrich, St Louis, MO, USA) was used to stain calcium deposits (mineralization) in the 
tissue, as indirect marker for the presence of osteoblasts. Details on staining procedures can 
be found in supplementary S1. 
 In total, tissue sections of 46 out of 47 donors could be used, as the sections of one donor 
were lost during almost every staining. Tissue sections were analysed with an Olympus BX43 
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light microscope (Olympus, Tokyo, Japan). Samples, stained for CD31, CD68 and vimentin, 
were ranked independently by two blinded observers based on their relative amount of 
positive stained area in three sections per sample, according to slight modifications on a 
previous protocol.[17] Briefly, ranking was done for each marker separately and samples 
were given a number between 1 (highest ranking) and 46 (lowest ranking) based on the 
visually estimated total stained area, and the total number of samples, namely 46. This 
resulted in two ranks from each observer per staining, which showed a >80% similarity in 
ranking scores. After consensus on the discrepancies with a third observer, one single rank 
was used for further analysis. Actual ranking of vimentin was hard due to relatively small 
differences in amount of stained area. However, the tissue samples could be subdivided 
into 3 groups representing either relatively little, intermediate or intensive amount of 
stained area. 
 For investigation of the proportion of macrophage subtypes within the tissue, we 
analysed the presence of CD68, CD86 and CD206 positive cells in the same tissue regions 
within each sample. In total tissue sections of 37 out of 46 were analysed, as tissue regions 
of these samples had CD68+ staining. 
Statistical analysis
Statistical analysis was performed using SPSS (IBM SPSS Statistics 21). For analysis of the gene 
expression data, principal component analysis (PCA) was done to reduce the multivariate 
gene expression data down to create summary variables (called principal components).[18] 
The goal of this method is to reduce the total number of variables analysed by explaining 
most of the variation in the data by one or a few new variables. Relative gene expression 
data of alkaline phosphatase, osteocalcin, vimentin, S100A4, endoglin, PECAM-1 and CD68 
were entered in the PCA. Percentage of variance explained by the components and Eigen 
values > 1 were used to determine the number of principal components. For each variable 
in the extracted component(s), a factor loading was calculated which can be interpreted 
as correlation measure between the observed variable and the underlying unobservable 
component. For analysis, only factor loading scores of > 0.4 qualified for loading of a variable 
on a component.[19] Factor loading scores of each donor were then plotted in a graph and 
classified as ‘high’ when factor loading scores were above the 75th percentile, ‘intermediate’ 
when they were between the 75th and 25th percentile, and as ‘low’ when they were below 
the 25th percentile. Linear regression analysis was used to study the relation between the 
factor loading scores and patient or prosthesis characteristics. 
 To compare between the histological ranking scores, patient- and prosthesis 
characteristics and the gene expression data, the Kruskal Wallis test, χ2, one-way ANOVA 





All tissue samples available for PCR analysis (n=41) showed expression of GAPDH, vimentin, 
endoglin and CD68, whereas expression of alkaline phosphatase (n=36), osteocalcin (n=34), 
S100A4 (n=38) and PECAM-1 (n=39) was observed in nearly all of the tissue samples. 
Generally, we observed a high inter-donor variability in all gene expression levels, as shown 
in Figure 1. Additionally, high correlations between the relative mRNA expression levels of 
all genes were found (Supplementary Table 1). 
 Principal component analysis (PCA) was used to reduce the correlated gene expression 
data. As PCA requires the use of samples with complete relative expression data sets, 
only data from 30 tissue samples could be used. As shown in Table 3, two components 
were extracted. The first component is determined by a combination of vimentin, alkaline 
phosphatase, osteocalcin, S100A4 and endoglin, and explains 49.4% of the total variation. 
The second component, explaining 18.9% of the total variation, is determined by a 
combination of endoglin, PECAM-1 and CD68. 
 Next, we identified donors who either scored ‘high’ (factor loading scores above the 75th 
percentile) or ‘low’ (factor loading scores below the 25th percentile) in the PCA components 
by plotting the factor loading scores of both components (supplementary Figure 1). Two 
donors (7 and 11) scored ‘high’ in both components and two donors (2 and 28) scored ‘low’ 
in both components. One donor (6) scored ‘high’ in the first component and ‘low’ in the 
second component, whereas four donors (14, 21, 29, 36) scored ‘low’ in the first component 
and ‘high’ in the second component. Overall, most donors (n= 21) scored intermediate for 
both components.
 Subsequently, we investigated the relationship between the extracted components 
and (several) patient- and prosthesis characteristics. No significant associations were found 
between gender and age of the donors and the extracted PCA components (Component 
1,   gender: β=0.021, p=0.681 and age: β=0.003, p=0.812 ; Component 2, gender: β=-0.196, 
p=0.613 and age: β=-0.010, p=0.524). The tissue samples scoring ‘low’ in the first component 
where observed to be primarily of donors who received an cementless prosthesis (5 out 
of 7), whereas samples of patients who received a cemented prosthesis generally scored 
relatively high in the first component (5 out of 7). Nevertheless, no significant association 
was found between type of fixation and the PCA components (Component 1: β=0.320, 
p=0.259; Component 2: β=-0.060, p=0.873). Unfortunately, we were not able to perform 
correlation analysis for type of bearing and the PCA components, since most of the donors 
(22 out of 30) received a prosthesis with polyethylene-metal bearing.  
 The presence of fibroblasts (vimentin+), endothelial cells (CD31+) and macrophages 
(CD68+) was shown in almost all samples. The presence of osteoblasts could not be 
shown using Special AT-rich sequence-binding protein 2 (SATB2), a recently discovered 
osteoblast marker which plays a critical role in osteoblast lineage commitment,[16] as this 
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staining did not work in our hands. However, in a few tissue samples calcium deposits 
(Alizarin Red S+ stained areas) were observed. In general, a high inter- and intra-sample 
variability in terms of amount of stained area and localization was seen for all stainings. 
Next, we examined the tissue samples by ordering them based on the factor loading 
scores of either Component 1 or Component 2. Figure 2 shows representative figures of 
the (immuno)histochemical stainings based on classification (high, intermediate and low) 
of the tissue samples according to the PCA analysis. However, no conclusions could be 
drawn analysing the tissue samples this way. Therefore, we ranked (CD31 and CD68) or 
subdivided (vimentin) the tissue samples based on the visually estimated total stained area. 























Figure 1: Relative gene expression levels (in Log 10 -scale) of cell related genes. Boxplots showing 
the relative expression of alkaline phosphatase (ALP; n=36), osteocalcin (OCN; n=34), S100A4(n=38), 
Vimentin (n=41), Endoglin (n=41), PECAM-1(n=39) and CD68 (n=41). Values represent mean ± SD, 
dots represents 1.5*IQR. IQR: Inter Quartile Range.











Variance explained (%) 49.4 18.9
Components with ‘Eigen values’ >1 are extracted after Varimax rotation with Kaiser Normalization, significant 









Figure 2: Representative images of (immuno)histochemical stainings based on factor loading scores 
according to the PCA analysis. Vimentin and CD31 positive cells are shown in red/brown. Cells positive 
for CD68 are red.
(A) Representative pictures of tissue samples which scored highest (top row, sample 11), intermediate 
(middle row, sample 40) and lowest (bottom row, sample 22) in Component 1 according to the PCA 
analysis. 
(B)  Representative pictures of tissue samples which scored highest (top row, sample 35), intermediate 
(middle row, sample 33) and lowest (bottom row, sample 6) in Component 2 according to the PCA 
analysis.
Bars represent 100µm. Arrows point to positively stained cells. 
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CD86 CD206  
Figure 3: Immunohistochemical stainings of macrophage polarization. CD68, CD86 and CD206 
positive cells are shown in red. 
(A) Representative tissue sample (sample 10) with more M1 (CD86+) staining than M2 (CD206+) 
staining. (B) Representative tissue sample (sample 26) with more M2 staining than M1 staining. (C) 
Representative tissue sample (sample 41) with equal amount of M1 and M2 staining.
Bars represent 100µm. Arrows point to positively stained cells.
This allowed us to investigate the relation between the tissue sample stainings and 
patient- and prosthesis characteristics and the relation between gene expression data and 
histology data. CD31 and CD68 ranking was not significantly different between male and 
female nor between different types of fixation and  did not correlate with age. Likewise, no 
significant associations were found between the subdivided vimentin staining and patient 
characteristics (gender or age) or type of fixation. Furthermore, no associations were found 
between the tissue sample stainings and the corresponding gene expression data or the 
factor loading scores of Component 1 and 2. 
 Next to the general macrophage marker CD68, we also stained the peri-prosthetic 
samples against CD86 and CD206, which are indicative for M1 and M2 macrophages, 
respectively. Both subsets were present within the tissue, however, large variation with 
respect to amount of stained area was observed. Representative figures are shown in Figure 
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3. In 37 tissue samples the relative proportion of CD86 and CD206 positive stained area/cells 
was determined. In 11 samples, no visual difference was observed between the amount 
of stained area of CD86 and CD206. Five samples showed more CD86 than CD206 stained 
area, whereas 21 samples showed more CD206 than CD86 stained area. No significant 
associations were found between the three groups (equal amount of CD86 and CD206 
stained area, > CD86+ stained area or > CD206+ stained area) and gender and age. With 
respect to type of fixation, tissues from cemented prostheses were observed to be more 
likely to have more CD206+ stained area than tissues from cementless prostheses. 
Discussion
In the current study, we explored the cellular content of peri-prosthetic tissue, obtained 
from aseptically loosened (hip)prostheses, using RT-PCR and (immuno)histochemistry. Since 
many cells are involved in the process of aseptic loosening, we studied a diverse panel of 
cell-specific markers. For RT-PCR, we assumed that a high RNA expression level of a certain 
gene was explained by the abundant presence of  the cell type that usually expresses this 
gene. The variable presence of the studied genes between the tissue samples as well as the 
variation in levels of expression indicates a high variability in cellular composition between 
tissue samples. These results corroborate previous studies on the cellular content of peri-
prosthetic tissues.[5, 7] We therefore took a further step in investigating the gene expression 
patterns between samples, using principal component analysis. This method revealed two 
components, clustering osteoblast- and fibroblast-related genes in the first component and 
macrophage- and endothelial cell-related genes in the second component. The clustering 
of osteoblast-related genes together with fibroblast-related genes in one component is 
not surprising since these cells are both from mesenchymal origin. In addition, fibroblasts 
have been reported to be able to express genes that are also expressed by osteoblasts.[20] 
Likewise, clustering of endothelial cell-related genes together with macrophage-related 
genes in the other component might be explained by the fact that inflammation is often 
accompanied by hypervascularization.[21, 22] The clustering of fibroblast and macrophage 
related genes in different components in our study population proposes the presence 
of two types of peri-prosthetic tissue: a fibrotic-like tissue predominantly containing 
fibroblasts and an inflammatory-like tissue containing macrophages as the major cellular 
component. Morawietz et al. already described the presence of distinct cell types in peri-
prosthetic tissues resulting in different histological classifications which represent different 
mechanisms of prosthesis loosening.[7] Considering the fact that the first component 
explained almost 50% of the observed variation in gene expression in our study population, 
this might indicate that in end-stage loosening the presence of fibroblasts outweighs the 
presence of macrophages, emphasizing the important role of fibroblasts within the peri-
prosthetic tissue and within the loosening process.
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 The observed variation in factor loading scores of the components between tissues 
showed differences in the proportion of cell populations within each tissue. Despite 
the identification of several samples with ‘high’ or ‘low’ factor loading scores of either 
component, the majority of the tissue samples had an ‘intermediate’ phenotype. Several 
studies have already shown that differences in the profiles of cell populations (and 
histological appearance) were dependent on prosthesis characteristics (e.g. fixation, type 
of bearing or prosthesis lifetime).[5-7, 23] In our study, patient- or prosthesis characteristics 
(i.e. age, gender, type of fixation) could not explain the observed variation in factor loading 
scores (representing different cellular profiles). Nevertheless, a ‘high’ factor loading score 
in Component 1 was more often observed in tissue samples from cemented implants, 
whereas a ‘low’ factor loading score of Component 1 was more often observed in tissues 
from cementless implants. This result is not in line with previous studies in which regions 
of fibroblastic connective tissue were often observed surrounding cementless implants, 
whereas in tissues obtained from cemented implants less fibroblasts and more macrophages 
were present.[5, 7, 23] Discrepancies between our study and previous studies can be caused 
by differences in methodologies, as well as sample size. Unfortunately, despite our relatively 
large number of samples, the sample size was still too small to perform proper association 
analyses between different clinical groups. Therefore, in future studies, larger sample sizes of 
peri-prosthetic tissue with more detailed patient- and implant- characteristics are essential 
to improve interpretation of results.
 Immunohistochemical staining of the tissue samples showed the predominant 
presence of fibroblasts and macrophages, as already known from literature. However, also 
endothelial cells where observed in several tissue samples, which indicate the importance 
of vascularization in the process of loosening.[24] Unfortunately, we were unable to identify 
osteoblasts in the tissue using immunohistology. However, we have observed calcium 
deposits in the extracellular matrix of a few tissue samples using Alizarin Red S, which might 
indicate the presence of osteoblasts. Combined with our interesting findings at the gene 
expression level, this definitely warrants further study of the osteoblast at the protein level.
 For each staining, a high inter- and intra-tissue sample variation regarding the amount 
of stained area as well as location of the staining was observed. As already discussed above 
with the gene expression data, these variations might be the result of differences in patient- 
and implant characteristics. However, no significant associations were found between the 
ranking scores of CD31, CD68 or the three vimentin groups and gender, age or prosthesis 
fixation. 
 The observed importance of CD68+ macrophages in the PCA analysis, along with 
the recent interest in macrophage polarization as potential therapeutic strategy for 
treatment of aseptic loosening, led us to study the subtypes of macrophages within the 
peri-prosthetic tissue. In our sample population, almost one-third of the samples showed 
no visual differences in amount of CD86+ and CD206+ stained area which indicates no 
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differences in M1 and M2 macrophage presence. However, almost two-third was observed 
to mainly contain CD206+ areas, indicating a predominance of M2 macrophages within 
the tissue. Our immunohistochemistry results corroborate the results of a gene expression 
study by Koulouvaris et al[10] in which they concluded that in the end-stage of osteolysis, 
M2 macrophage activation predominates. However, other studies either showed a 
predominance of M1 macrophages within the peri-prosthetic tissue[25] or could not 
come to a conclusion regarding differences in presence of macrophage phenotypes.[26] 
Discrepancies between studies can be caused by differences in methodologies, patient- 
and prosthesis characteristics as well as sample size. Although more CD206 staining was 
observed in tissues obtained from cemented compared to cementless prostheses, no 
significant associations between macrophage subtype and study characteristics were 
observed. Therefore, the data concerning the macrophage phenotype in peri-implant 
tissues remain controversial and warrants further study.
 In this study, we have analysed a diverse panel of cell specific markers, including markers 
for macrophage polarization, in peri-prosthetic tissue of loosened total hip implants. For 
this purpose we combined both gene expression analysis and immunohistochemistry, 
to strengthen this study. The heterogeneity in patient- and prosthesis characteristics in 
this study makes our study sample representative of the general population, however, it 
also hampers data analysis. Therefore, despite our relatively large sample size, associations 
were often not significant, probably due to a lack of statistical power. In addition, the lack 
of information on the exact in situ location and orientation of the tissue samples further 
complicated interpretation of the results, especially the histology results. Therefore, future 
studies should aim to provide a more in-depth description of prosthesis-, patient-, and 
tissue-related characteristics in order to address the mechanism of aseptic loosening more 
effectively. 
 In conclusion, in-depth investigation of the peri-prosthetic tissue using RT-PCR and 
(immuno)histochemistry showed fibroblasts and osteoblasts to be at least as important in 
the aseptic loosening process as macrophages. With respect to macrophages, in particular 
M2 macrophages seem to be involved in the end-stage loosening process. As high inter- 
and intra-variability was seen at all levels studied, further study is warranted for even more 
detailed delineation of the mechanisms in aseptic prosthesis loosening.
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Factor score Component 2








Supplementary figure 1: Peri-prosthetic tissue sample plot of factor loading scores PCA analysis. 
Scatter plot of the factor scores extracted from the PCA analysis. Each dot represents one tissue 
sample. Lines represents 25th and 75th percentile of the component scores. 
Supplementary table 1: Spearman correlations among gene expression data of peri-prosthetic 
tissue samples.  
P-Value
ALP OCN S100A4 Vimentin Endoglin Pecam-1 CD68
ALP 4.42x10-4* 0.130 0.052 0.017* 0.044* 0.128
OCN 0.585 0.254 0.199 0.009* 0.025* 0.165
S100A4 0.261 0.204 0.001* 0.006* 0.054 0.446
Vimentin 0.326 0.226 0.534 2.11x10-4* 0.002* 7.81x10-5*
Endoglin 0.395 0.440 0.438 0.548 3.20x10-6* 0.002*
Pecam-1 0.343 0.390 0.320 0.487 0.669 1.29x10-8*
CD68 0.259 0.243 0.127 0.577 0.467 0.766
Spearman correlation




(Immuno)histochemical stainings of peri-prosthetic tissue 
 
CD68, CD86 and CD206
After deparaffinization, antigen retrieval (CD68, CD206: citrate buffer pH6 ; CD86: citrate 
buffer pH9) was done followed by pre-incubation with 10% goat serum. Samples were then 
incubated (1hr) with  monoclonal antibodies against CD68 (Abcam), CD86 (Genetex) and 
CD206 (Abcam), followed by incubation with link (30min) and label (30min) from the link-
label kit (CD68: goat-anti mouse; CD86,CD206: goat-anti rabbit) (BioGenex, San Ramon, CA, 
USA). Freshly prepared neo-fuchsin was used as substrate. 
CD31 and SATB2





) followed by antigen retrieval (CD31: Proteinase-K 5µg/ml ; 
SATB2: citrate buffer pH6) and pre-incubation with 2,5% goat serum (CD31 only). Samples 
were then incubated (o/n) with monoclonal antibodies against CD31 and SATB2, followed 
by incubation with IMPRESS™ (CD31) (VECTOR) or EnVision™ (SATB2) (DAKO). Nova Red was 
used as a substrate. A cell was considered positive when stained red. 
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Both bone morphogenetic protein (BMP) and Wnt signalling have significant roles in 
osteoblast differentiation and the interaction between BMP and Wnt signalling is well 
known. Sclerostin is an important inhibitor of bone formation, inhibiting Wnt signalling and 
downstream effects of BMP such as alkaline phosphatase activity and matrix mineralization 
in vitro. However, little is known about the effect of BMP and Wnt signalling interaction on 
the regulation of SOST, the gene encoding sclerostin. Possibly, uncoupling of osteoblast 
differentiation regulators and SOST expression could increase osteoblast differentiation. 
Therefore, we investigated the effect of BMP and Wnt signalling interaction on the expression 
of SOST and the subsequent effect on osteoblast differentiation. Human osteosarcoma cells 
(SaOS-2) and murine pre-osteoblast cells (KS483) were treated with different concentrations 
of Wnt3a, a specific GSK3β inhibitor (GIN) and BMP4. Both Wnt3a and GIN increased BMP4-
induced BMP signalling and BMP4 increased Wnt3a and GIN-induced Wnt signalling. 
However, the effect of GIN was much stronger. Quantitative RT-PCR analysis showed that 
SOST expression dose-dependently decreased with increasing Wnt signalling, while BMP4 
induced SOST expression. GIN significantly decreased the BMP4-induced SOST expression. 
This resulted in an increased osteoblast differentiation as measured by ALP activity in the 
medium and matrix mineralization. We conclude that GSK3β inhibition by GIN caused an 
uncoupling of BMP signalling and SOST expression, resulting in an increased BMP4-induced 
osteoblast differentiation. This effect can possibly be used in clinical practice to induce local 
bone formation, e.g. fracture healing or osseointegration of implants.
Keywords: osteoblast differentiation, SOST, sclerostin, BMP, GSK3β inhibition.
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Introduction
Bone formation is a complex process that involves the differentiation of mesenchymal cells 
into pre-osteoblasts and osteoblasts that eventually leads to the synthesis and deposition 
of bone matrix proteins.[1] Bone is continuously remodelled by bone-forming osteoblasts 
and bone-resorbing osteoclasts.[2, 3] An imbalance in the remodelling process can 
result in bone diseases as sclerosteosis or osteoporosis. Osteoporosis is one of the most 
prevalent diseases in elderly [4] and is likely to become more prevalent with the further 
aging of the population. The expected higher prevalence of osteoporotic fractures and joint 
replacements due to the increase of the elderly population calls for the identification of 
regulatory molecules in differentiation of osteoblasts that can potentially serve as targets 
for treatment of osteoporosis. In addition, these molecules could possibly improve either 
fracture healing or osseointegration of implants.
 Bone morphogenetic proteins (BMPs) and Wnts are well-known regulators of 
bone formation and have important roles in promoting osteoblast differentiation and 
mineralization. BMPs were identified as the factors responsible for induction of ectopic bone 
formation [5] and the role of BMPs in inducing osteoblast differentiation has been described 
for several BMPs.[6, 7] BMPs activate the type I and type II BMP receptor complexes, leading 
to initiation of signalling via phosphorylation of intracellular Smad proteins.[8] Activated 
Smads regulate expression of transcriptional factors and transcriptional co-activators 
important in osteoblast differentiation like Runx2 and Osterix.[7] Wnts are a family of secreted 
proteins that regulate many developmental processes, for example body axis formation, 
chondrogenesis and limb development.[9, 10] Canonical Wnt/β-catenin signalling has 
been shown to promote osteogenesis by stimulation of Runx2 gene expression.[11] In 
addition, activation of Wnt/β-catenin signalling promotes osteoblast cell proliferation 
and mineralization activity, reduces osteoblast apoptosis, and can suppress osteoclast 
differentiation induced by osteoblasts.[12] In the absence of Wnt activation, β-catenin 
is phosphorylated by glycogen synthase kinase 3β (GSK3β) in a complex with axin and 
adenomatous polyposis coli (APC), resulting in subsequent degradation. When Wnts bind 
to the Frizzled receptor and LRP5/6 co-receptor, axin is recruited to the membrane and the 
destruction complex is disrupted. Consequently, the phosphorylating action of GSK3β is 
prohibited and β-catenin accumulates in the cytoplasm, translocate into the nucleus and 
activates the transcription of Wnt target genes by binding to the TCF/LEF transcription 
complex.[13] 
 Hence, both Wnt and BMP signalling have important roles in promoting osteoblast 
differentiation and mineralization, and there are many reports showing an interaction 
between Wnt and BMP signalling.[14-18] Wnt signalling has been shown to increase BMP2 
and BMP4 expression [19, 20] and on the other hand, Wnt1 and Wnt3a expression was 
increased by BMP2 [21], suggesting that both BMP and Wnt signalling may synergistically 
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regulate each other. The activity of BMP and Wnt is also controlled by their intrinsic 
antagonists, which include noggin and sclerostin.[22, 23] Apart from natural produced 
inhibitors, many synthetic inhibitors have been developed to inhibit different aspects of the 
Wnt signalling pathway. One of these synthetic molecules is XAV939, a tankyrase inhibitor. 
Tankyrase marks axin for degradation, leading to disruption of the axin/APC/GSK3β complex. 
Thus, inhibition of tankyrase leads to accumulation of axin, breakdown of β-catenin and 
inhibition of the Wnt pathway.[24] PNU74654 binds to β-catenin, preventing it from binding 
to the TCF/LEF transcription complex and subsequently inhibits Wnt signalling.[25] 
 Sclerostin, produced by osteocytes, is an important regulator of bone formation and 
one of several known Wnt signalling inhibitors. Sclerostin inhibits canonical Wnt signalling 
in a similar manner as dickkopf-1 (Dkk-1) by binding to the LRP5/6 co-receptor.[26-28] 
Mutations in the gene encoding sclerostin, SOST, or the surrounding regulatory regions 
lead to sclerostin deficiency and bone overgrowth in sclerosteosis and van Buchem 
disease respectively.[29-32] In mice overexpressing SOST there is a significant reduction 
in osteoblast activity and subsequently bone formation.[30, 33] In vitro sclerostin inhibits 
the differentiation of pre-osteoblast cells.[28] Loss of sclerostin might prolong the 
bone formation phase of osteoblasts, resulting in the increase of bone mass. Sclerostin 
physiologically acts as a downstream molecule of BMP signalling to inhibit canonical Wnt 
signalling and negatively regulates bone mass.[23, 34]
 The fact that sclerostin, a major regulator of bone formation through Wnt and BMP 
signalling, is limited to skeletal tissue and absence of sclerostin leads to an increase in bone 
formation, makes it an ideal drug target for bone formation. Recently it had been shown 
that treatment with romosozumab, a monoclonal antibody which binds to sclerostin, 
increases bone formation in patients suffering from osteoporosis.[35] BMPs are the most 
potent inducers of SOST expression and strong regulators of osteoblast differentiation.
[36] Uncoupling of osteoblast differentiation regulators and their intrinsic inhibitors could 
possibly increase or prolong the BMP response, leading to more osteoblast differentiation 
and subsequent bone formation. Therefore the goal of this study was to investigate 
the effect of BMP and Wnt signalling on SOST expression and osteoblast differentiation. 
Materials and methods
Cells, materials and reagents
The human osteosarcoma cell line SaOS-2 (ATCC, Manassas, VA, USA) was cultured in 
DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% Fetal Calf Serum (FCS; Greiner 
Bio One, Kremsmünster, Austria), 100U/ml penicillin and 100µg/ml streptomycin (Gibco). 
Murine mesenchymal progenitor cells KS483 were cultured in α-MEM without phenol 
red (Gibco) supplemented with FCS, penicillin and streptomycin and glutamax (Gibco). 
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Recombinant BMP4, Wnt3a and DKK1 were purchased from R&D Systems (Minneapolis, MN, 
USA). The specific GSK3β inhibitor 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4]
diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-dione (further referred to as GIN) was kindly 
provided by Dr. Rawadi (Prostrakan, France) and previously described by Engler et al. (2004) 
and Miclea et al. (2001).[15, 37] The Wnt signalling inhibitors XAV939 and PNU74654 were 
purchased at Sigma (St. Louis, MO, USA). The Wnt-responsive luciferase reporter BAT-luc 
has been described previously [15, 38] as is also the case for the BMP responsive element 
luciferase reporter BRE-luc.[39] 
 
Luciferase experiments
SaOS-2 cells were seeded in 96-well plates at a density of 21,000 cells/cm2 and cultured 
overnight to 70-80% confluence. The cells were transfected with BAT-luc or BRE-luc reporter 
construct and a pGL4-CAG renilla luciferase construct using FuGene HD transfection reagent 
(Promega Fitchburg WI USA) according to the manufacturer’s instructions. After 24 hours of 
treatment with the indicated reagents, luciferase activity was determined using the Dual-
Glo Luciferase assay system (Promega, Fitchburg, WI, USA) with a SpectraMax L luminometer 
(Molecular Devices, Sunnyvale, CA, USA). Relative luminescence was calculated as luciferase/
renilla luciferase and expressed as fold change versus control.
Differentiation experiments 
KS483 cells were seeded at a density of 9,210 cells/cm2. Every 3 to 4 days, the medium was 
changed. At confluence (from day 4 of culture onwards), ascorbic acid (50 μg/ml. Merck 
Inc., NY, USA) was added to the culture medium. When nodules appeared (from day 11 
of culture onwards) β-glycerophosphate (5 mM; Sigma) was added. Every 3 to 4 days, 
medium samples (25ul) were analysed for alkaline phosphatase (ALP) activity by adding 





 buffer (pH 10.5) and reading for 10 min using a VERSAmax Tunable Microplate 
Reader (Molecular Devices) at 405 nm. ALP activity was determined as the slope of the 
kinetic measurement (mOD/min). Mineralization of the cultures was quantified using the 
fluorescent dye Bonetag as described previously.[40] Briefly, cells were incubated with 2 
nM Bonetag 800 (Perkin Elmer) for 24 hours, washed with phosphate-buffered saline (PBS) 
and fixed with 3.7% buffered formaldehyde. The fixed cells were scanned with the Odyssey 
Infrared Imaging System (Li-COR) at a resolution of 42 µm, medium quality and intensity 5.0-
6.5. Integrated intensity (counts/mm2) of each well was calculated by the Odyssey software.
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Quantitative RT-PCR and primers
Total RNA was isolated from SaOS-2 and KS483 cells using TriPure Isolation Reagent (Roche, 
Penzberg, Germany) 24 hours (SaOS-2 cells) or 8-10days (KS483 cells) after treatment with 
indicated reagents, respectively. cDNA was synthesized using M-MLV reverse transcriptase 
(Promega) according to the manufacturer’s instructions. Quantitative RT-PCR was performed 
using the Quantitect SYBRgreen PCR kit (Qiagen, Venlo, the Netherlands) with an iQ5 PCR 
cycler (BioRad, Hercules, CA, USA). For used primer sets (Eurogentec, Seraing, Belgium) 
see Table 1. β2-Microglobulin (β2M) was used as an internal control. Measurements were 
performed in triplicate and analysed using the ΔΔCt method.[41]
Table 1: Oligonucleotides used in RT-PCR
Gene   Forward Reverse
β2M Human 5’-TGCTGTCTCCATGTTTGATGTATCT-3’ 5’-TCTCTGCTCCCCACCTCTAAGT-3’
 Murine 5’-TGACCGGCTTGTATGCTATC-3’ 5’-CAGTGTGAGCCAGGATATAG-3’
SOST Human 5’-TGCTGGTACACACAGCCTTC-3’ 5’-GTCACGTAGCGGGTGAAGTG-3
  Murine 5’-TCCTCCTGAGAACAACCAGAC-3 5’-TGTCAGGAAGCGGGTGTAGTG-3’
Statistical analysis
Values represent mean ± SD. Differences were tested by one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test using Graphpad Prism 5 software (La Jolla, 
CA, USA). Results were considered significant at p < 0.05.
Results
To address the interaction between Wnt and BMP signalling, different combinations of 
BMP4, Wnt3a or the GSK3β inhibitor (GIN) were added to SaOS-2 cells. Unfortunately we 
were unable to efficiently transfect KS483cells; therefore all transfection experiments were 
performed in SaOS-2 cells. The effect on BMP signalling was investigated using a BMP-
responsive element driving luciferase expression, further referred to as BRE-luc. BMP4 alone 
dose-dependently increased the BRE-luc activity in SaOS-2 cells (Figure 1A). Although 
Wnt3a alone did not induce BRE-luc activity, it significantly increased BMP4-induced 
luciferase activity (Figure 1B). The BMP4-induced luciferase activity increased more than 
5-fold in combination with 10-8M GIN, even though GIN alone did not have any effect on 
the reporter (Figure 1C). 
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A B
C
Figure 1: BMP reporter BRE-luc activity after stimulation with BMP4, Wnt3a and GIN. SaOS-2 cells 
were transfected with the BMP reporter construct BRE-luc and were stimulated with the indicated 
concentrations for 24 hours. Luciferase (n = 6) was measured, values represent mean ± SD. BRE-luc 
activity increased dose-dependently with BMP4 (A). Combined Wnt3a and BMP4 increased BRE-luc 
activation (B). GIN was more potent in increasing BMP4 induced BRE-luc activation (C). *** p < 0.001 
compared to control. ### p<0.001 compared to BMP4.
 
 The influence of the interaction between Wnt and BMP on Wnt signalling was 
investigated using the Wnt-responsive BAT-luc reporter. We observed a dose-dependent 
increase of BAT-luc activity after Wnt3a or GIN stimulation (Figure 2A,C). However, GIN 
was more potent in inducing BAT-luc activation, stimulating activity more than 400-fold 
compared to control at 10-8M (Figure 2C). The GIN-induced BAT-luc activity increased more 
than 4-fold when combined with BMP4, even though BMP4 alone was not able to induce 
BAT-luc activity (Figure 2D). The Wnt-induced Bat-luc activity was not significantly increased 






Figure 2: Wnt reporter BAT-luc activity after stimulation with Wnt3a, GIN and BMP4. SaOS-2 cells 
were transfected with the Wnt reporter construct BAT-luc and were stimulated with the indicated 
concentrations for 24 hours. Luciferase (n = 6) was measured, values represent mean ± SD. BAT-luc 
activity increased dose-dependently with Wnt3a (A) and GIN (C). Combined Wnt3a and BMP4 did not 
increase Wnt3a-induced BAT-luc activity (B), while combined GIN and BMP4 increased BAT-luc activity 
significantly (D). *** p < 0.001 compared to control. ### p<0.001 compared to GIN 10-8M. 
 To address the interaction between Wnt and BMP signalling on SOST expression we used 
SaOS-2 cells, since these cells can express constitutively levels of mRNA SOST and therefore 
are a good model for studying the effect of GIN and BMP4 on SOST expression [42]. GIN 
dose-dependently decreased SOST expression levels. Even at a concentration of 3 x 10-9M 
GIN, which showed no effect on BAT-luc activity, SOST expression was decreased (Figure 3A). 
Wnt3a was able to significantly decrease SOST expression only at a high concentration (100 
ng/ml) (Figure 3B). Although BMP4 induced SOST expression (Figure 3C), a combination of 
BMP4 and GIN significantly decreased SOST expression (Figure 3C). When Wnt3a was added to 
BMP4-stimulated cells only a slight decrease in expression of SOST was observed (Figure 3C). 
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BA
C
Figure 3: SOST mRNA expression (n=3) after stimulation with Wnt3a, GIN and BMP4. Values represent 
mean ± 95% CI. SOST expression decreased dose-dependently with GIN (A) and Wnt3a (B). Wnt3a 
did not decrease BMP4-induced SOST expression, while GIN even decreased BMP4-induced SOST 
expression below control levels (C). *p < 0.05 compared to control. ** p < 0.01 compared to control. 
*** p < 0.001 compared to control. ### p < 0.001 compared to BMP4.
 Next, we investigated whether the down regulation of SOST expression observed after 
stimulation with GIN was a direct effect of Wnt/β-catenin signalling. To this purpose, three 
inhibitors of the Wnt signalling pathway were tested for their ability to counteract the effect 
of GIN on SOST expression. The extracellular inhibitor DKK1 could not inhibit Wnt signalling 
after stimulation with GIN (Figure 4A), whereas XAV939 and PNU74654 significantly inhibited 
the BAT-luc reporter activity (Figure 4A). However, neither of these inhibitors was able to 





Figure 4: Wnt reporter BAT-luc activity and SOST expression after incubation with GIN and different 
Wnt signalling inhibitors. (A) Wnt reporter BAT-luc activity in SaOS-2 cells after stimulation with GIN (n 
= 6). Values represents mean ± SD. The extracellular inhibitor DKK1 could not inhibit GIN-induced BAT-
luc activity. Both XAV939 and PNU74654 significantly inhibited BAT-luc activity. B) RNA from SaOS-2 
cells was isolated after 24 hours incubation with GIN and other Wnt signalling inhibitors (n = 3). Values 
represent mean ± 95% CI. None of the inhibitors could restore SOST expression to control levels.** p < 
0.01 compared to control, *** p < 0.001 compared to control, ### p < 0.001 compared to GIN control
 Finally, we assessed the biological effect of down regulation of SOST expression by GIN 
in KS483 cells. This cell line provides a well-established model for investigating the process 
of osteoblast differentiation, rather than SaOS-2 cells, which represent human osteogenic 
osteosarcoma cells with late osteoblast characteristics [43, 44]. Since SOST mRNA expression 
is restricted after the onset of mineralization in osteoblastic cultures [45], we investigated 
the effect of GIN on SOST mRNA expression during the first days of mineralization (e.g. 
after 13 or 14 days of culture). Osteogenic differentiation of the cultures was monitored 
by measuring alkaline phosphatase activity in the medium and matrix mineralization. As 
shown in Figure 5A, addition of BMP4 significantly increased ALP activity on day 7, 11 and 
14. Addition of GIN even further increased BMP4-increased ALP activity. Treatment of the 
cells with BMP4 resulted in an increase of mineralization, while addition of GIN increased 
BMP4-induced mineralization even further (Figure 5B,D). Consistent with the increase in 
mineralization by BMP4, SOST mRNA expression was also increased by BMP4 (Figure 5C). 
GIN alone has a slight but not significant inhibitory effect on both mineralization and SOST 
expression (Figure 5B,C). However, when GIN was added in combination with BMP4, SOST 
mRNA expression was reduced (Figure 5C). 
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Figure 5: Osteoblast differentiation of KS483 cells after stimulation with BMP4 and GIN. (A) Alkaline 
Phosphatase (ALP) activity in medium. BMP4 increased ALP activity during differentiation, while GIN 
increased the BMP4 induced ALP activity even further. (B+D) Mineralization measured by Bonetag. 
BMP4 increased mineralization, while GIN slightly inhibited mineralization. A combination of BMP4 
and GIN increased the mineralization significantly. (C) SOST mRNA expression (n = 4). BMP4 increased 
SOST expression, while GIN slightly decreased BMP4 induced SOST expression. Values represent 
mean ± SD of four independent experiments, except for (D) which represents pictures from one 
representative experiment. ** p < 0.01 compared to control, *** p < 0.001 compared to control, ## p 




Both BMP and Wnt signalling have been shown to play important roles in promoting 
osteoblast differentiation and mineralization.[7, 12] Interaction between both signalling 
pathways has been found in several studies, suggesting that both BMP and Wnt signalling 
may synergistically regulate osteoblast differentiation.[14-18] Since BMP and Wnt signalling 
induce their intrinsic antagonists [23] and SOST seems to be involved in both pathways, 
we investigated the effect of these pathways on SOST expression, both separately and in 
combination.
 SaOS-2 cells represent human osteogenic osteosarcoma cells with late osteoblast 
characteristics, transitioning towards osteocytes.[44] These cells belong to one of the few 
cell lines constitutively expressing SOST, are easy to transfect and are therefore used for 
studying signalling pathways and the influence on SOST expression. However, this cell line is 
less appropriate to investigate the process of osteoblast differentiation. Therefore, we used 
KS483 cells, a murine mesenchymal progenitor cell line, which represents a more accurate 
model to study effects on osteoblast differentiation.[43]
 Our results in SaOS-2 cells show that inhibition of GSK3β, either via the Wnt pathway 
by stimulation with Wnt3a or by direct inhibition using the GSK3β inhibitor GIN, resulted 
in a decreased expression of the Wnt signalling inhibitor SOST. Interestingly, GIN was much 
more potent in the down regulation of SOST. Moreover, BMP4-induced SOST expression 
was decreased by GIN, but not by Wnt3a.We suggest this is the result of the more potent 
induction of the Wnt pathway by GIN compared to Wnt3a, as was shown by a much higher 
induction of BAT-Luc by GIN. In addition, when Wnt3a or GIN was combined with BMP4, both 
Wnt as well as BMP signalling were further increased, suggesting a synergistic mechanism. 
Again, GIN was much more potent in inducing both pathways in combination with BMP4.
 Because of its clear connection to regulation of bone cells, canonical Wnt signalling 
seems the most plausible pathway involved in the down regulation of SOST. However, 
SOST expression was also decreased at a concentration of GIN where no increase in BAT-
luc activity was seen. Moreover, the β-catenin binding inhibitor PNU74654 was not able 
to restore SOST expression after treatment with GIN. This suggests that down regulation of 
SOST by GIN is not a direct effect of the canonical Wnt pathway, but appears to be mediated 
independent of β-catenin. Although GIN was thoroughly screened for selectivity against 
a panel of kinases [37], further experiments are needed to exclude cross-reactivity or off-
target effects of GIN. In addition, we found a connection between GSK3β inhibition and 
BMP signalling on the down regulation of SOST. Therefore, we can rule out the involvement 
of solely canonical Wnt signalling in the regulation of SOST. Previous studies already 
described a mechanism in which GSK3β phosphorylation primes Smad1 for ubiquitination 
and degradation. With this mechanism GSK3β controls the duration of Smad1 activation 
and therefore BMP signalling.[46, 47] A similar mechanism may be true for the duration of 
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Smad6 and Smad7 activation, which have been shown to inhibit SOST promoter activity.
[48] 
 The combined effect of GSK3β inhibition and BMP on SOST expression observed in 
SaOS-2 cells was also observed in KS483 cells. The biological effect of downregulation 
of SOST by GIN was measured by alkaline phosphatase (ALP) activity in the medium and 
mineralization of the matrix in KS483cells. A combination of GIN and BMP4 increased 
osteoblast differentiation. Our results are in line with Fukuda et al. (2010) who have shown 
that BMP4 and canonical Wnt cooperatively induced osteoblast differentiation through a 
GSK3β-dependent and β-catenin independent mechanism.[18] Although the decrease in 
BMP4-induced SOST expression by GIN in our experiments was not statistically significant, 
we hypothesize that the increase in osteoblast differentiation is due to the uncoupling of 
BMP signalling and SOST expression. 
 In conclusion, this study showed that uncoupling of BMP signalling and SOST expression 
could increase BMP-induced osteoblast differentiation. Furthermore, our results propose 
the existence of a new regulatory pathway for expression of SOST, which is mediated by 
GSK3β but independent of β-catenin. Further studies are necessary to identify the exact 
mechanism of regulating sclerostin via GSK3β and the way it interacts with other pathways 
during bone metabolism. 
 Inhibition of sclerostin has interesting clinical applications. Recently, a monoclonal 
antibody inhibiting sclerostin has been shown to enhance bone formation and to prevent 
implant loosening in preclinical studies [49, 50] and is currently tested in clinical trials phase 
III (ClinicalTrials.gov number, NCT01631214).[35] Another approach of inhibiting sclerostin 
and subsequently increasing bone mass would be via GSK3β inhibition as shown in our 
study. However, we propose that this approach of inhibiting sclerostin would be suitable for 
local applications only, since a study of Miclea et al. (2011) showed that systemic treatment 
with GIN induced osteoarthritis-like features in mice.[15] For example, local inhibition 
of sclerostin via GSK3β could have advantages in fracture healing or could improve 
osseointegration of implants by local increase of bone growth. 
Acknowledgements
This work was supported by Grants from the Netherlands Institute for Regenerative 
Medicine (NIRM, FES0908) and the Dutch Arthritis Foundation (Reumafonds LLP-13). The 




1. Bilezikan, J.P., Raisz, L.G. and Martin, T.J., Priciples of Bone Biology. 3th ed. Vol. 1. 2008: Elsevier.
2. Harada, S. and Rodan, G.A., Control of osteoblast function and regulation of bone mass. Nature, 2003. 
423(6937): p. 349-355.
3. Teitelbaum, S.L. and Ross, F.P., Genetic regulation of osteoclast development and function. Nat.Rev.
Genet., 2003. 4(8): p. 638-649.
4. Sambrook, P. and Cooper, C., Osteoporosis. Lancet, 2006. 367(9527): p. 2010-2018.
5. Kingsley, D.M., What do BMPs do in mammals? Clues from the mouse short-ear mutation. Trends 
Genet., 1994. 10(1): p. 16-21.
6. Vukicevic, S. and Sampath, K.T., Bone Morphogenetic Proteins: From Local to Systemic Therapeutics. 
2008: Birkhäuser Verlag, Basel.
7. Chen, G., Deng, C.and Li, Y.P., TGF-beta and BMP signaling in osteoblast differentiation and bone 
formation. Int.J.Biol.Sci., 2012. 8(2): p. 272-288.
8. Miyazono, K., Maeda, S. and Imamura, T., BMP receptor signaling: transcriptional targets, regulation of 
signals, and signaling cross-talk. Cytokine Growth Factor Rev., 2005. 16(3): p. 251-263.
9. Cadigan, K.M. and Nusse, R., Wnt signaling: a common theme in animal development. Genes Dev., 
1997. 11(24): p. 3286-3305.
10. Yang, Y., Wnts and wing: Wnt signaling in vertebrate limb development and musculoskeletal 
morphogenesis. Birth Defects Res.C.Embryo.Today, 2003. 69(4): p. 305-317.
11. Gaur, T., et al., Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene 
expression. J.Biol.Chem., 2005. 280(39): p. 33132-33140.
12. Glass, D.A., et al., Canonical Wnt signaling in differentiated osteoblasts controls osteoclast 
differentiation. Dev.Cell, 2005. 8(5): p. 751-764.
13. Logan, C.Y. and Nusse, R., The Wnt signaling pathway in development and disease. Annu.Rev.Cell Dev.
Biol., 2004. 20: p. 781-810.
14. Mbalaviele, G., et al., Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new 
bone formation. J.Cell Biochem., 2005. 94(2): p. 403-418.
15. Miclea, R.L., et al., Inhibition of Gsk3beta in cartilage induces osteoarthritic features through activation 
of the canonical Wnt signaling pathway. Osteoarthritis.Cartilage., 2011. 19(11): p. 1363-1372.
16. Bain, G., et al., Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and 
participates in BMP2 mediated signal transduction. Biochem.Biophys.Res.Commun., 2003. 301(1): p. 
84-91.
17. Chen, Y., et al., Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce 
new bone formation. J.Biol.Chem., 2007. 282(1): p. 526-533.
18. Fukuda, T., et al., Canonical Wnts and BMPs cooperatively induce osteoblastic differentiation through a 
GSK3beta-dependent and beta-catenin-independent mechanism. Differentiation, 2010. 80(1): p. 46-
52.
19. Zhang, R., et al., Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in 
osteoblasts. Bone, 2013. 52(1): p. 145-156.
20. Winkler, D.G., et al., Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect 
and mediated by bone morphogenetic proteins. J.Biol.Chem., 2005. 280(4): p. 2498-2502.
21. Rawadi, G., et al., BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a 
Wnt autocrine loop. J.Bone Miner.Res., 2003. 18(10): p. 1842-1853.
22. Yanagita, M., BMP antagonists: their roles in development and involvement in pathophysiology. 
Cytokine Growth Factor Rev., 2005. 16(3): p. 309-317.
4
81
GSK3B INHIBITION DECREASES SOST EXPRESSION
23. Kamiya, N., et al., Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the 
type IA receptor (BMPRIA) in osteoblasts. J.Bone Miner.Res., 2010. 25(2): p. 200-210.
24. Huang, S.M., et al., Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature, 2009. 
461(7264): p. 614-620.
25. Trosset, J.Y., et al., Inhibition of protein-protein interactions: the discovery of druglike beta-catenin 
inhibitors by combining virtual and biophysical screening. Proteins, 2006. 64(1): p. 60-67.
26. Li, X., et al., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J.Biol.Chem., 2005. 
280(20): p. 19883-19887.
27. Semenov, M.V., et al., Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr.Biol., 2001. 
11(12): p. 951-961.
28. van Bezooijen, R.L., et al., Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on 
BMP-stimulated bone formation. J.Bone Miner.Res., 2007. 22(1): p. 19-28.
29. Brunkow, M.E., et al., Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel 
cystine knot-containing protein. Am.J.Hum.Genet., 2001. 68(3): p. 577-589.
30. Loots, G.G., et al., Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van 
Buchem disease. Genome Res., 2005. 15(7): p. 928-935.
31. Moester, M.J., et al., Sclerostin: current knowledge and future perspectives. Calcif.Tissue Int., 2010. 
87(2): p. 99-107.
32. van Hul, W., et al., Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 
17q12-q21. Am.J.Hum.Genet., 1998. 62(2): p. 391-399.
33. Winkler, D.G., et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO 
J., 2003. 22(23): p. 6267-6276.
34. Krause, C., et al., Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt 
signaling pathways. J.Biol.Chem., 2010. 285(53): p. 41614-41626.
35. McClung, M.R., et al., Romosozumab in postmenopausal women with low bone mineral density. 
N.Engl.J.Med., 2014. 370(5): p. 412-420.
36. Sutherland, M.K., et al., Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones 
in human osteoblasts. Bone, 2004. 35(2): p. 448-454.
37. Engler, T.A., et al., Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-
hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. 
J.Med.Chem., 2004. 47(16): p. 3934-3937.
38. Maretto, S., et al., Mapping Wnt/beta-catenin signaling during mouse development and in colorectal 
tumors. Proc.Natl.Acad.Sci.U.S.A, 2003. 100(6): p. 3299-3304.
39. Korchynskyi, O. and ten Dijke, P., Identification and functional characterization of distinct critically 
important bone morphogenetic protein-specific response elements in the Id1 promoter. J.Biol.Chem., 
2002. 277(7): p. 4883-4891.
40. Moester, M.J., et al., Validation of a simple and fast method to quantify in vitro mineralization with 
fluorescent probes used in molecular imaging of bone. Biochem.Biophys.Res.Commun., 2014. 443(1): 
p. 80-85.
41. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids 
Res., 2001. 29(9): p. e45.
42. Keller, H. and Kneissel, M., SOST is a target gene for PTH in bone. Bone, 2005. 37(2): p. 148-158.
43. van der Horst, G., et al., Differentiation of murine preosteoblastic KS483 cells depends on autocrine 




PERI-PROSTHETIC TISSUE CELLS 
SHOW OSTEOGENIC CAPACITY 
TO DIFFERENTIATE INTO THE 
OSTEOBLASTIC LINEAGE
J Orthop Res. 2016 Oct 7.
Monique A.E. Schoeman1
Angela E. Oostlander1
Karien E. de Rooij1  
Edward R. Valstar1,2
Rob G.H.H. Nelissen1
1 Department of Orthopaedics, Leiden University Medical 
Center, Leiden, The Netherlands
2 Department of Biomechanical Engineering, Faculty of 
Mechanical, Maritime, and Materials Engineering,  




During the process of aseptic loosening of prostheses, particulate wear debris induces a 
continuous inflammatory-like response resulting in the formation of a layer of fibrous peri-
prosthetic tissue at the bone-prosthesis interface. The current treatment for loosening is 
revision surgery which is associated with a high morbidity rate, especially in old patients. 
Therefore, less invasive alternatives are necessary. One approach could be to re-establish 
osseointegration of the prosthesis by inducing osteoblast differentiation in the peri-
prosthetic tissue. Therefore, the aim of this study was to investigate the capacity of peri-
prosthetic tissue cells to differentiate into the osteoblast lineage. Cells isolated from peri-
prosthetic tissue samples (n=22) – obtained during revision surgeries – were cultured 
under normal and several osteogenic culture conditions. Osteogenic differentiation was 
assessed by measurement of Alkaline Phosphatse (ALP), mineralization of the matrix and 
expression of several osteogenic genes. Cells cultured in osteogenic medium showed a 
significant increase in ALP staining (p=0.024), mineralization of the matrix (p<0.001) and 
ALP gene expression (p=0.014) compared to normal culture medium. Addition of bone 
morphogenetic proteins (BMPs), a specific GSK3β inhibitor (GIN) or a combination of BMP 
and GIN to osteogenic medium could not increase ALP staining, mineralization and ALP 
gene expression. In one donor, addition of GIN was required to induce mineralization of 
the matrix. Overall, we observed a high inter-donor variability in response to osteogenic 
stimuli. In conclusion, peri-prosthetic tissue cells, cultured under osteogenic conditions, can 
produce alkaline phosphatase and mineralized matrix and therefore show characteristics of 
differentiation into the osteoblastic lineage.
Keywords: Aseptic loosening, peri-prosthetic tissue, osteogenic differentiation, regenerative 
medicine, total hip revision.
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Introduction
Aseptic loosening is the most common long-term cause of failure in total joint arthroplasty.
[1] The process of loosening is thought to be a complex interplay between mechanical as 
well as biological factors. Particulate wear debris, continuously generated by articulating 
motion at the bearing surfaces, has been implicated as one of the primary causes initiating 
peri-prosthetic bone loss.[2] Subsequently, a fibrous-like peri-prosthetic tissue layer 
with poor mechanical properties is formed, triggering bone resorption and prosthesis 
displacement.[3] 
The current treatment for aseptically loosened prostheses is invasive revision surgery, 
which consists of removal of the old prosthesis together with the peri-prosthetic tissue, 
and insertion of a new prosthesis. Sometimes, in addition, bone augmentation has to be 
done with allograft bone, depending on the severity of bone loss. This procedure is highly 
demanding for the patient and is associated with blood loss, complications, and morbidity, 
especially in elderly patients with a poor general health condition.[4-6] Furthermore, 
revision prostheses display poorer clinical and functional performance than that of the 
primary prosthesis.[7-9] Therefore, less demanding therapies alternative to extensive 
revision surgery but with adequate functional performance are necessary. Currently, several 
minimally invasive techniques are being investigated to remove the peri-prosthetic tissue 
and stabilize the loosened prosthesis by subsequent bone cement injection.[10, 11] 
 Another approach would be to promote bone formation in the peri-prosthetic tissue 
in order to compensate peri-prosthetic bone loss and subsequently stabilize the loosened 
prosthesis. This could be accomplished in a minimally invasive way by percutaneous, local 
introduction of osteogenic factors at the peri-prosthetic space, which will drive osteogenic 
differentiation of peri-prosthetic tissue cells. 
 However, little is known about the role of peri-prosthetic tissue cells in bone formation. 
Most effort so far has been concentrated on understanding the role of these cells in bone 
resorption around the implant. The few studies investigating their role in bone formation 
show that peri-prosthetic tissue cells produce factors that suppress osteoblast function 
and induce production of inflammatory cytokines.[12, 13] Moreover, wear particles and 
metal ions can directly affect osteoblasts by reducing type 1 collagen production[14, 15] 
and decreasing alkaline phosphatase activity as well as calcium deposition.[16] In addition, 
wear particles have been shown to decrease osteoblast proliferation[15, 17], change the 
phenotype of mature osteoblasts[18], and stimulate osteoblasts to secrete inflammatory 
cytokines.[14-16, 19] Remarkably, one study revealed that cells from the peri-prosthetic 
tissue produce several osteoblastic proteins themselves.[20] In agreement, histological 
assessment of peri-prosthetic tissue demonstrated that this tissue exhibits osteogenic 
characteristics as shown by the presence of intramembranous formation of osteoid[21, 22], 
an increased mineral apposition rate and bone formation rate with active osteoblast lining 
86
Chapter 5
and production of immature bone matrices with poor bone quality.[22] Furthermore, an 
increased expression of several bone morphogenetic proteins (BMPs) in several cell types 
of the peri-prosthetic tissue was found.[23] As BMPs are regulators and potent inducers of 
osteoblast differentiation[24], the local increase of BMP synthesis in peri-prosthetic tissue 
could be an attempt to regenerate or maintain implant fixation. However, to our knowledge, 
nothing is known about the capability of peri-prosthetic tissue cells to (re)generate bone 
themselves. Therefore, the aim of this study is to investigate whether cells within the peri-
prosthetic tissue are able to differentiate into the osteoblastic lineage. 
Materials and methods 
Peri-prosthetic tissue samples
Peri-prosthetic tissue samples harvested from aseptically loosened femoral stems or 
acetabular components of 22 patients were obtained during revision surgery of total hip 
replacements.  The peri-prosthetic tissue was collected as “waste” material and as such 
should not be traceable to specific patients according to Dutch Medical Ethics laws and 
legislation. Therefore, only limited donor characteristics are available (see Table 1). Collected 
samples were kept in sterile NaCl 0.9% at 4°C, for a maximum of 24 hours, until they were 
processed. This study was approved by the Medical Ethics Committee of Leiden University 
Medical Center (C12-107). 
 
Cell culture 
Collected tissue samples were minced and incubated at 37°C for two hours in α-MEM 
(Gibco, Carlsbad, CA, USA) with collagenase I A (2mg/mL; Sigma-Aldrich, St Louis, MO, USA). 
The cell suspension was then centrifuged and washed twice in α-MEM supplemented with 
10% Fetal Calf Serum (FCS; Greiner Bio One, Kremsmünster, Austria). Cells were cultured in 
petri-dishes in α-MEM supplemented with 10% FCS, 1% Glutamax (Gibco), 3% penicillin and 
streptomycin (Gibco) and 25µg/ml Amphotericin B (Gibco) for 72 hours. Thereafter, cells 
were cultured in the same medium but without Amphotericin B. When cultures reached 
90% confluence, the cells were transferred to 75cm2 flasks. For the experiments cells from 
passage 1 or 2 were used. 
 The human osteosarcoma cell line SaOS-2 (ATCC, Manassas, VA, USA) and the human 
dermal fibroblast cell line (HDF-a; ScienCell, Carlsbad, CA, USA) were cultured in DMEM 
(Gibco) supplemented with 10% FCS and 1% penicillin and streptomycin (Gibco). These cell 
lines were used as positive and negative controls in the experiments, respectively. 
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Table 1: Demographic data from included peri-prosthetic tissue samples. 
Donor Sex Age Fixation Bearing Cup/Stem Years in situ
Visible presence
of wear debris
1 F 81 Cemented Metal/PE Cup >5 Yes
2 M 74 Cementless Metal/PE Cup >5 No
3 F 85 Cemented Metal/PE Cup >5 Yes
4 M 59 Cemented Metal/PE Stem >5 Yes
5 M 81 Cemented Metal/PE Cup >5 No
6 F 79 Cemented Metal/PE Stem >5 Yes
7 M 55 Cementless Metal/Metal Cup >5 Yes
8 F 80 Cemented Metal/PE Cup >5 No
9 F 73 Cementless N/A N/A >5 Yes
10 F 75 Cementless Ceramic/PE N/A >5 No
11 F N/A Cemented Metal/PE Cup >5 Yes
12 M 79 Cemented Metal/PE Cup+Stem >5 No
13 F 80 Cementless Metal/PE Cup >5 No
14 F 86 Cemented Ceramic/PE Cup >5 Yes
15 M 32 Cemented Metal/PE Cup 2-5 Yes
16 F 76 Cementless Ceramic/PE Cup >5 No
17 F 74 Cemented Metal/PE Cup+Stem >5 No
18 M 69 Cemented Metal/PE N/A >5 Yes
19 M 84 Cemented Metal/PE Stem >5 Yes
20 F 71 Cementless Metal/PE N/A >5 No
21 M 66 Cemented Metal/PE Cup >5 Yes
22 F 80 Cemented Metal/PE Stem 2-5 Yes
F = female, M = Male, PE = Polyethylene, N/A = not available 
Osteogenic differentiation experiments 
Peri-prosthetic tissue cells were seeded at a density of 8,650 cells/cm2. To induce osteoblast 
differentiation, normal culture medium (NM, as described above) was supplemented with 
freshly added ascorbic acid (50μg/ml; Merck Inc., NY, USA), β-glycerophosphate (5mM; 
Sigma-Aldrich) and dexamethasone (0.1μM; Sigma-Aldrich) with or without recombinant 
human BMP-2, BMP- 6 (50ng/mL; R&D Systems, Minneapolis, MN, USA) or a specific GSK3β 
inhibitor (GIN; 10nM; kindly provided by Dr. Rawadi, Prostrakan, France; Engler et al.[25]) 
Cell cultures were subjected randomly to either BMP-2 or BMP-6. The culture medium was 




Alkaline Phosphatase (ALP) activity was assessed by both histochemical staining and a 
colorimetric assay.  For ALP staining, cells were cultured for 18/21 days after which they 
were fixed in 3.7% buffered formaldehyde and stained with a solution containing 0.1mg/
ml naphthol AS MX phosphate (Sigma), 0.5% N, N- dimethylformamide, 2mM MgCl
2
, and 
0.6mg/ml of fast blue BB salt (Sigma) in 0.1mM Tris–HCl (pH 8.5) for 5 minutes. Thereafter, 
ALP staining was completely washed out of the cell layer with a freshly prepared solution of 
50mM NaOH in EtOH. The absorbance was measured at 500nM using a VERSAmax Tunable 
Microplate Reader (Molecular Devices). Enzymatic ALP activity was measured after 4, 6, 13, 
18, 21, 25, 28 and 32 days of culture using  p-nitrophenyl phosphate (pNPP) as described 
by van der Horst et al. 2002.[26] Briefly, the cells were lysed and ALP activity was measured 
kinetically using 6 mmol/L pNPP at 405nm using a VERSAmax Tunable Microplate Reader. 
DNA concentration in the cell lysate was measured using the fluorescent dye bisBenzimide 
H 33258 (Hoechst 33258, Sigma) and was calibrated against a DNA standard (0.5–10μg/mL 
herring sperm DNA). ALP activity was corrected for the amount of DNA in the culture.
Mineralization
Mineralization of the cultures was assessed using the fluorescent dye Bonetag (Li-COR 
Biosciences, Lincoln, NE, USA) as described previously.[27] Briefly, 24 hours before fixation 
with 3.7% buffered formaldehyde, 2nM Bonetag 800 was added to the culture medium. The 
fixed cells were scanned with the Odyssey Infrared Imaging System (Li-COR) at a resolution 
of 42µm, intensity 6.5 and medium quality. Integrated intensity (counts/mm2) of each well 
was calculated by the Odyssey software.
Quantitative RT-PCR
Total RNA was isolated from cells using RNA-Bee (Tel-Test Inc., Friendswood, TX, USA). cDNA 
was synthesized using M-MLV reverse transcriptase (Promega, Fitchburg WI USA) according 
to the manufacturer’s instructions. Quantitative RT-PCR was performed using the Quantitect 
SYBRgreen PCR kit (Qiagen, Venlo, The Netherlands) with an iQ5 PCR cycler (BioRad, 
Hercules, CA, USA). For used primer sets, all spanning at least one intron, see Table 2. Data 
were normalized relative to GAPDH expression. Levels of gene expression in differentiation 
experiments were expressed as fold-change relative to expression in SaOS-2 and HDFA cells 
using the 2-ΔΔCt method. Basal levels of gene expression at beginning of experiments were 
expressed as fold-change relative to expression in positive controls (e.g. SaOS-2 cells, HDFA 
cells, human endothelial cells and human monocytes).
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S100A4 5’-TTGGTTTGGTGCTTCTGAGATGT-‘3 5’- TCACCCTCTTTGCCCGAGTA-‘3
Vimentin 5’- CCAAACTTTTCCTCCCTGAACC-‘3 5’- CGTGATGCTGAGAAGTTTCGTTGA-‘3
Endoglin 5’- TCACCACAGCGGAAAAAGGT-‘3 5’- CAGGAACTCGGAGACGGATG-‘3
PECAM 5’- AGACGTGCAGTACACGGAAG-‘3 5’- CTTTCCACGGCATCAGGGA-‘3
CD68 5’- AGGCTGGCTGTGCTTTTCTC-‘3 5’- TCTCTGTAACCGTGGGTGTC-‘3
 
Statistical analysis
Statistical analysis was performed using SPSS (IBM SPSS Statistics 23). To account for 
treatment clustering within donors during osteogenic differentiation, linear mixed-effects 
modelling was used to analyse the ALP activity staining, mineralization and gene expression 
data, while two-way (mineralization) or three-way (ALP cell layer) ANOVA was used for the 
outcome measures in the time-dependent experiments.
 Linear regression was performed for testing the relation between variability levels of ALP 
activity and/or mineralization and patient- and implant characteristics as well as between 
levels of mineralization and basal gene expression levels of “cell-specific” genes. For all tests, 
a p-value of <0.05 was regarded as statistically significant. Values represent mean ± SD, 
unless stated otherwise.
Results 
The effect of osteogenic stimuli on osteogenic differentiation of peri-prosthetic tissue cells 
was studied in 22 donors after 18 to 21 days of culture. When cultured in normal medium 
(NM), cells displayed ALP activity (1A). Stimulation of cells with osteogenic medium (OM) 
significantly increased ALP activity (p=0.024). OM supplemented with either BMP-2, GIN and 
BMP-2+GIN or, alternatively, supplemented with BMP-6 and BMP-6+GIN did not significantly 
increase ALP activity (Figure 1B). In all culture conditions, variation in the level of ALP activity 
was observed between donors (Figure 1A, B). These variations between donors makes it 
impossible to assess differences between BMP-2 and BMP-6. Mineralization of the matrix 
was studied using the fluorescent dye Bonetag. When cells were cultured in NM, little to 
no fluorescence was observed, whereas OM induced mineralization in 15 out of 22 donors, 
although to (very) different extents (Figure 2A, B). In 5 out of 15 donors mineralization could be 

































Figure 1: Alkaline Phosphatase (ALP) staining. (A) Pictures of ALP staining of cell cultures of five 
representative donors cultured in NM or stimulated with OM or OM supplemented with either BMP-
2 or BMP-6, GIN and BMP-2 or BMP-6 + GIN. Bars represent 1 mm. (B) Boxplot showing the mOD 
after extraction of ALP staining from the cultures of twenty-two donors cultured in NM, OM or OM 
supplemented with either BMP-2, GIN or BMP-2 + GIN. Values represent mean ± SD, dots represents 
1.5*IQR. NM: normal medium; OM: osteogenic medium; BMP: bone morphogenetic protein; GIN: 
GSK3β inhibitor; IQR: Inter Quartile Range.  
* p<0.05 compared to NM.
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Figure 2: Mineralization of the matrix as measured by Bonetag (fluorescent dye). (A) Pictures of Bonetag 
fluorescent staining of cultures of five representative donors stimulated with OM or OM supplemented 
with BMP-2 or BMP-6, GIN and BMP-2 or BMP-6 + GIN. Normal culture medium served as a negative 
control. Bars represent 5 mm. (B) Boxplot showing the Integrated Intensity of the fluorescence of 
twenty-two donors stimulated with OM or OM supplemented with either BMP-2, GIN or BMP-2 + GIN. 
Values represent mean ± SD, dots represents 1.5*IQR. NM: normal medium; OM: osteogenic medium; 
BMP: bone morphogenetic protein; GIN: GSK3β inhibitor; IQR: Inter Quartile Range.  
92
Chapter 5
Interestingly, in donor 3, mineralization could not be induced by OM alone, but addition of 
GIN was needed to induce mineralization. Furthermore, in donor 19, mineralization could not 
be induced by OM alone nor OM with additives (Supplementary Figure 1). Overall, addition 
of BMP, GIN or BMP+GIN could not significantly increase mineralization compared to OM 
(Figure 2B). Subsequently, we also investigated the response to continuous stimulation with 
BMP-6. However, there were no significant differences in ALP activity and mineralization 












































































































































































Figure 3: Relative gene expression (2-ΔΔCq) of cells stimulated with osteogenic stimuli. Expression of 
alkaline phosphatase (ALP), alpha-1 type I collagen (Col1a1) and osteocalcin (OCN) was corrected for 
internal control GAPDH and the geometric mean of calibrators SaOS-2 and HDFA. Boxplot showing 
the mean ± SD, dots represent 1.5*IQR. NM: normal medium; OM: osteogenic medium; BMP: bone 
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 The effect of osteogenic stimuli on ALP, Alpha-1 type I collagen (Col1a1) and osteocalcin 
(OCN) gene expression was investigated in 19 donors (Figure 3). OM and OM supplemented 
with GIN or BMP-2+GIN could significantly increase ALP gene expression (resp. p=0.014, p< 
0.001, p=0.023) compared to NM. Col1a1 and OCN gene expression were not significantly 
different between culture conditions. 
 We investigated whether the observed variation in levels of ALP activity and 
mineralization between donors could be explained by patient- and implant characteristics. 
Type of fixation (ALP: β=0.026, p=0.538 ; Mineral: β=-174.30, p=0.875), gender (ALP: β=0.06, 
p=0.187 ; Mineral: β=80.21, p=0.947) or age (ALP: β=0.001, p=0.693 ; Mineral: β=-21.14, 
p=0.661)  could not explain the found variations in ALP activity and mineralization.
 Next, we tested whether variation observed in levels of ALP activity and mineralization 
between donors could be explained by degree of responsiveness to osteogenic stimuli. 
Since ALP activity and mineralization as described above were only measured at a single 
time-point (e.g. after 18-21 days of culture), variations observed in these markers for 
osteogenic differentiation could be explained by differences in response-rate / degree 
of responsiveness of the cells from different donors to osteogenic conditions. Therefore, 
in five donors, we investigated the response to osteogenic stimuli over time. Since there 
was almost no additional effect of BMPs and/or GIN compared to OM alone, we decided 
to investigate only the response to OM over time. In all donors, at each time-point, we 
observed a significant difference (p<0.001) between culture conditions in ALP activity in 
the cell layer (Figure 4A). For mineralization, all donors showed a significant different pattern 
in mineralization when cultured with OM, with mineralization observed from day 13, 21 or 
28 onwards (Figure 4B, C). In all cases, mineralization occurred directly after a decrease in 
ALP activity was seen (Figure 4A). 
 Furthermore, we investigated whether the observed variation in osteogenic 
responsiveness could be explained by the heterogeneous composition of the cell population 
at the start of experiments. Therefore, we selected several ‘cell-specific’ genes to compare 
cell populations between donors. All samples showed the presence of macrophage, 
fibroblast, osteoblast and endothelial cells, however, a high inter-donor variability in basal 
gene expression levels of peri-prosthetic tissue was observed  (Figure 5). No significant 
associations were found between levels of Integrated Intensity (mineralization at day 18-21) 
and gene expression levels of ALP (β=-474.89, p=0.91), OCN (β=-72.15, p=0.115), S100A4 
(β=-141.80, p=0.49), Vimentin (β=-562.25, p=0.72), Endoglin (β=-13287.76, p=0.194), 
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Figure 4: Analysis of differentiation of time course experiment. (A) ALP activity measured kinetically 
over time in cell cultures of five donors cultured in normal medium (NM) or stimulated with osteogenic 
medium (OM).  Pictures (B) and Integrated Intensity (C) of mineralization of the matrix over time of 
these cultures measured using the fluorescent dye Bonetag. SaOS-2 cells and HDFA cells served as 
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Figure 5: Relative gene expression (2^-ΔΔCq) of peri-prosthetic tissue cells. Expression of alkaline 
phosphatase (ALP) and osteocalcin (OCN) was corrected for internal control GAPDH and relative gene 
expression in SaOS-2 cells. Expression of S100A4 and vimentin was corrected for internal control 
GAPDH and relative gene expression in HDFA cells. Expression of Endoglin and Pecam-1 was corrected 
for internal control GAPDH and relative gene expression in human endothelial cells. Expression of 
CD68 was corrected for internal control GAPDH and relative gene expression in human monocytes.  
Discussion 
In the current study, we subjected peri-prosthetic tissue cells to osteogenic stimuli to 
investigate whether these cells could differentiate into the osteoblastic lineage. We observed 
an increase in alkaline phosphatase (ALP) activity and a production of a mineralized matrix 
upon induction/stimulation with osteogenic stimuli. Increase of ALP activity in early stages 
of osteoblast differentiation is assumed to reflect the number of progenitor cells committed 
to osteogenic differentiation in a cell population.[28] In general during differentiation, 
ALP first increases and then decreases when mineralization is well progressed.[28] In 
agreement, in peri-prosthetic tissue cultures ALP activity reached a peak at the onset of 
mineralization. We also observed cells stained for ALP activity after 18-21 days of culture in 
NM. Furthermore, in one donor, we noticed an increase in enzymatic ALP activity over time 
when cells were cultured in NM. In a study by Heinemann et al.[29] it was found that cells 
obtained from granuloma explants from endoprosthetic revisions stained positive for ALP 
activity, indicating that in peri-prosthetic tissue a population of cells could be present that 
is already committed to the osteoblastic lineage. 
 Mineralization of the matrix describes the final stage of osteoblast/osteogenic 
differentiation. Instead of using conventional staining techniques like Alizarin Red S, 
we have chosen Bonetag to assess the level of mineralization in our cultures, since we 
previously showed Bonetag to be more sensitive to small changes in mineralization.[27] 
In the current study, we observed an increase in mineralization when cells were cultured 
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with OM. Moreover, since BMPs are known inducers of osteogenic differentiation[24], 
and a local increase of synthesis of several BMPs in the peri-prosthetic tissue has been 
reported[23] we also stimulated cells with OM supplemented with either BMP-2 or BMP-6. 
Several BMPs, including BMP-2 and BMP-6, have shown positive effects on bone formation, 
fracture healing and implant osseointegration in several in vitro and in vivo animal models.
[30-33] BMP-2 is even used in clinical practice for accelerating healing of fractures and for 
spinal fusions.[30]; [34] In our recent study using the murine cell-line KS483, a combination 
of BMP-4 and GIN (a stimulator of Wnt-signalling) was found to enhance mineralization and 
decrease the expression of Sclerostin (an inhibitor of bone formation) compared to BMP-4 
alone.[35] Therefore, we also stimulated cells with OM supplemented with either GIN or a 
combination of GIN and BMP-2 or BMP-6. Our results show large inter-donor differences in 
response to these stimuli, ranging from no additional effect to necessity for mineralization 
to occur.  When all data were put together no significant increase of mineralization using 
BMP, GIN or BMP+GIN was observed. Therefore, we were not able to ascertain a standard 
formula or one common pathway which guarantees osteogenic differentiation in peri-
prosthetic tissue cells. 
 To confirm our hypothesis that there was an inter-donor degree of responsiveness 
to osteogenic stimuli, we performed a time-series experiment using five representative 
donors from the first set of experiments. Indeed, we observed an inter-donor degree of 
responsiveness as expressed by differences in peak-height of ALP activity and differences in 
time till onset of mineralization. Furthermore, we noticed an intra-donor difference in degree 
of mineralization at day 21 between both types of experiments. We speculate that this results 
from differences in cell densities or the fact that the cells were at different passages when 
cells were subjected to osteogenic stimuli, and therefore responses were slower or faster. 
 The RT-PCR results obtained in this study should be interpreted with care, since we 
observed variations between osteogenic and non-osteogenic conditions regarding the 
expression of our reference gene (data not shown). The variation could not be explained 
by any type of technical error. Literature, presenting RT-PCR data of peri-prosthetic tissue 
cells, shows the use of several different reference genes like GAPDH, 18S, β-actin, PBGD, 
HPRT and RPL32.[36-39] We tested all these genes, widely used as reference genes in peri-
prosthetic tissue samples, but all showed  differences in expression between osteogenic 
and non-osteogenic conditions in at least some donors. Variation in the gene expression 
levels of reference genes under different experimental conditions has already been found in 
other studies,[40, 41] indicating that it is not surprising we were not able to find the optimal 
reference gene for these types of cells (under these types of experimental conditions). 
Because of the variation in the expression level of the reference genes, calculation of cellular 
proportions was not possible. Therefore, in future studies, for example FACS analysis could 
be used to obtain data on percentages of different cell types within each sample.
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 In this study, we used peri-prosthetic tissue cells from early passages, since at higher 
passages the risk of substantial in vitro growth selection exists.[42, 43] To our opinion, a 
heterogeneous population of cells could reflect a more in vivo-like response to osteogenic 
stimuli. We tried to characterize the cell content of the tissue by investigating gene 
expression patterns of peri-prosthetic tissue cells at the beginning of the experiments (day 
0). Since there is no suitable tissue to serve as a control for peri-prosthetic tissue, we used 
different control cell lines to determine the relative expression. A high variation in the gene 
expression levels between donors was observed, indicating heterogeneous populations of 
cells, which is in line with several studies evaluating the cellular content of peri-prosthetic 
tissue.[43-45] Although we did not find an association between the responsiveness 
to osteogenic stimuli and the cell content, it is not excluded that the high inter-donor 
variability in gene expression levels might account for the high inter-donor variability in 
response to osteogenic stimuli. 
 Besides tissue characteristics (such as cell content of the tissue), implant and/or 
patients characteristics, might explain some of the observed variability in the osteogenic 
responsiveness between the peri-prosthetic tissue of the patients. In our study, prosthesis 
characteristics (i.e. type of fixation) could not explain the variability in response to osteogenic 
stimuli. However, other studies showed that surface characteristics of implants can influence 
the inflammatory response to implant material and subsequently affect the expression of 
bone formation markers (e.g. BMP-2 and ALP).[46, 47] Therefore, in future studies, the effect 
of different implant materials and surface characteristics on osteogenic differentiation of 
peri-prosthetic tissue cells should be investigated. In addition, potentially relevant patient- 
and tissue-related characteristics, such as type of bone loss (linear vs. erosive) and in situ 
location of the tissue should be taken in to account. Despite our relatively large number of 
samples for an in vitro study, the sample size was still too small to perform proper association 
studies between different clinical groups. Therefore, in future studies, larger sample sizes of 
peri-prosthetic tissue with more detailed patient-, implant- and tissue characteristics might 
be essential to explain the inter-donor variability in response to osteogenic stimuli. As the 
primary aim of this study was to determine whether or not peri-prosthetic cells are capable 
to differentiate into the osteoblastic lineage, the experimental set-up was relatively simple. 
Further study is needed to determine the influence of number, size and type of particles, as 
well as immune cells, on the osteogenic capacity of the cells.
 To our knowledge, this is the first (in vitro) study investigating the response of peri-
prosthetic tissue cells to osteogenic stimuli. Altogether, our results indicate that these 
cells, cultured under osteogenic conditions, show characteristics of differentiation into the 
osteoblastic lineage (i.e. over time increase of ALP activity and production of a mineralized 
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Supplementary Figure 1: Mineralization of the matrix as measured by the fluorescent dye Bonetag. 
Pictures of cell cultures of all donors stimulated with osteogenic medium (OM) or OM supplemented 
with BMP-2 or -6, GIN and BMP-2 or -6 +GIN. Normal culture medium (NM) served as a negative 
control. Bars represent 5 mm. BMP: bone morphogenetic protein; GIN: GSK3β inhibitor.
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To allow prediction of the risk of loosening prior to surgery, we investigated the relationship 
between innate immune cytokine response via TLR2 stimulation and early migration of 6 
different knee prostheses using RSA (radiostereometry). This study included 114 patients 
of a prospective RSA-cohort who received a total knee arthroplasty. Whole blood cytokine 
responses were obtained by ex vivo stimulation with tripalmitoyl-S-glycerylcysteine 
(Pam3Cys-SK4) for assessment of the TLR2 immune response. Early migration was calculated 
using the maximum total point motion (MTPM) one year post surgery. Principal component 
analysis (PCA) was applied to the cytokine data to reduce the correlated data of individual 
cytokines and identified 2 components. Subsequently, linear mixed model analyses were 
applied with adjustments for gender, age, BMI, time-to-blood sampling and prosthesis type. 
Component 1, consisting of IFNγ, IL-12p40, IL-10, IL-1β, TNFα and IL-6, showed a significant 
inverse association (β=-0.128; p=0.041) with MTPM. Further analysis showed that IFNγ (β=-
0.161, p=0.008) had the highest contribution to this association and is particularly found 
in patients receiving another prosthesis than Nexgen (β= -0.239; p<0.001). In conclusion, 
patients with high levels of IFNγ upon stimulation of TLR2 are at lower risk of early migration 
of their knee prosthesis. 
Keywords: Aseptic loosening, migration, IFNγ, TLR2
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Introduction 
Aseptic loosening is the most common cause for failure in total joint arthroplasty at long-
term follow-up.[1,2] Mechanical as well as biological factors play an important role in the 
loosening process. Inadequate initial fixation and repeated strains and stresses during 
normal gait cycles affect the bone-implant interface.[3,4] On the other hand, loss of 
fixation can be caused by particle-induced osteolysis around the implant. Particulate wear 
debris, continuously generated by articulating motion at the bearing surfaces, is thought 
to trigger an aseptic inflammatory response and cause an increase in osteoclast activity 
and subsequent peri-prosthetic bone resorption.[5] In vitro studies have shown that wear 
particles stimulate macrophages to produce cytokines including tumor necrosis factor α 
(TNFα), interleukin (IL)-1β and IL-6.[6-9] Consistent with these in vitro findings, several clinical 
studies have demonstrated increased production of these cytokines in peri-prosthetic 
tissues and fluids of loosened prostheses.[9-11]
 The mechanism of the initial cellular interaction with wear particles and the subsequent 
production of inflammatory mediators is still largely unknown. Recent studies suggest 
a critical role of Toll like receptors (TLRs) in this process.[12-14] TLRs belong to a class of 
receptors that enable the innate immune system to recognize foreign material and to 
mediate inflammatory responses.[15] It is known that different TLRs detect different 
pathogen associated molecular patterns (PAMPs). TLR2 mainly detects lipoproteins 
whereas TLR4 binds lipopolysaccharides (LPS) that are part of the membrane of gram-
negative bacteria.[15] Both TLRs have been shown to be present in peri-prosthetic tissue 
of patients with aseptic loosening.[16] Furthermore, TLR2 has been shown to recognize 
wear particles and to mediate the subsequent inflammatory reaction via the TLR2 specific, 
MyD88 dependent signalling pathway.[12,13,17] However, a large variation in the response 
to wear particles both in magnitude as well as the inflammatory cytokine profile between 
individuals has been observed.[18] Hence, this raises the question whether diversity in 
clinical susceptibility to wear particles can be explained by variations in cytokine release 
due to differences in innate immune responses.[3] Genetic studies have already shown that 
associations between aseptic loosening and polymorphisms in cytokine genes exist.[19,20]
 Early detection of loosening, even before symptoms occur, is possible by measuring sub 
millimeter migration of the prosthesis relative to the host bone.[21-23] Radiostereometric 
analysis (RSA) allows in vivo three-dimensional measurement of prosthetic migration with a 
high level of accuracy.[22-24] Studies have shown that increased early migration (one or two 
years post-surgery) is associated with increased risk of aseptic loosening and subsequent 
revision at the long term.[23,25] However, RSA measurements require the insertion of 1 
mm tantalum in the patient’s bone.  Therefore, RSA can only be used to early assess 
loosening in patients that have been included in clinical RSA studies. Since we hypothesize 
that differences in innate immunity are related to the susceptibility of aseptic loosening, 
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markers of the innate immunity might be suitable as predictors for loosening even before 
the patient receives joint replacement surgery. 
 Therefore, the aim of this study was to investigate whether there is an association 
between innate immunity, as reflected by the capacity to produce cytokine responses 
upon stimulation with the TLR2 agonist Pam3Cys-SK4, and early prosthesis migration, as 
measured by RSA in a cohort of patients with a total knee arthroplasty (TKA). 
Material & Methods 
Study design (Level of Evidence): This is a cross-sectional study (Level III).
Patients
Our cohort consisted of 137 patients who received a total knee arthroplasty (TKA) and were 
included previously in one of our prospective clinical RSA studies. Between February 2010 
and June 2011, all patients in our cohort visited the Leiden University Medical Center for 
routine RSA measurements and collection of blood samples. Twenty-three patients were 
excluded from this study for various reasons, see Figure 1. In total 34 patients received a 
bilateral TKA. However, from eleven of these patients only one knee was included in the 
study as the other prosthesis was less than one year in situ. As a result, in the current study we 
have included 114 patients with 137 knee prostheses. Within this cohort, patients received 
different designs of knee prostheses, including Nexgen (Zimmer Inc), Triathlon (Stryker Inc), 
Rocc (Biomet Inc), Interax, Interax ISA, Interax PS (Howmedica Osteonics Corp).[22,26-28] 
The study was approved by the Medical Ethical Committee of the Leiden University Medical 
Center (P09.228), and informed consent was obtained from all patients.
  
RSA analysis
RSA radiographs were made in a uniplanar setup using a highly accurate carbon calibration 
box (Carbon box, Leiden, The Netherlands) positioned underneath the examination table. 
The first RSA examination was made before weight-bearing on the second postoperative 
day and served as the reference for all further examinations. All evaluations are related to the 
relative position of the prosthesis to the bone at that time. The RSA data was analyzed using 
commercially available software (Model-based RSA, version 3.34, RSAcore, LUMC, Leiden, 
The Netherlands) and enables determination of the relative 3D position of the markers of the 
prosthesis in relation to the bone markers. In situations where less than three markers could 
be detected, the Marker Configuration Model RSA technique was used.[29] The parameter 
indicating the largest three-dimensional migration of any point on the prosthesis surface 
is called Maximal Total Point Motion (MTPM).[24] The reason for using MTPM as measure 
for migration, other than translation and rotation of the prosthesis, is that motion implies a 
biological effect and this effect is liable to be greatest at the point of maximum motion. To 
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measure early migration of the prosthesis, MTPM of the tibial component was assessed one 
year postoperatively.
Eligible patients (RSA cohort )
(137 patients )
Blood sample collection 
(127 patients )
Included in study 
(114 patients)
Excluded : 
- declined participation (4 patients)
- revision (3 patients)
- no reliable MTPM -value (2 patients)
- less than one year in situ (11 TKA ) 
Excluded : 
- Blood sample could not be collected 
- infection in first year postoperative 
 ( 2 patients)
   (11 patients)
Figure 1: Flowchart of patient inclusion
Cytokine measurement 
The innate immune response of patients was assessed by measuring the cytokine production 
capacity of whole blood samples upon ex vivo stimulation as described elsewhere.[30] The 
cytokine production capacity was assessed by ex vivo stimulation of 2 ml of whole blood with 
Pam3Cys-SK4, which stimulates the TLR2 response. Blood was collected in heparinized tubes 
and samples were diluted twofold with RPMI-1640 (Sigma, St. Louis, MO, USA). Samples were 
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incubated for 24 hours with 25 µg/ml N-Palmitoyl- S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-
(R)-cysteinyl-(S)-seryl-(S)- lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine (EMC Microcollections, Tübingen, 
Germany) at 37 °C and 5% CO
2
. After centrifugation, the supernatants were stored at -80 °C 
until assayed for IL-4, IL-13, IFNγ, GM-CSF, IL-6, TNFα, IL-12p40, IL-1ra, TGFβ, IL-10 and IL-1β 
using standard ELISA techniques according to manufacturers’ guidelines (Central Laboratory 
of the Blood Transfusion Service, Amsterdam, The Netherlands). Data on IL-4, IL-13 and GM-
CSF production upon stimulation was not available, since in most samples, levels of these 
cytokines were below the detection limit (4 pg/ml for IL-4 and IL-13; 30 pg/ml for GM-CSF). 
Statistical analysis 
Due to the non-normal distribution of MTPM values and cytokine levels, a log transformation 
was applied to these variables in all statistical models applied. A principal component 
analysis (PCA) was performed to reduce the multitude of correlated cytokine variables by 
creating ‘summary’ variables, so called principal components.[31] Data of IFNγ, IL-6, TNFα, 
IL-12p40, IL-1ra, TGFβ, IL-10 and IL-1β were entered in the PCA. Percentage of variance 
explained by the components and Eigen values > 1 were used to determine the number of 
principal components. For each variable in the extracted component(s), a “factor loading” 
was calculated which can be interpreted as correlation measure between the observed 
variable and the component. For analysis, only factor loading scores of > 0.4 (significant) 
qualified for loading of a variable on a component.[32]
 In order to assess the relationship between early migration and the innate immune 
response, a multivariate generalized estimating equations (GEE) model was fitted with MTPM 
as dependent variable and the extracted principal components as independent variables. In 
all analyses, gender, age, body mass index (BMI), time-to-blood sampling and prothesis type 
were added as covariables. Since every knee has its own MTPM value, patients with bilateral 
knee replacements have two MTPM values but only one data-set of cytokine responses. 
To model the intrapatient MTPM correlation in patients with bilateral knee replacement, 
family identity numbers were included as random effect variables. Results of the GEE model 
analyses are expressed as estimates (β) that represent the association between MTPM and 
extracted principal components of cytokine levels. Statistical analyses were performed 
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Results 
Baseline patient characteristics of our study are presented in Table 1. Maximal total point 
motion (MTPM) values of 137 knees in 114 patients were available. Median MTPM was 0.66 
mm and had a range of 0.15-8.19 mm. Cytokine levels were measured from whole blood 
samples collected one to seventeen years postoperative. Table 2 shows the cytokine levels 
of whole blood samples stimulated with TLR2 agonist Pam3Cys-SK4. As cytokine responses 
are likely to act simultaneously in the innate immune response, high correlation between 
secreted cytokines (see Supplementary Table 1) was observed. To reduce the correlated 
data of the cytokines principal component analysis (PCA) was performed on all cytokines 
for which a quantitative measure was available. As shown in Table 2, two components were 
extracted. The first component is determined by a combination of IFNγ, IL-12p40, IL-10, IL-1β, 
TNFα and IL-6, and explains 53.0% of the total variation. The second component, explaining 
15.4% of the total variation, is determined by a combination of TGFβ, IL-1ra and IL-10. 
 Next, we investigated the relationship between MTPM and the principal components 
extracted. We observed a significant and independent inverse association between MTPM 
and the first component (β= -0.128; p=0.041), however, the association with the second 
component (β= 0.007; p=0.911) was not significant. Respective effect sizes of covariables 
age, gender, BMI, time-to-blood sampling and prosthesis type are shown in Supplementary 
Table 2; model 1.
 To explore whether the cytokine(s) of component 1 contributed equally to the 
association with MTPM, we performed a multivariate analysis with MTPM as dependent 
variable and the cytokines from component 1 as separate covariables. We found  a significant 
inverse association with MTPM only for IFNγ (β= -0.161; p=0.008), which was independent 
of the other cytokine levels and age, gender, BMI, time-to-blood sampling and prosthesis 
type. Respective effect sizes of covariables other cytokines, age, gender, BMI, time-to-blood 
sampling and the prostheses types are shown in Supplementary Table 2; model 2 and 3. 
 Finally, it was assessed whether the association of IFNγ with MTPM showed interaction 
with prosthesis type. A significant interaction between IFNγ and prosthesis type was 
observed only for Nexgen (β= 0.337; p=0.019), independent of the covariables age, gender, 
time-to-blood sampling and BMI (Supplementary Table 2, model 4), indicating that the 
relationship between IFNγ and MTPM among patients with a Nexgen prosthesis is different 
when compared to patients with other prostheses types. Stratified analyses, by “Nexgen” and 
“other” prostheses types, subsequently showed in the “other” strata an inverse association 
between IFNγ and MTPM (β= -0.239; p<0.001), whereas no association was observed in the 
‘Nexgen” strata (β= -0.006; p=0.938), independent of the covariables age, gender, time-to-
blood sampling and BMI. Exclusion of uncemented protheses, all belonging to the “other” 
strata, did not change the observed inverse association between IFNγ and MTPM.
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Table 1: Study characteristics 
MTPM median (range)
Total number of patients (N) 114 0.66 (0.15-8.19)
Patients with bilateral prosthesis 23 
Women 90 0.64 (0.18-8.19)
Age (yrs) 66.5 ± 10.7
BMI 27.9 ± 5.3
Blood collection after surgery (yrs)a 6.6 ± 4.3
Prosthesis type (N)
    Nexgen (Zimmer) 63 0.53 (0.17-5.03)
    Triathlon (Stryker Inc. corp.) 33 0.54 (0.17-8.19)
Interax ISA (Howmedica osteonics corp.) 9 0.38 (0.21-1.31)
  Interax PS (Howmedica osteonics corp.) 8 0.60 (0.15-0.73)
    Interax (Howmedica osteonics corp.) 18 0.60 (0.19-3.40)
    Rocc (Biomet Inc.) 6 1.27 (0.58-4.10)
Fixation method (N)
    Cemented 125 0.54 (0.15-8.19)
    Non-cemented 12 0.84 (0.19-3.40)
Data are expressed as N or mean ± SD. 
Data of MTPM are expressed as median (range) in mm.  
a Mean number of years between surgery and blood sample collection. 




IFNγ 33 (40) 0.69
TGFβ1 2737 (1432) 0.79
IL-12p40 279 (545) 0.82
IL-1ra 16242 (10661) 0.71
IL-10 276 (432) 0.81 0.41
IL-1β 118 (180) 0.64
TNFα 148 (446) 0.86
IL-6 6189 (12770) 0.84
Variance explained (%) 53.0 15.4
a Data are expressed as median (IQR) bComponents with ‘Eigen values’ >1 are extracted after Varimax rotation with 
Kaiser Normalization, significant coefficients with values >0.4 are displayed.
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Discussion 
In the current study, the association between three-dimensional migration of knee 
prostheses as measured with RSA and the innate immune responses via specific stimulation 
of TLR2 was evaluated in a cohort of total knee arthroplasty (TKA) patients. We observed a 
beta of -0.128, representing an inverse association of the cytokines IFNγ, IL-12p40, IL-10, IL-
1β, TNFα and IL-6, clustered in component 1 of the PCA, with respect to MTPM. Subsequent 
multivariate analysis showed that IFNγ independently confers this inverse effect on MTPM 
particularly among patients who received a prosthesis type other than Nexgen (β= -0.239; 
p<0.001).  It should, however, be noted that the Nexgen prosthesis occurred most frequent 
in our cohort and had, therefore, the highest power in the interaction analyses. Since studies 
have shown that increased early migration expressed by increased MTPM is associated with 
increased loosening and revision of knee prostheses at the long term [23,25], our results 
indicate that low levels of IFNγ upon TLR2 stimulation could be a biomarker, able to predict 
such loosening particularly in patients who carry a prosthesis type other than Nexgen. 
Given the relative small sample size of our study, replication of our findings is necessary in 
larger cohorts and follow-up studies, before such a clinical application of IFNγ as biomarker 
becomes feasible. In this study, we did not include raw data or calculated back the respective 
INFg levels with MTPM values in mm because of the skewness of both the MTPM values and 
IFNγ values. Finding a ‘beneficial’ threshold level of IFNγ for clinical utility would be very 
desirable. However, our study should be considered an initial discovery that needs to be 
replicated in larger studies preferably large enough to set such a threshold.
 This study is the first to indicate an inverse association between IFNγ and migration of 
knee prostheses. Nevertheless, the role of IFNγ in bone remodelling, which is relevant to 
implant fixation, has been investigated in several studies. Several in vitro studies showed 
that IFNγ either suppressed [33,34] or enhanced [35,36] osteoclastogenesis whereas 
another in vitro study showed that IFNγ positively stimulates osteoblastogenesis of human 
mesenchymal stem cells.[37] Furthermore, an in vivo study, using different mouse models 
of bone loss showed that the net effect of IFNγ is that of stimulating bone resorption [36], 
whereas administration of IFNγ increased bone formation in wild-type mice and rescued 
ovariectomized mice from osteoporosis.[38] Taken together, the role of IFNγ in the bone 
remodelling process is not completely clear, yet, based on our data, we hypothesize that 
IFNγ might have a beneficial effect on early migration. Whether this effect is due to either 
a decrease in osteoclastogenesis or an increase in osteoblastogenesis during initial fixation 
warrants further investigation. Furthermore, an in vitro study showed that titanium and 
polymethylmethacrylate (PMMA) bone cement particles have different effects on IFNγ 
signalling in osteoclast progenitor cells.[39] Therefore, it could be that the role of IFNγ in 
early migration differs between type of fixation. Although interesting, we were not able 
to compare cemented and non-cemented TKA prostheses in our data set, as less than ten 
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percent of the measured prostheses were non-cemented. Moreover, the only non-cemented 
prosthesis included was the Interax prosthesis. Since the uncoated, non-cemented Interax 
prosthesis was shown to migrate excessively and have a three times higher revision rate 
compared to the cemented Interax prosthesis, we cannot exclude the role of type of 
fixation as possible confounder.[22,28] Nevertheless, in this dataset when we excluded the 
uncemented prostheses from our analyses, the observed association between IFNγ and 
MTPM did not change. In this study, ex vivo blood stimulation with the TLR2 specific agonist 
Pam3Cys-SK4 was used rather than stimulation with wear particles. The use of wear particles 
may have given a more representative biological response, however,  a study by Matthews 
et al.  has shown that cells cultured with wear particles of different materials or sizes, secrete 
different types of functional inflammatory mediators.[18] In this respect, Pam3Cys-SK4 
responses have been shown to be easily reproduced and not to suffer from a possible 
contamination of endotoxins on wear particles.[13,17] Furthermore, within literature, 
the possible role of TLR4 signalling activated by endotoxins of cell wall of gram-negative 
bacteria that reside on wear particles has been frequently addressed.[12,40] For that matter, 
both TLR2 as TLR4 are found in tissue around loosened joint replacements.[16] Additional 
studies are, therefore, necessary to investigate the role of TLR4 triggered innate immune 
responses in early migration of prostheses, as reflected by the capacity of blood cells to 
produce cytokine responses upon stimulation with lipopolysaccharides. These studies may 
confirm the here identified inverse association of MTPM and IFNγ also via TLR4 activation. 
 A drawback of this study is that not all blood samples were collected exactly one year 
after surgery. Cytokine levels were measured from blood samples collected one to seventeen 
years postoperative. However, the observed association between cytokine levels, including 
IFNγ alone, and MTPM did not change when corrected for follow-up time as confounder. 
Therefore, it seems unlikely that the time to blood sampling has influenced the outcome. 
 Altogether our results indicate that patients with low levels of IFNγ upon stimulation 
of TLR2 are at higher risk of early migration of their prosthesis, particularly among patients 
who have received a prosthesis other than Nexgen. Eventually, our findings can be used 
to develop a preoperative prediction model for implant failure with specific focus on 
aseptic loosening. Such a prediction model will be important for patient’s follow-up (i.e. the 
frequency of postoperative radiographic control after TKA) as well as patient assessment in 
the preoperative state (i.e. postponing surgery if a reasonable risk for loosening is present). 
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Supplementary data 
Supplementary table 1: Pearson correlations among cytokines of Pam3Cys-SK4-stimulated blood 
samples.  
P-value
IFNγ TGFβ1 IL-12p40 IL-1ra IL-10 IL-1β TNFα IL-6
IFNγ 0.721 6x10-6* 0.402 1x10-6* 2x10-3* 0x10-8* 2x10-6
TGFβ1 -0.06 9x10-4* 2x10-5* 9x10-5* 8x10-2* 1x10-4* 9x10-6*
IL-12p40 0.34 0.25 2x10-8* 1x10-32* 6x10-12* 8x10-22* 1x10-38*
IL-1ra 0.07 0.36 0.45 1x10-10* 1x10-3* 2x10-3* 5x10-6*
IL-10 0.36 0.31 0.79 0.51 1x10-8* 1x10-23* 2x10-39*
IL-1β 0.24 0.11 0.52 0.26 0.44 3x10-11* 5x10-10*
TNFα 0.50 0.28 0.68 0.25 0.70 0.50 2x10-29*
IL-6 0.36 0.33 0.83 0.38 0.84 0.47 0.76
Pearson correlations
Log transformed values of cytokines were used. 
*Significant at the p-values.
Supplementary table 2: Effect sizes of the linear relationship between MTPM as dependent variable 
and all covariates in four different models. 
Model 1 Model 2 Model 3 Model 4
β p β p β p β p
Gender 0.058 0.744 0.095 0.577 0.067 0.684 0.115 0.485
Age 0.002 0.675 0.000 0.931 0.001 0.817 0.004 0.482
BMI -0.008 0.525 -0.006 0.613 -0.007 0.549 -0.011 0.381
Prosthesis type
   Interax (reference) 0 0 0 0
   Nexgen -0.133 0.670 -0.174 0.560 -0.109 0.702 -1.423 0.035*
   Triathlon -0.044 0.930 -0.174 0.727 -0.005 0.991 -0.567 0.509
   Rocc 0.544 0.285 0.517 0.275 0.604 0.198 -1.430 0.218
   Interax ISA -0.311 0.338 -0.320 0.297 -0.308 0.310 -1.105 0.344
   Interax PS -0.325 0.334 -0.322 0.259 -0.287 0.305 0.180 0.742
Component 1 -0.128 0.041*
   IFNγ -0.161 0.008* -0.159 0.002* -0.336 0.003*
   IL-12p40 0.000 0.999
   IL-10 0.054 0.576
   IL-1β -0.078 0.134
   TNFα 0.035 0.589
   IL-6 -0.054 0.450
Component 2 0.007 0.911
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Supplementary table 2: Effect sizes of the linear relationship between MTPM as dependent variable 
and all covariates in four different models. 
Model 1 Model 2 Model 3 Model 4
β p β p β p β p
IFNγ*Prosthesis type
   Interax (reference) 0
   Nexgen 0.337 0.019*
   Triathlon 0.097 0.520
   Rocc 0.530 0.052
   Interax ISA 0.225 0.512
   Interax PS -0.031 0.791
Time-to-blood sampling a -0.013 0.706 -0.024 0.491 -0.009 0.767 -0.030 0.385
Model 1: Relationship between MTPM and the principal components extracted. 
Model 2: Relationship between MTPM and the cytokines from component 1.  
Model 3: Relationship between MTPM and IFNγ.
Model 4: Relationship between MTPM and IFNγ, including an interaction term. 
a Years between surgery and blood sample collection.
*Significant at the p<0.05 level. 







SUMMARY AND GENERAL DISCUSSION
The research in this thesis represents part of a project aimed at developing a minimally 
invasive treatment for aseptic loosened orthopaedic implants (e.g. hip-, knee implants). 
In this thesis the biology of the process of aseptic loosening of implants was explored. 
Ultimately, these findings may lay down the foundation for the identification of biological 
targets to counteract the aseptic implant loosening process. Eventually a biological 
refixation approach for loosened orthopaedic implants may be developed. In Chapter 1, 
the process of aseptic loosening as well as aspects of the peri-prosthetic interface tissue 
were introduced. Aseptic loosening is the most common reason for complex implant 
revision surgeries, which affects on average 10-20% of total hip and knee replacement 
patients 10-20 years after the primary joint replacement.[1-3] During the implant loosening 
process a fibrous-like tissue, the so-called peri-prosthetic interface tissue, is formed at the 
bone-implant interface. This interface tissue usually contains a wide variety of cells, which 
produce cytokines and chemokines triggering bone resorption around the implant. This 
leads to mechanically unstable implants and ultimately a need for revision surgery due 
to incapacitating pain or even a peri-prosthetic fracture. Aseptic loosening of implants 
occurs secondary to a biological response to implant wear-debris particles, originating 
from the articulating joint, of which the most important cellular target is believed to be the 
macrophage. Nevertheless, the precise biological mechanisms underlying the loosening 
process have still to be elucidated. Consequently, biologic targets for successful treatment 
of aseptic loosening have not been found yet. Therefore, the aim of this thesis was to 
increase the knowledge on the biological responses around aseptic loosened prostheses by 
(1) characterizing the cellular content of the peri-prosthetic interface tissue, (2) studying the 
osteogenic potential of peri-prosthetic interface tissue cells, and (3) exploring the individual 
host-immune responses in relation to early migration of prostheses.
Does the cellular content of peri-prosthetic interface tissue shed new light on 
the mechanism of implant loosening?
Characterization of the peri-prosthetic interface tissue is one of the ways of studying 
the underlying mechanisms of aseptic loosening and potential therapeutic targets for 
treatment. Numerous studies have provided information about the cellular content of 
peri-prosthetic interface tissue as well as the cytokines and chemokines it produces.[4-
6] In a recent review, on histological and immunological aspects of aseptic loosening, a 
predominance of macrophages, multinucleated cells and signs of inflammation was 
reported in the peri-prosthetic interface tissue.[5] However, a lack of information on the 
role of fibroblasts and osteocytes amongst others was noted. Since only studies based 
on histological evaluation (e.g. cell/tissue/organ cultures) were included in that review, 
important cellular and molecular mechanisms associated with aseptic implant loosening 
may have been missed. Therefore, in Chapter 2, we conducted a systematic literature search 
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aimed at summarizing the characteristics of peri-prosthetic interface tissue based on in vitro 
findings, in order to provide an overview of the currently proposed cellular mechanisms 
involved in implant loosening. Besides macrophages also fibroblasts, derived from the peri-
prosthetic interface tissue, were shown to be actively involved in osteoclastogenesis with 
subsequent pathologic bone resorption through production of inflammatory cytokines, 
chemokines, matrix degrading enzymes, osteoclastogenic factors and angiogenic 
factors. Moreover, fibroblasts were reported to be considered as potential therapeutic 
target in treating aseptic loosening. Again, only a few papers addressed the involvement 
of osteoblasts/osteogenesis in the process of implant loosening. Two papers suggested 
that the peri-prosthetic interface tissue of some patients with aseptic loosening exhibits 
osteogenic characteristics.[7, 8] Another paper showed a potentially disturbed osteogenic 
signalling in these patients.[9] Thus, (effects on) osteoblasts do seem to play a role in the 
process of aseptic loosening. Therefore, we concluded that besides the well-known role of 
macrophages and osteoclasts in the mechanism of loosening, the role of fibroblasts and 
osteoblasts should be taken into account.
 These findings led us to perform a tissue characterization study of peri-prosthetic interface 
tissue samples collected during revision surgery for aseptic loosened hip prostheses. In 
that study both gene expression analysis and (immuno)histochemistry were combined to 
evaluate the presence of various cell types, including fibroblasts and osteoblasts (Chapter 3). 
Results showed that peri-prosthetic interface tissue samples express macrophage-, 
fibroblast-, osteoblast- and endothelial cell-related genes. Exploring gene expression 
patterns between samples revealed two components, clustering osteoblast- and fibroblast-
related genes in another component than macrophage- and endothelial cell-related genes. 
Overall, a high inter-tissue sample variability in factor loading scores of the components was 
observed, which could not be explained by patient- or prosthesis characteristics. (Immuno)
histochemical staining of the tissue samples showed predominance of both fibroblasts and 
macrophages with high inter- and intra-tissue sample variation in stained area and staining 
location. No significant associations were found between the stained area and patient- or 
prosthesis characteristics or gene expression data. Besides studying the macrophage in 
general, we also investigated the presences of macrophage subtypes in the tissue samples. 
In one-third of the samples M1(pro-inflammatory phenotype) and M2 (anti-inflammatory, 
pro-tissue healing phenotype) macrophages were present in comparable amounts, 
whereas almost two-third showed the predominance of M2 macrophages. In conclusion, 
fibroblasts and osteoblasts seem to be at least as important as macrophages in the aseptic 
loosening process. In addition, in particular M2 macrophages were present in our peri-
prosthetic tissue samples.   
 The observed clustering of fibroblast- and osteoblast-related genes in a different 
component than macrophage- and endothelial cell-related genes, underscores the 
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different roles these (clusters of ) cell types have in the process of implant loosening. 
Furthermore, differences in component scores between tissue samples indicate that the 
implant loosening process as such is based on a variety of cellular mechanisms between 
patients but also within patients. Morowietz et al. showed that the (proportional) 
presence of distinct cell types within peri-prosthetic interface tissue characterize different 
mechanisms of loosening (i.e. wear-debris induced, inadequate initial fixation).[10] Both 
fibroblasts and macrophages are the prominent cell types within the peri-prosthetic 
interface tissue (Chapter 3) and can produce similar osteolytic factors in response to 
wear-debris particles (Chapter 2). However, fibroblasts might also be involved in another 
mechanism of loosening, where inadequate initial mechanical fixation of the implant 
results in an expanding fibrous tissue (like scar tissue) with subsequent micromovement 
of the implant. The latter preventing a close interconnection between bone and implant.
[10, 11] Fibroblasts can therefore significantly influence prosthesis survival because of their 
inflammatory response to wear debris particles and their capacity to produce and remodel 
the extracellular matrix around implants.[12] The observed differences in cellular content 
between patients might be the reason why therapeutic strategies which (only) interfere 
with the osteolytic process of aseptic loosening (e.g. non-steroidal anti-inflammatory drugs 
(NSAIDs), antibodies to specific osteolytic mediators) [13-19] showed inconclusive results. 
A combined therapy, which not only targets the inflammatory response to wear debris 
particles and the subsequent osteolytic process but also targets the extracellular matrix 
production and modulation, might therefore be necessary to successful interfere with the 
aseptic loosening process.
 Although the role of macrophages within the peri-prosthetic interface tissue has been 
extensively studied, recently, the role of macrophage polarization showed seemingly 
contradictive results. Based on retrieval and in vitro studies, it has been shown that the 
presence of macrophages of the M1 phenotype (pro-inflammatory) in the peri-prosthetic 
interface tissue outweighs the presence of macrophages of the M2 phenotype (anti-
inflammatory, pro-tissue healing).[13] Additionally, inflammatory wear debris responses are 
aggravated in M1-macrophages but are suppressed in M2-macrophages.[14, 15] However, 
other studies reported either a predominance of M2-macrophage activation or presence of 
equal proportions of both macrophage subtypes. [9, 16] In our study samples, the presence 
of M2-macrophages outweighed the presence of the M1 phenotype, although some of 
our samples showed no differences between both subtypes. Koulouvaris et al. proposed 
that in the final stages of loosening (i.e. revision is required), the pro-inflammatory response 
to wear debris particles might not be decisive anymore, resulting in a more prominent 
presence of M2-macrophages.[9] Moreover, a local dynamic shift in the macrophage 
phenotype from the inflammatory M1 to the anti-inflammatory M2 phenotype is presumed 
a transition from a state of inflammation to tissue regeneration.[17-19] Therefore, the 
126
Chapter 7
abundance of M2-macrophages within the peri-prosthetic interface tissue might be 
indicative for a regenerative capacity of this tissue and proposes the prospective use of 
macrophage modulation as an potential early therapeutic strategy in the loosening 
process. Local modulation of the macrophage phenotype, which was already pointed out 
and investigated by several other authors[13, 20-22], might limit the wear particle-induced 
inflammation with subsequent less peri-prosthetic osteolysis.
 In general, a large variability in outcome measures as well as study population 
characteristics exists, which makes comparison between studies almost impossible. In the 
context of patient heterogeneity, most in vitro studies make use of selected cell types of 
animal or human origin (i.e. cell lines or specific primary cell types) to reduce heterogeneity. 
Although, this approach facilitates interpretation of the results, it ignores the complexity 
of the variety of cellular mechanisms in aseptic prosthesis loosening. As aseptic loosening 
involves the cross-talk between a variety of cells and the subsequent production of a wide-
range of inflammatory mediators and matrix degrading factors, such basic experimental 
approaches are not representative of the in vivo situation. Therefore, despite the relatively 
high variability, more research should be focused on studying the complete peri-prosthetic 
interface tissue instead of selected cells, like in our study in Chapter 3. Another general 
limitation of (characterization) studies on peri-prosthetic interface tissue is the relatively 
small sample size. For that matter, to increase the ability to compare study results, studies 
with a sufficient sample size and more detailed and comparable description of study and 
tissue characteristics should be conducted.
 
Do peri-prosthetic interface tissue cells have potential osteogenic capacity?
The current strategy for the treatment of aseptic implant loosening (i.e. revision surgery) is 
successful with 10-year survival rates of 70-80%.[1-3, 23] However, the burden to the patient 
is large due to the duration of the surgical procedure, (e.g. risks for infection) and extensive 
blood loss causing morbidity (e.g. cardiovascular, renal) to the patient in the postoperative 
period.[24] Minimally invasive percutaneous implant refixation procedures have therefore 
been developed in order to reduce morbidity, while stabilizing the primary prosthesis with 
bone cement either or not in combination with eradication of the peri-prosthetic interface 
tissue.[25-28] Other strategies aimed at reducing the prevalence of aseptic loosening by 
improving the quality of the primary implant (e.g. design and material) or on interfering with 
the osteolytic process of aseptic loosening (e.g. the use of non-steroidal anti-inflammatory 
drugs (NSAIDs), bisphosphonates and antibodies to specific osteolytic mediators).[29-36] 
Bone resorption (osteolysis) is part of the bone remodelling process which also involves 
bone formation. Surprisingly, only limited attention has been paid to the role of bone 
formation (osteogenesis) in aseptic loosening and even less is reported on the role of 
osteogenesis in treatment of aseptic loosening.
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 Osteogenesis can be stimulated in a variety of ways, for example, growth factors can 
stimulate signalling pathways that are involved in osteoblast differentiation. Important 
osteogenic signalling pathways include the bone morphogenetic protein (BMP) and the 
Wingless (Wnt) signalling pathway and several studies have even shown interactions 
between these two pathways.[37-41] However, little is known about uncoupling these 
pathways and their intrinsic inhibitors (like sclerostin) and the effect on osteoblast 
differentiation. Since, sclerostin, acts physiologically as a downstream molecule of BMP 
signalling to inhibit Wnt signalling and negatively regulates bone mass [42, 43], interference 
with both pathways and sclerostin might prolong the effect of BMPs on osteoblast 
differentiation or bone formation. Therefore, in Chapter 4, the possibility to enhance bone 
regeneration by interference with BMP and Wnt signalling pathways was studied in human 
and murine cell lines. The interaction of both pathways on the effect on expression of SOST 
(the gene encoding sclerostin) was investigated using human osteosarcoma cells. Results 
showed that SOST expression could be either decreased with increasing Wnt signalling 
or increased by stimulation of BMP signalling. However, GIN (a specific inhibitor of GSK3β, 
which is an important part/member in Wnt signalling) could significantly decrease the 
BMP4-induced SOST expression and thereby uncouple BMP signalling and SOST expression. 
In addition, using the murine pre-osteoblastic cell line KS483, combined BMP4 and GIN 
stimulation could enhance osteoblast differentiation (increase both ALP activity and matrix 
mineralization) compared to BMP4 alone. Altogether, this study showed that uncoupling 
BMP signalling and SOST expression (using GIN) leads to an enhanced BMP4-induced 
osteoblast differentiation. This effect has potential to be used in clinical practice to induce 
local bone formation, e.g. osseointegration of implants or fracture healing.
 Until now, stimulation of osteogenesis within the peri-prosthetic interface tissue itself 
has never been studied. Therefore, in Chapter 5, the actual capacity of peri-prosthetic 
interface tissue cells to differentiate into the osteoblast lineage was investigated. In addition, 
the potential to (further) increase osteoblast differentiation using the bone formation 
enhancing factors tested in Chapter 4 was examined. Results showed that culturing peri-
prosthetic interface tissue cells in osteogenic medium increased ALP staining as well as 
gene expression levels and resulted in production of a mineralized matrix in the majority of 
the donors, when compared to cells cultured in normal culture medium. In general, addition 
of BMPs, GIN or a combination of BMPs and GIN to the osteogenic culture medium could 
not significantly further increase the studied osteogenic characteristics, although in some 
donors it could be increased. Overall, a high inter- and intra-donor variability in response to 
different osteogenic stimuli was observed, which hampered the identification of a standard 
formula inducing osteogenic differentiation. Nonetheless, peri-prosthetic interface tissue 
cells were proven to possess osteogenic potential and as such stimulation of osteogenesis 
within the peri-prosthetic interface tissue could possibly counteract or slow down osteolysis 
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in the aseptic loosening process. Several animal studies already showed that BMP2 can 
enhance neo-bone formation to fill critical-sized bone defects.[44-46] In addition, a case-
report study showed that implantation of a construct with BMP2 in combination with bone 
marrow derived mesenchymal stem cells could fill the critical bony defect after revision 
surgery.[47] Furthermore, preclinical studies showed the potential of inhibiting sclerostin 
via a monoclonal antibody in enhancing bone formation and preventing implant loosening.
[48, 49]
 The ability of peri-prosthetic interface tissue to respond to osteogenic stimuli suggests 
that a population of cells is (already) committed to the osteoblastic lineage. As we did 
not find an association between the responsiveness to osteogenic stimuli and the cell 
content of the tissue, we were not able to pinpoint the exact cell type(s) responsible for 
the osteogenic capacity of peri-prosthetic interface tissue. Both our characterization 
study and the systematic review showed macrophages and fibroblasts to be the main 
cell type in peri-prosthetic interface tissue. Therefore, likely one of these cell-types, or a 
specific subpopulation of these cell types, is able to increase ALP production and matrix 
mineralization in response to osteogenic stimuli. In a study by Heinemann et al., the main 
cell type found in granulomas obtained from prosthetic revisions was shown to stain 
positive for ALP as well as CD68 (a macrophage marker).[50] In a study by Zreiqat et al, 
foamy macrophages but not spindle-shaped mesenchymal cells, both obtained from 
loosened prostheses, were shown to express and produce several osteoblastic genes and 
proteins.[7] On the other hand, literature also shows fibroblasts to be able to express several 
osteoblast related genes.[51] Interestingly, several studies have showed that specific human 
fibroblasts (i.e. dermal and periodontal fibroblasts) are able to differentiate into osteoblasts.
[52-54] Thus, finding a population of cells within the interface tissue, which can differentiate 
into the osteoblastic lineage is likely to provide a new opportunity to interfere with the 
altered balance in bone remodelling and bone resorption in aseptic loosening. 
 Almost all tissue samples responded to either one of the applied osteogenic stimuli, 
however, there was not one single, nor a combination of factor(s) that effectively induced 
osteogenic differentiation in all donors. Studies investigating the osteogenic differentiation 
of human bone marrow derived mesenchymal stem cells also showed inter-individual 
variation in the osteogenic capacity of these cells.[55, 56] Moreover, in a study using adipose 
derived mesenchymal stem cells inter-individual variation in response to BMP2 was shown.
[57] Therefore, stimulation of the osteogenic capacity of peri-prosthetic interface tissue cells 
warrants either further research into one universal stimulus for all patients or requires a 
more personalized medicine approach. In addition, further research into the influence of 
clinical parameters (e.g. patient- and prosthesis characteristics) on the osteogenic capacity 
of peri-prosthetic interface tissue cells could also be necessary to be able to develop such a 
universal or personalized approach.     
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Does the individual host immune response relate to prosthesis migration?
Cellular responses to wear debris particles play a key role in the progression of osteolysis 
around aseptic loosened prostheses. Phagocytosis of wear debris particles triggers the 
release of (pro-)inflammatory cytokines, activating pathways which lead to bone resorption. 
The extent of osteolysis may vary between patients due to, amongst others, differences in 
individual host-immune responses to wear debris, which can be related to an individual 
genotype.[58-60] Therefore, evaluation of differences in host-immune responses between 
patients could possibly help to predict the risk of aseptic loosening of the prosthesis. 
Currently, loosening can be detected by measuring sub millimetre migration of the 
prosthesis relative to the host bone using simultaneous two standard radiographs with 
radiostereophotogrammatric analysis (RSA).[61-64] However, RSA measurements require 
the insertion of 1 mm tantalum beads in the patient’s bone, thus (early) assessment of 
loosening using RSA can only be used in patients that have been included in clinical RSA 
studies. Because of the genetic nature of host-immune responses it might be possible to 
detect the risk of loosening early, even before the patient needs joint replacement surgery. 
Therefore, in Chapter 6, the relation between innate immune responses and implant 
migration, using RSA, was investigated. For this purpose, whole-blood of TKA patients, with 
different designs of knee prostheses, was stimulated with a peptide inducing the Toll-like 
receptor 2 (TLR2) immune response. As a result, a variety of cytokines was produced, which 
were shown to cluster in two components. The component containing (primarily) pro-
inflammatory cytokines correlated inversely with migration. Further analysis showed IFNγ 
to have the highest contribution to this association. The latter was only observed in those 
patients who had a prosthesis other than the Nexgen knee prosthesis, for which we have no 
explanation yet. In conclusion, this study shows that patients with high levels of IFNγ upon 
stimulation of TLR2 are at lower risk of early migration of their knee prosthesis.
 Several studies have shown that progressive early migration, as measured with RSA, is 
associated with an increased risk at revision of knee and hip prostheses at the long term.[64, 
65] Therefore, the observed association between specific cytokines and early migration of 
knee prostheses (Chapter 6), indicates that the host-immune responses might potentially be 
used as predictor for implant loosening. Since IFNγ showed the highest contribution to the 
observed association, this might be a potential “loosening” biomarker. Some studies [66-71] 
have reported on the role of IFNγ in bone remodelling, a continuous dynamic process, which 
is present around implants, leading to either implant fixation or loosening. Nevertheless, the 
exact role of IFNγ in these responses has not yet been fully established, since both in vitro 
studies investigating the effect of IFNγ on osteoblastogenesis or osteoclastogenesis and 
in vivo studies on IFNγ and bone remodelling have reported inconclusive results.[66-71] 
For that matter, biomarker panels instead of single biomarkers, are likely to have far greater 
potential to predict, diagnose and monitor the progression of peri-prosthetic osteolysis 
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which ultimately results in aseptic implant loosening.[72] Future studies using biomarker 
panels might be able to identify patients with a specific cytokine profile upon stimulation 
of their innate immune system, which could potentially predict a patient’s susceptibility 
to aseptic loosening. Eventually, identification of patients’ specific host-immune responses 
to implant material could help to develop a preoperative prediction model for implant 
failure. This may also guide patient’s follow-up moments (i.e. more frequent if at risk in order 
to prevent gross bone loss and subsequent peri-prosthetic fracture) as well as patient’s 
assessment preoperatively, taking patients’ specific host-immune responses into the shared 
decision making process for choosing for joint replacement surgery or a more conservative 
approach in osteoarthritis patients.  
 As the study in Chapter 6 was the first study to investigate the relation between an 
individual innate immune response and early migration of knee prostheses, future studies 
have to confirm our found association. In the current study, the host-immune response was 
determined using stimulation of TLR2, which has been shown to be easily reproducible and 
not to suffer from possible contamination of endotoxins on wear debris particles.[73, 74] 
However, particle size or type of material influences the secreted inflammatory cytokine 
profile [58] and as such stimulation with wear debris particles would provide a more 
realistic approach investigating the association of host-immune responses and prosthesis 
migration. Therefore, future studies using wear debris particles should be conducted. Due 
to heterogeneity in patient- and prosthesis characteristics within our study, pin-pointing 
possible confounders in the observed association was impossible. Nevertheless, the 
absence of the association between IFNγ and early migration in patients receiving the 
Nexgen type of knee prosthesis is an indication that prosthesis characteristics might be 
important in the observed association. Previous studies already showed that type of fixation 
or prosthesis design are of influence on migration and failure rate of prostheses.[62, 75] 
Future association studies, with more homogenous patient and prosthesis characteristics, 
are therefore essential to clarify the link between individual host immune responses and 
prosthesis migration and ultimate implant failure due to loosening.
General conclusions and future perspectives
The findings in this thesis support the significant role of macrophages in the aseptic 
loosening process of orthopaedic implants. Variation regarding the presence of M1- and 
M2-macrophages within the peri-prosthetic interface tissue implies a potentially important 
contribution of macrophage polarization in the loosening process. Nevertheless, besides 
macrophages, the role of fibroblasts and osteoblasts in the mechanism of loosening should 
not be underestimated and warrants further investigation. Furthermore, the demonstrated 
osteogenic potential of peri-prosthetic interface tissue cells accentuates the regenerative 
capacity of this tissue, which provides a (new) opportunity to interfere with the altered 
balance (i.e. imbalance) in bone remodelling in aseptic loosening. 
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 The large inter-tissue differences observed at all levels in all studies within this thesis, 
as well as described in other studies investigating the loosening process, clearly show the 
complexity of the loosening process. Nevertheless, this thesis provides clues for alternative 
therapeutic strategies to interfere with the loosening process as such and shows the potential 
for the use of specific host-immune responses for (early) detection and possibly prediction 
of loosened implants. However, further research into these directions is warranted. 
 General recommendations for future research are to mimic as much as possible in vivo 
like experimental settings, for that matter the use of the complete peri-prosthetic interface 
tissue, for example in organ cultures, in combination with the presence of wear particles, 
inflammatory cells and resorptive cells might be an option to be explored. Moreover, a 
sufficient sample size and detailed information on patient- and prosthesis characteristics 
are needed to improve the generalizability of the results.
 Identification of the specific cell type(s) which possess(es) osteogenic capacity within 
the peri-prosthetic interface tissue might help to more specific stimulate osteogenesis. 
In addition, pro-osteogenic compounds other than BMP and/or GIN, like compounds 
influencing the Hedgehog or IGF signalling, might induce a more potent stimulation of 
osteogenesis of the peri-prosthetic interface tissue. Ultimately one universal osteogenic 
stimulus could be found, although it is more likely, to find different patient more specific 
osteogenic stimuli in a personalized medicine approach.
 The effect of modulation of macrophage subtypes should be delineated into more 
detail. Converting pro-inflammatory M1-macrophages to an anti-inflammatory pro-tissue 
healing M2 phenotype [22, 76] might reduce the inflammatory response to wear debris 
particles and is thus a possible target for an early intervention in the loosening process. In 
this respect, specialized pro-resolving lipid mediators (SPMs)[77, 78] could be interesting 
to investigate, as SPMs are able to modulate the inflammatory response to biomaterials 
through M2 macrophage polarization.[79]
 Early intervention can only be realized when loosening is detected at an early stage. 
With this respect, the use of biomarker panels to predict a patient’s susceptibility to aseptic 
loosening should be studied. In addition, large prospective association studies are needed 
to further elucidate the link between individual host immune responses and the failure, due 
to aseptic loosening, of implants.[59, 80, 81]
 Continuing research on the biological responses around aseptic loosened prostheses 
will provide a rationale for better understanding aseptic loosening of orthopaedic implants. 
Ultimately this knowledge provides the basis for the development of therapeutic strategies 
for the treatment of loosened prostheses at an earlier stage, before gross loosening due 
to severe osteolysis is present. In the end, this will hopefully result in the redundancy of 
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Peri-prothetisch interfase weefsel rondom aseptisch losgelaten 
prothesen: geen afval, maar een mogelijk therapeutisch doelwit?
Het onderzoek dat in dit proefschrift wordt beschreven maakt deel uit van een project om 
een minimaal invasieve behandeling van aseptisch loslatende orthopedische prothesen te 
ontwikkelen. Van alle heup- en knieprothesen faalt gemiddeld 10-20% binnen een periode 
van 10-20 jaar na plaatsing. De meest voorkomende reden van het falen is aseptische 
loslating. Aseptische loslating is een proces waarbij de verbinding tussen de prothese en 
het bot verzwakt raakt door een niet-infectieuze oorzaak. Tijdens dit proces wordt het bot 
rondom de prothese afgebroken, ook wel osteolyse genoemd. Het afbreken van bot is het 
gevolg van een afweerreactie, de zogenaamde immuunrespons, tegen de slijtagedeeltjes 
die vrijkomen van het gewrichtsoppervlak van de prothese. Het loslatingsproces gaat ook 
gepaard met de vorming van een littekenachtig (fibreus) weefsel, ook wel peri-prothetisch 
interfase weefsel genoemd. Interfase weefsel bestaat uit verschillende celtypen die, in 
reactie op slijtagedeeltjes, cytokines en chemokines produceren die botafbraak rondom de 
prothese uitlokken. Het gevolg is dat de prothese ten opzichte van het bot gaat bewegen, 
ook wel mechanische instabiliteit genoemd, wat gepaard gaat met pijn en een beperking 
van de functie van het gewricht. Uiteindelijk is het vaak noodzakelijk om een voor de patiënt 
belastende en technisch complexe revisie operatie uit te voeren, waarbij de prothese wordt 
vervangen door een nieuw exemplaar meestal samen met donorbot.
 In dit proefschrift werd de biologie omtrent het aseptische loslatingsproces bestudeerd 
aan de hand van 3 onderzoeksvragen: (1) Kan het bestuderen van de cellulaire inhoud 
van peri-prothetisch interfase weefsel nieuwe inzichten geven in de mechanismes van 
het aseptisch loslatingsproces? (2) Hebben peri-prothetisch interfase weefsel cellen 
de capaciteit om bot aan te maken, de zogenaamde ‘osteogenic potential’? (3) Hebben 
individuele immuunresponses invloed op prothese migratie? De kennis verkregen uit deze 
onderzoeken zal uiteindelijk bijdragen aan de ontwikkeling van een (biologische) minimaal 
invasieve behandeling van loslatende orthopedische implantaten.
Hoofdstuk 2 en 3 van dit proefschrift richtten zich op het karakteriseren van het peri-
prothetisch interfase weefsel. In Hoofdstuk 2 werden, middels een systematisch 
literatuuronderzoek, de kenmerken van het peri-prothetisch interfase weefsel (verkregen 
met behulp van in vitro studies) in kaart gebracht. Dit had als doel om een overzicht te 
krijgen van de huidige voorgestelde cellulaire mechanismen betrokken in het aseptische 
loslatingsproces. Naast macrofagen produceren ook fibroblasten inflammatoire cytokines, 
chemokines en enzymen die bijdragen aan de vorming en activatie van botafbrekende 
cellen (osteoclasten), wat uiteindelijk leidt tot osteolyse. Sommige auteurs noemen ook 
fibroblasten als mogelijk therapeutisch doelwit om aseptische loslating van prothesen te 
behandelen. Maar weinig studies onderzochten de betrokkenheid van botaanmakende 
140
Chapter 8
cellen (osteoblasten) en het proces van botaanmaak zelf, ook wel osteogenese genoemd, in 
het loslatingsproces. Twee studies suggereerden dat het peri-prothetisch interfase weefsel 
van sommige patiënten osteogene karakteristieken bevat. Een andere studie liet zien dat de 
osteogene signalering in patiënten met falende prothesen mogelijk verstoord is. Allemaal 
aanwijzingen dat (effecten op) osteoblasten mogelijk een rol spelen in het aseptische 
loslatingsproces. Op basis van dit review concluderen wij dat naast de bekende rol van 
macrofagen en osteoclasten in het loslatingsproces, de rol van fibroblasten en osteoblasten 
wellicht net zo belangrijk is..
 Geïntrigeerd door deze bevindingen verrichtten we een experimentele karakterisatie-
studie (Hoofdstuk 3). Met behulp van cel-specifieke genexpressie en (immuno)histochemie 
werd het peri-prothetisch interfase weefsel van 47 patiënten onderzocht op de aanwezigheid 
van diverse celtypen, waaronder fibroblasten en osteoblasten. Resultaten lieten zien dat 
deze interfase weefsels macrofaag-, fibroblast-, osteoblast- en endotheel cel-gerelateerde 
genen tot expressie brengen. Een zogenaamde hoofdcomponentenanalyse werd gebruikt 
om van alle individuele cel-specifieke genen groepen van genen (componenten) te 
identificeren om zo gen expressie patronen tussen weefsels te bestuderen. Hieruit kwamen 
twee componenten naar voren, waarbij osteoblast- en fibroblast-gerelateerde genen in 
een ander component zaten dan macrofaag- en endotheel cel-gerelateerde genen. Over 
het algemeen werden er grote verschillen gevonden in de hoogte van expressie van elke 
component tussen de weefsels. Deze verschillen konden niet worden verklaard door 
patiënt- of prothese-karakteristieken. (Immuno)histochemische kleuring van de weefsels 
liet de overheersende aanwezigheid van zowel fibroblasten als macrofagen zien, waarbij 
eveneens grote variabiliteit binnen weefsels en tussen patiënten werd gezien in zowel 
de mate van aangekleurd oppervlak als de locatie van de kleuring. Echter, de mate van 
aankleuring associeerde niet significant met patiënt- of prothese-karakteristieken en ook 
niet met de genexpressie data. Daarnaast bestudeerden we het peri-prothetisch interfase 
weefsel op de aanwezigheid van macrofaag subtypes: de relatieve aanwezigheid van pro-
inflammatoire M1 macrofagen en anti-inflammatoire M2 macrofagen. In bijna 2/3 van 
de weefsel samples was meer M2 macrofaag-aankleuring aanwezig dan M1 macrofaag 
aankleuring. Samengevat, heeft deze studie inzicht gegeven in mogelijke (nieuwe) cellulaire 
mechanismen in het aseptisch loslatingsproces, waarin fibroblasten en osteoblasten net zo 
belangrijk lijken te zijn als macrofagen. Daarnaast spelen met name type 2 macrofagen een 
rol in het eindstadium van loslating, dat wil zeggen wanneer revisie nodig is. 
Osteolyse maakt deel uit van het botremodelleringsproces waar ook osteogenese deel 
van uit maakt. Tot nu toe hebben studies naar mogelijke therapeutische behandelingen 
van aseptische loslating zich primair gericht op osteolyse en is er maar weinig aandacht 




en 5 van dit proefschrift zich op osteogenese en de stimulatie hiervan in peri-prothetisch 
interfase weefsel. Osteogenese kan op verschillende manieren worden beïnvloed, 
bijvoorbeeld door stimuleren van signaleringsroutes die belangrijk zijn voor osteogenese 
en differentiatie van osteoblasten, zoals de BMP en Wnt signaalroutes. Echter, door het 
stimuleren van deze signaleringsroutes worden tegelijkertijd remmers van osteogenese 
gestimuleerd, zoals bijvoorbeeld Sclerostin. In Hoofdstuk 4 werd onderzocht of door 
het interfereren met BMP en Wnt signaalroutes en Sclerostin, osteoblast differentiatie 
en osteogenese gestimuleerd konden worden. De interactie van beide signaalroutes op 
de expressie van SOST, het gen dat Sclerostin codeert, werd onderzocht in een humane 
botkanker cellijn. De genexpressie van SOST kon ofwel verlaagd worden door stimulatie 
van de Wnt signaalroute ofwel verhoogd worden door stimulatie van de BMP signaalroute. 
Echter, GIN, een specifieke remmer van GSK3ß, dat een belangrijk onderdeel is van de Wnt 
signaalroute, kon de BMP-4 geïnduceerde SOST expressie significant verlagen en daarmee 
BMP signalering loskoppelen van SOST expressie. Daarnaast werd in de muis osteoblast-
voorloper cellijn KS483 aangetoond dat in vergelijking met stimulatie met alleen BMP-4 een 
combinatie van BMP-4 en GIN een verhoogde osteoblast differentiatie gaf, dat wil zeggen 
meer alkalische fosfatase activiteit (ALP) en matrix mineralisatie. Samenvattend liet deze 
studie zien dat het ontkoppelen van BMP signalering en SOST expressie, met behulp van 
GIN, leidt tot een versterkte BMP-4 geïnduceerde osteoblast differentiatie. Dit effect kan 
mogelijk worden gebruikt in een klinische setting om lokaal osteogenese te stimuleren, 
bijvoorbeeld rondom loslatende protheses of bij fractuurgenezing. In Hoofdstuk 5 werd de 
mogelijkheid om peri-prothetische interfase cellen te laten differentiëren in osteoblasten 
onderzocht. Daarnaast onderzochten we het in hoofdstuk 4 geobserveerde versterkende 
effect van BMP en GIN op osteoblast differentiatie, maar nu in peri-prothetische interfase 
cellen. Resultaten lieten zien dat wanneer peri-prothetische interfase cellen in celkweek 
werden gebracht met osteogenese stimulerend groeimedium, ALP kleuring en ALP gen 
expressie hoger waren in vergelijking tot celkweek met normaal groeimedium. Daarnaast 
produceerden peri-prothetische interfase cellen een gemineraliseerde extracellulaire matrix 
wanneer ze met osteogeen groeimedium in celkweek werden gebracht. Over het algemeen 
werden de bestudeerde osteogene eigenschappen van peri-prothetische interfase cellen 
niet significant versterkt door de toevoeging van BMPs, GIN of een combinatie van BMPs 
en GIN aan het osteogene groeimedium. Echter, in sommige weefseldonoren konden 
de osteogene eigenschappen wel worden versterkt of was de toevoeging van deze 
stoffen zelfs noodzakelijk om osteoblast differentiatie te veroorzaken. Ondanks dat er veel 
variabiliteit in reactie op de verschillende osteogene stimuli werd waargenomen tussen 
de weefseldonoren en zelfs binnen de weefsels, concludeerden we dat peri-prothetische 
interfase cellen kunnen differentiëren in osteoblasten. Deze studie toont daarmee een 
regeneratieve capaciteit van peri-prothetisch interfase weefsel aan, wat een (nieuwe) 
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mogelijkheid biedt om in te grijpen in de verstoorde botremodellering in het aseptische 
prothese loslatingsproces. 
 Immuunresponses tegen prothese slijtagedeeltjes spelen een sleutelrol in de progressie 
van osteolyse rondom prothesen. Uit eerdere onderzoeken is gebleken dat de mate van 
osteolyse kan variëren tussen patiënten door onder andere individuele verschillen in de 
immuunrespons op slijtagedeeltjes. Verschillen in immuunresponses tussen patiënten 
kunnen daardoor mogelijk het risico op aseptische loslating van prothesen voorspellen. 
Meerdere studies hebben al laten zien dat progressieve migratie, wat kan worden 
gemeten met röntgen stereophotogrammetrische analyse (RSA), kan worden geassocieerd 
met een verhoogd risico op het uiteindelijk falen van heup- en knieprothesen. In 
Hoofdstuk 6 onderzochten we de relatie tussen immuunresponses en de migratie 
van knieprothesen. Hiervoor werden bloedmonsters van patiënten met verschillende 
ontwerpen van knieprothesen gestimuleerd met een eiwit die de Toll-like receptor 2 
(TLR2) immuunrespons opwekte. Dit resulteerde in de productie van diverse cytokines 
die (na uitvoeren van een hoofcomponentenanalyse) in twee verschillende groepen, ook 
wel componenten genoemd, bleken te clusteren. Het component wat voornamelijk pro-
inflammatoire cytokines bevatte, correleerde omgekeerd met migratie. Verdere analyse 
liet zien dat interferon gamma (IFNγ) het hoogste aandeel had in de gevonden associatie, 
maar dit verband was alleen aanwezig in patiënten die bepaalde typen prothesen hadden. 
Daarom kan uit deze studie geconcludeerd worden dat patiënten die hoge waarden van 
IFNγ hadden na stimulatie van TLR2, een lager risico hebben op vroege migratie van hun 
knieprothese. Deze studie toont daarmee aan dat immuunresponses kunnen worden 
gebruikt om migratie te voorspellen. In de toekomst kunnen deze immuunresponses 
mogelijk gebruikt worden om een preoperatief predictiemodel voor het falen (gericht op 
aseptische loslating) van prothesen te ontwikkelen.
 In Hoofdstuk 7 worden alle onderzoeken van dit proefschrift samengevat en 
bediscussieerd en worden toekomst perspectieven besproken. Macrofagen spelen een 
belangrijke rol in het aseptisch loslatingsproces, waarbij variaties in de aanwezigheid van 
M1 en M2-macrofagen in peri-prothetisch weefsel duiden op een belangrijke invloed 
van verschillende macrofaag subtypes in dit proces. Daarnaast zijn fibroblasten en 
osteoblasten minstens zo belangrijk in het aseptische loslatingsproces. De mogelijkheid 
tot het differentiëren van peri-prothetische interfase cellen naar osteoblasten benadrukt 
de regeneratieve capaciteit van het weefsel en biedt een (nieuwe) mogelijkheid om in te 
grijpen in het verstoorde botremodelleringsproces rond een prothese. Echter, de grote 
verschillen tussen peri-prothetisch interfase weefsels gezien in o.a. weefsel karakteristieken 
en respons op osteogene stimuli, laten zien dat aseptische loslating een complex proces is.
 Vervolgonderzoek naar de biologische reacties rondom loslatende prothesen en het 




daarom nodig om een nog beter beeld te krijgen van dit complexe proces. Niettemin, 
levert dit proefschrift aanwijzingen voor alternatieve therapeutische strategieën om in te 
grijpen in het loslatingsproces en laat het de potentie zien voor het gebruik van specifieke 
immuunresponses voor (vroege) detectie en mogelijk zelfs het voorspellen van loslatende 
prothesen. Hierdoor kan in de toekomst mogelijk een deel van de uitgebreide revisie 
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